Analogues of n-acetylserotonin and combinations of tropomyosin receptor kinase b (TRKB) agonist and a mammalian target of rapamycin (MTOR) inhibitor
Specific NAS analogues and low-dose mTOR inhibitors, when combined, address the binding issues of NAS and adverse effects of rapamycin, offering an effective treatment for neurodegenerative disorders and metabolic diseases.
Patent Information
- Application Number
- PCT/EP2026/063335
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing NAS analogues often result in ineffective docking/binding to TrkB receptors, and rapamycin-based mTOR inhibitors have adverse effects at clinical doses, limiting their utility in treating neurodegenerative disorders and metabolic diseases.
Development of specific NAS analogues and combination pharmaceuticals comprising a TrkB agonist and a low-dose mTOR inhibitor, administered together to enhance therapeutic efficacy while minimizing adverse effects.
The combination therapy improves neurogenesis and reduces adverse effects, providing effective treatment for neurodegenerative disorders and metabolic diseases.
Smart Images

Figure EP2026063335_12112026_PF_FP_ABST
Abstract
Description
[0001] Analogues and Combination Pharmaceuticals
[0002] Field of the invention
[0003] This invention relates to analogues of N-Acetylserotonin (NAS), also known as normelatonin, and uses thereof. The invention also relates to pharmaceutical compositions comprising these compounds and to the manufacture and use of these compounds and compositions in the treatment, amelioration or prevention of a disease. This invention also relates to combination pharmaceuticals comprising a tropomyosin receptor kinase B (TrkB) agonist and a mammalian target of rapamycin (mTOR) inhibitor, and uses thereof.
[0004] Background
[0005] TrkB, also known as tyrosine receptor kinase B, or BDNF / NT-3 growth factors receptor or neurotrophic tyrosine kinase receptor, type 2 is a protein that in humans is encoded by the NTRK2 gene. TrkB is a receptor for brain-derived neurotrophic factor (BDNF). Abnormal and maladaptive TrkB, and its endogenous ligand BDNF, signalling is implicated in the pathology and progression of Alzheimer's disease (AD) and other neurodegenerative disorders.
[0006] N-Acetylserotonin (NAS), also known as normelatonin, is a naturally occurring chemical intermediate in the endogenous production of melatonin from serotonin. NAS is shown below:
[0007]
[0008] It is believed that the antidepressant and neurotrophic actions of NAS are due, at least in part, to the capability of this molecule to activate the TrkB receptor in a BDNF-independent manner. Various synthetic modifications to the structure of NAS have been made in the prior art. However, such modifications often result in a decrease in activity. Ineffective docking / binding of these compounds to the appropriate receptors may result from such structural modifications.
[0009] There remains a need in the art for NAS analogues, and improved compositions and uses thereof. mTOR, also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a protein kinase that in humans is encoded by the MTOR gene. mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue, and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers.
[0010] Rapamycin is a naturally occurring macrolide compound, produced by the bacterium Streptomyces hygroscopicus, and inhibitor of mTOR kinase. Rapamycin is approved in the EU for use in the prophylaxis of organ rejection and also for use in the treatment of facial angiofibroma with tuberous sclerosis complex. Rapamycin has also been investigated for possible use as a longevity-promoting drug. However, rapamycin has complex effects on the immune system and produces adverse effects (such as sepsis, venous thromboembolism, diabetes, bone necrosis and melanoma), which impose limits on its clinical utility. There is therefore a need in the art for improved methods of treatment incorporating rapamycin at dose levels and dosing regimens which avoid such adverse effects.Brief description of the figures
[0011] Figure 1 (1A, 1B, 1C, 1D) shows the results of an in vitro neurogenesis assay for BPL-NAS36.
[0012] Figure 2 (2A, 2B, 2C, 2D) shows the results of an in vitro neurogenesis assay for BPL-NAS11, 36 and 21.
[0013] Figure 3 (3A, 3B, 3C, 3D) shows the results of an in vitro neurogenesis assay for BPL-NAS28b, 28 and 29. Figure 4 (4A, 4B, 4C, 4D) shows the results of an in vitro neurogenesis assay for BPL-NAS9, 44 and 55.
[0014] Figure 5 (5A, 5B, 5C, 5D) shows the results of an in vitro neurogenesis assay for BPL-NAS45, 43 and 50.
[0015] Figure 6 (6A, 6B, 6C, 6D) shows the results of an in vitro neurogenesis assay for BPL-NAS38, 31 and 35.
[0016] Figure 7 (7A, 7B, 7C, 7D) shows the results of an in vitro neurogenesis assay for BPL-NAS51, 24 and 41.
[0017] Figure 8 (8A, 8B, 8C, 8D) shows the results of an in vitro neurogenesis assay for BPL-NAS43b, 40 and 49. Figure 9 (9A, 9B, 9C, 9D) shows the results of an in vitro neurogenesis assay for BPL-NAS16, 57a and 58a. Figure 10 (10A, 10B, 10C, 10D) shows the results of an in vitro assay investigating the effect of BPL-NAS55, 29, 50 and 21 on dopaminergic TH-positive neurons injured with a-syn PFF and CBE.
[0018] Figure 11 (11A, 11B, 11C, 11D) shows the results of an in vitro assay investigating the effect of BPL-NAS28, 43, 40 and 36 on dopaminergic TH-positive neurons injured with a-syn PFF and CBE.
[0019] Figure 12 shows the results of an in vitro assay investigating the effect of BPL-NAS21 and rapamycin on dopaminergic TH-positive neurons injured with a-syn PFF.
[0020] Figure 13 shows the results of an in vitro assay investigating the effect of BPL-NAS28 and rapamycin on dopaminergic TH-positive neurons injured with a-syn PFF.
[0021] Figure 14 shows the results of an in vitro assay investigating the effect of BPL-NAS50 and rapamycin on dopaminergic TH-positive neurons injured with a-syn PFF.
[0022] Figure 15 shows a further representation of the results of the in vitro assay of Example 7.
[0023] Summary
[0024] In an embodiment, there is provided a compound, or pharmaceutically acceptable salt thereof, selected from the following:
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043] In an embodiment, the compound is not:
[0044]
[0045] In an embodiment, the compound is not:
[0046] N-[2-(5-(Prop-2-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamide (2-7), N-[2-(5-(Cyclopentyloxy)-1H-indol-3-yl)ethyl]acetamide (2-17),
[0047] N-[2-(5-(2-Phenylethoxy)-lH-indol-3-yl)ethyl]acetamide (2-20),
[0048] N-[2-(5-Trifluoromethoxy-lH-indol-3-yl)ethyl]acetamide (2-31),
[0049] N-[2-[5-[2-(Methoxycarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamide (2-54),
[0050] N-[2-[5-(3-Hydroxypropoxy)-lH-indol-3-yl]ethyl]acetamide (2-57),
[0051] N-[2-[5-(2-Hydroxyethoxy)-lH-indol-3-yl]ethyl]acetamide (2-58) or
[0052] N-[2-(5-Dimethylamino-lH-indol-3-yl)ethyl]acetamide (2-66).
[0053] In an embodiment, the compound is a compound of formula (I):
[0054]
[0055] or a pharmaceutically acceptable salt thereof, wherein of R1is selected from: C1, optionally substituted straight or branched chain alkyl, C3, 10 optionally substituted cycloalkyl, C3, 10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron, wherein the compound is not N-Acetylserotonin.
[0056] In an embodiment, R1is an C1,
[0057]
[0058] substituted straight or branched chain alkyl, wherein said alkyl group is substituted with one or more of: deuterium, C1, 10 optionally substituted straight or branched chain alkyl, C3, e, -10 optionally substituted cycloalkyl, C3, -10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0059] In an embodiment, R1is a C3,
[0060]
[0061] -10 substituted cycloalkyl or a C3,
[0062]
[0063] -10 substituted aromatic ring, wherein said C3,
[0064]
[0065] -10 substituted cycloalkyl or a C3,4,5,6, -10 substituted aromatic ring is substituted with one or more of: deuterium, C1, optionally substituted straight or branched chain alkyl, C3, -10 optionally substituted cycloalkyl, C3,4, -10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl,isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0066] In an embodiment, R1 is selected from:
[0067] OCH2CH2CH2CH3, OCH2CH2CH2CH2CH3, OCH2CH2CH2CH2CH2CH3, OC(CH3)3, OCH(CH3)CH3, OCH(CH3)CH2CH3, OCH2C(CH3)3, OCH2CHCH2, OCH2CHCH, OCH2CH2C(CH3)3 or OCH2CH2CH2C(CH3)3.
[0068] In an embodiment, R1 is selected from:
[0069] OCH2F, OCH(F2), OC(F3), OCH2CI, OCH2Br, OCH2F, OCH2CH2F, OCH2CH2Br, OCH2CH2CI, OCH2C(F3), OCH2C(F3), OCH2CH(F2), OCH2CH2C(F3) or OCH2CH2CH2F.
[0070] In an embodiment, R1 is selected from:
[0071] OCH2X, OCH(X2), OC(X3), OCH2CH2X, OCH2C(X3), OCH2CH(X2), OCH2CH2C(X3) or OCH2CH2CH2X, wherein X is a halogen.
[0072] In an embodiment, R1 is selected from:
[0073] OCH2X, OCH(X2), OC(X3), OCH2CH2X, OCH2C(X3), OCH2CH(X2), OCH2CH2C(X3) or OCH2CH2CH2X, wherein X is fluorine, bromine, chlorine or iodine.
[0074] In an embodiment, R1 is selected from:
[0075] OCH(CH3)3, OCH2CH(CH3)CH2CH3, OCH(CH3)CH2CH3 or OCH2CH(CH2CH3)2.
[0076] In an embodiment, R1 is selected from:
[0077] OCH2OCH3, OCH2OCH2CH3, OCH2OCH2CH2CH3, OCH2CH2OCH3 or OCH2CH2OCH2CH3.
[0078] In an embodiment, R1 is selected from:
[0079] OCH2CH2N(CH3)2, OCH2CH2CH2N(CH3)2, OCH2CH2SCH3, OCH2CH2C(O)OCH3, OCH2CH2CH2C(O)OCH3, OCH2CH2CH2C(O)OCH2CH3, OCH2CH2CH2OH or OCH2CH2OH.
[0080] In an embodiment, R1 is selected from:
[0081] SC(CH3)3, SCH(CH3)2or SCH2CH3.
[0082] In an embodiment, R1 is selected from:
[0083] CH2CH2CH3 or C(CH3)3.
[0084] In an embodiment, R1 is selected from:
[0085] CH2CI, CH2Br, CH2F, CH2I, C(Cl3), C(F3), C(Br3) or C(I3).
[0086] In an embodiment, R1 is selected from:
[0087] NHCH2CH3or N(CH3).
[0088] In an embodiment, there is provided a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or excipients and a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, as described herein.In an embodiment, there is provided a TrkB agonist and one or more of: an mTOR inhibitor, an agonist / activator of a downstream target of mTOR or an antagonist / inhibitor of a downstream target of mTOR for use in a method of treatment of a disease or condition thereof. In an embodiment, the downstream target is PI3K / AKt.
[0089] In an embodiment, there is provided an agonist of tropomyosin receptor kinase B (TrkB) and an inhibitor of mammalian target of rapamycin (mTOR) for use in a method of treatment of a disease or condition in a patient in need thereof, wherein the method of treatment comprises the co-administration of the TrkB agonist and the mTOR inhibitor to the patient.
[0090] In an embodiment, the mTOR inhibitor is administered at a dose which is substantially lower than a dose at which said mTOR inhibitor is active when administered alone.
[0091] In an embodiment, the mTOR inhibitor is administered at a dose which does not produce known adverse effects of said mTOR inhibitor.
[0092] In an embodiment, the mTOR inhibitor is administered at a dose of 0.1 to 1mg / kg or below the body weight of a patient.
[0093] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered at the same time.
[0094] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered at the same time in the same dosage form.
[0095] In an embodiment, TrkB agonist and the mTOR inhibitor are administered at the same time in the same single dosage form.
[0096] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered at the same time via the same administration route.
[0097] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered within 1 to 180 minutes of one another.
[0098] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered within 1 to 24 hours of one another.
[0099] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered within 1 to 28 days of one another.
[0100] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered within 1 to 28 weeks of one another.
[0101] In an embodiment, the TrkB agonist is administered one or more times every 1 to 28 days.
[0102] In an embodiment, the TrkB agonist is administered one or more times every 1 to 26 weeks.
[0103] In an embodiment, the TrkB agonist is administered one or more times every 1 to 12 months.
[0104] In an embodiment, the mTOR inhibitor is administered one or more times every 1 to 28 days.In an embodiment, the mTOR inhibitor is administered one or more times every 1 to 26 weeks.
[0105] In an embodiment, the mTOR inhibitor is administered one or more times every 1 to 12 months.
[0106] In an embodiment, the TrkB agonist is administered followed by administration of the mTOR inhibitor.
[0107] In an embodiment, the mTOR inhibitor is administered followed by administration of the TrkB agonist.
[0108] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered as the same dosage form. In an embodiment, the TrkB agonist and the mTOR inhibitor are administered as different dosage forms. In an embodiment, the TrkB agonist and the mTOR inhibitor are administered via the same administration route.
[0109] In an embodiment, the TrkB agonist and the mTOR inhibitor are administered via different administration routes.
[0110] In an embodiment, the mTOR inhibitor is selected from: rapamycin, temsirolimus, everolimus, ridaforolimus, ridaforolimus, umirolimus, zotarolimus, quinoxaline, torin-1, torin-2 or vistusertib, or derivatives thereof. In an embodiment, the mTOR inhibitor is rapamycin.
[0111] In an embodiment, the TrkB agonist is selected from: BDNF, NT-4, NT-3, 7,8-dihydroxyflavone, N-Acetylserotonin or derivatives thereof.
[0112] In an embodiment, the TrkB agonist is a compound of formula (II):
[0113]
[0114] or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, wherein each of Ri-Rio is independently selected from: hydrogen, deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.In an embodiment, the TrkB agonist is a compound of formula (II), wherein R1-R5 and R7-R10 are hydrogen and R6 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0115] In an embodiment, the TrkB agonist is a compound of formula (II), wherein R2-R10 are hydrogen and Ri is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0116] In an embodiment, the TrkB agonist is a compound of formula (II), wherein Ri and R3-R10 are hydrogen and R2 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0117] In an embodiment, the TrkB agonist is a compound of formula (II), wherein Ri, R2 and R4-R10 are hydrogen and R3 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0118] In an embodiment, R1-R3 and R5-R10 are hydrogen and R4 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio,butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0119] In an embodiment, R1-R4 and R6-R10 are hydrogen and R5 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0120] In an embodiment, R1-R5 and R7-R10 are hydrogen and R6 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0121] In an embodiment, R1-R6 and R8-R10 are hydrogen and R7 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0122] In an embodiment, R1-R7 and R9 and R10 are hydrogen and R8 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0123] In an embodiment, R1-R8 and R10 are hydrogen and R9 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio,ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0124] In an embodiment, Ri-Rg are hydrogen and Rio is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
[0125] In an embodiment, the TrkB agonist is a compound of formula (II):
[0126]
[0127] or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, wherein
[0128] R1-R4 are hydrogen;
[0129] Rs is OH, S-C4alkyl, S-C3 alkyl, SO2-C3alkyl, O-CH2CH(CH3)2or O-CH2CH2-S-C4alkyl;
[0130] Rs is hydrogen or methyl; and
[0131] R7-R10 are hydrogen.
[0132] In an embodiment, the TrkB agonist is a compound of formula (II):
[0133]
[0134] or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, wherein
[0135] Ri is hydrogen, methyl, ethyl, propyl or butyl;
[0136] R2-R4 are hydrogen;Rs is OH, C4alkyl, CH2CH(CH3)2, S(O)-C3alkyl, C(O)H, COOC2 alkyl, S-C2 alkyl, S-C3alkyl, S-C4alkyl, S- CH(CH3), S-CH2CH(CH3)2, SO2-C2 alkyl, SO2-C3alkyl, SO2-CH2CH(CH3)2, O-CH(CH3), O-CH2CH(CH3)2, O- CH2CH2-S-C1 alkyl, O-(CH2)3-S-CI alkyl or O-CH2CH2-S-C4alkyl;
[0137] Rs is hydrogen, methyl
[0138]
[0139] R7-R10 are hydrogen.
[0140] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0141] N-[2-(5-lsopropoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-2-methyl-lH-indol-3- yl)ethyl]acetamide, N-[2-(5-Formyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylsulfonyl-lH-indol-3- yl)ethyl]acetamide, N-[2-(5-Methylamino-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutoxy-lH-indol- 3-yl)ethyl]acetamide, N-[2-(5-Methylthiomethyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutyl-lH- indol-3-yl)ethyl]acetamide, N-[2-(5-Cyclopropyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Fluoromethyl- lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Ethylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butylthio- lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-lH-indol-2-yl)ethyl]acetamide, N-[2-(5-lsopropylthio- lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-3-methyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5- Cyclohexyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylthiomethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutylthio-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-4-methyl-lH-indol-3- yl)ethyl]acetamide, N-[2-(5-Butylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-2-propyl-lH- indol-3-yl)ethyl]acetamide, N-[2-(5-Butyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Ethylthiomethoxy- lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Propylthio-lH-indol-3-yl)ethyl]acetamide, N-[2-(5- Methylthioethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutylsulfonyl-lH-indol-3- yl)ethyl]acetamide, N-[2-(5-Hydroxy-3-ethyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butylthiomethoxy- lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Fluoro-3-methyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5- Hydroxy-2-butyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Propylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylthiopropoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsopropylthiomethoxy-lH-indol-3- yl)ethyl]acetamide, N-[2-(5-Hydroxy-4-ethyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-3-propyl- lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butylthioethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5- Fluoro-4-methyl-lH-indol-3-yl)ethyl]acetamide
[0142] N-[2-(5-Butoxy-lH-indol-3-yl)ethyl]acetamide
[0143] N-[2-(5-Pentoxy-lH-indol-3-yl)ethyl]acetamide
[0144] N-[2-(5-Hexoxy-lH-indol-3-yl)ethyl]acetamide
[0145] N-[2-(5-(2-Methylpropan-2-yloxy)-lH-indol-3-yl)ethyl]acetamide
[0146] N-[2-(5-(Butan-2-yloxy)-lH-indol-3-yl)ethyl]acetamide
[0147] N-[2-(5-(2,2-Dimethylpropoxy)-lH-indol-3-yl)ethyl]acetamide
[0148] N-[2-(5-(Prop-2-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamide
[0149] N-[2-(5-(Prop-2-yn-l-yloxy)-lH-indol-3-yl)ethyl]acetamide
[0150] N-[2-(5-(But-3-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamide
[0151] N-[2-[5-(Pent-4-enyloxy)-lH-indol-3-yl]ethyl]acetamide
[0152] N-[2-(5-Cyclopropylmethoxy-lH-indol-3-yl)ethyl]acetamide
[0153] N-[2-(5-Cyclobutylmethoxy-lH-indol-3-yl)ethyl]acetamide
[0154] N-[2-(5-Cyclopentylmethoxy-lH-indol-3-yl)ethyl]acetamide
[0155] N-[2-(5-Cyclohexylmethoxy-lH-indol-3-yl)ethyl]acetamide
[0156] N-[2-(5-(Cyclopropyloxy)-lH-indol-3-yl)ethyl]acetamide
[0157] N-[2-(5-(Cyclobutyloxy)-lH-indol-3-yl)ethyl]acetamide
[0158] N-[2-(5-(Cyclopentyloxy)-lH-indol-3-yl)ethyl]acetamide
[0159] N-[2-(5-(Cyclohexyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(4-Methylbenzyloxy)-lH-indol-3-yl)ethyl]acetamide
[0160] N-[2-(5-(2-Phenylethoxy)-lH-indol-3-yl)ethyl]acetamide
[0161] N-[2-(5-((4-Fluorophenyl)methoxy)-lH-indol-3-yl)ethyl]acetamide
[0162] N-[2-[5-(2-Fluoroethoxy)-lH-indol-3-yl]ethyl]acetamide
[0163] N-[2-(5-Thienylmethoxy-lH-indol-3-yl)ethyl]acetamide
[0164] N-[2-(5-Pyrrolylmethoxy-lH-indol-3-yl)ethyl]acetamide
[0165] N-[2-(5-(Tetrahydrofuran-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-(5-(Tetrahydrothiophen-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-[5-[2-(Piperidin-l-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamide
[0166] N-[2-[5-[2-(Morpholin-4-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamide
[0167] N-[2-[5-(Oxetan-3-yloxy)-lH-indol-3-yl]ethyl]acetamide
[0168] N-[2-[5-(Oxetan-3-ylmethoxy)-lH-indol-3-yl]ethyl]acetamide
[0169] N-[2-(5-Trifluoromethoxy-lH-indol-3-yl)ethyl]acetamide
[0170] N-[2-(5-Chloromethoxy-lH-indol-3-yl)ethyl]acetamide
[0171] N-[2-(5-Bromomethoxy-lH-indol-3-yl)ethyl]acetamide
[0172] N-[2-(5-(2-Fluoroethoxy)-lH-indol-3-yl)ethyl]acetamide
[0173] N-[2-(5-(2-Chloroethoxy)-lH-indol-3-yl)ethyl]acetamide
[0174] N-[2-(5-(2,2,2-Trifluoroethoxy)-lH-indol-3-yl)ethyl]acetamide
[0175] N-[2-[5-(2,2-Difluoroethoxy)-lH-indol-3-yl]ethyl]acetamide
[0176] N-[2-[5-(3,3,3-Trifluoropropoxy)-lH-indol-3-yl]ethyl]acetamide
[0177] N-[2-[5-(3-Fluoropropoxy)-lH-indol-3-yl]ethyl]acetamide
[0178] N-[2-(5-tert-Butoxy-lH-indol-3-yl)ethyl]acetamide
[0179] N-[2-(5-(2-Methylbutoxy)-lH-indol-3-yl)ethyl]acetamide
[0180] N-[2-[5-(l-Methylpropoxy)-lH-indol-3-yl]ethyl]acetamide
[0181] N-[2-[5-(3-Methylbutoxy)-lH-indol-3-yl]ethyl]acetamide
[0182] N-[2-[5-(2-Ethylbutoxy)-lH-indol-3-yl]ethyl]acetamide
[0183] N-[2-(5-Methoxymethoxy-lH-indol-3-yl)ethyl]acetamide
[0184] N-[2-(5-Ethoxymethoxy-lH-indol-3-yl)ethyl]acetamide
[0185] N-[2-(5-Propoxymethoxy-lH-indol-3-yl)ethyl]acetamide
[0186] N-[2-(5-(2-Methoxyethoxy)-lH-indol-3-yl)ethyl]acetamide
[0187] N-[2-(5-(2-Ethoxyethoxy)-lH-indol-3-yl)ethyl]acetamide
[0188] N-[2-(5-(2-(Dimethylamino)ethoxy)-lH-indol-3-yl)ethyl]acetamide
[0189] N-[2-(5-(2-(Pyrrolidin-l-yl)ethoxy)-lH-indol-3-yl)ethyl]acetamide
[0190] N-[2-[5-[3-(Dimethylamino)propoxy]-lH-indol-3-yl]ethyl]acetamide
[0191] N-[2-[5-[2-(Methoxycarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamide
[0192] N-[2-[5-[3-(Ethoxycarbonyl)propoxy]-lH-indol-3-yl]ethyl]acetamide
[0193] N-[2-[5-[2-(Aminocarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamide
[0194] N-[2-[5-(3-Hydroxypropoxy)-lH-indol-3-yl]ethyl]acetamide
[0195] N-[2-[5-(2-Hydroxyethoxy)-lH-indol-3-yl]ethyl]acetamide
[0196] N-[2-(5-(2-(Methylthio)ethoxy)-lH-indol-3-yl)ethyl]acetamide
[0197] N-[2-(5-Propyl-lH-indol-3-yl)ethyl]acetamide
[0198] N-[2-(5-tert-Butyl-lH-indol-3-yl)ethyl]acetamide
[0199] N-[2-(5-tert-Butylthio-lH-indol-3-yl)ethyl]acetamide
[0200] N-[2-(5-Chloromethyl-lH-indol-3-yl)ethyl]acetamide
[0201] N-[2-(5-Bromomethyl-lH-indol-3-yl)ethyl]acetamide
[0202] N-[2-(5-Trifluoromethyl-lH-indol-3-yl)ethyl]acetamide
[0203] N-[2-(5-Ethylamino-lH-indol-3-yl)ethyl]acetamide
[0204] N-[2-(5-Dimethylamino-lH-indol-3-yl)ethyl]acetamide
[0205] N-[2-(5-Cyclobutyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclopentyl-lH-indol-3-yl)ethyl]acetamide
[0206] N-[2-(5-Benzyl-lH-indol-3-yl)ethyl]acetamide
[0207] N-[2-[5-[2-(Pyridin-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide
[0208] N-[2-[5-[2-(Pyridin-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide
[0209] N-[2-[5-[2-(Pyridin-4-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide
[0210] N-[2-[5-[2-(Thiophen-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide or
[0211] N-[2-[5-[2-(Thiophen-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide.
[0212] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0213] N-[2-(2-Hydroxy-5-hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Methoxy-5-hydroxy-lH-indol-3- yl)ethyl]acetamide, N-[2-(2-Fluoro-5-hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Hydroxy-5- Hydroxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(2-Methyl-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Chloro-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Bromo-5-Hydroxy-lH-indol-3- yl)ethyl]acetamide or N-[2-(2-Ethoxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide.
[0214] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0215] N-[2-(5-Hydroxy-4-methoxy-1H-indol-3-yl)ethyl]acetamide
[0216] N-[2-(5-Hydroxy-4-fluoro-1H-indol-3-yl)ethyl]acetamide,
[0217] N-[2-(5-Hydroxy-4-chloro-1H-indol-3-yl)ethyl]acetamide,
[0218] N-[2-(5-Hydroxy-4-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0219] N-[2-(5-Hydroxy-4-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0220] N-[2-(5-Hydroxy-4-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0221] N-[2-(5-Hydroxy-4-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0222] N-[2-(5-Hydroxy-4-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0223] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0224] N-[2-(5-Hydroxy-1-methyl-1H-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-l-ethyl-lH-indol-3- yl)ethyl]acetamide,
[0225] N-[2-(5-Hydroxy-1-propyl-1H-indol-3-yl)ethyl]acetamide,
[0226] N-[2-(5-Hydroxy-1-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0227] N-[2-(5-Hydroxy-1-Ethyl-1H-indol-3-yl)ethyl]acetamide,
[0228] N-[2-(5-Hydroxy-1-Propyl-1H-indol-3-yl)ethyl]acetamide,
[0229] N-[2-(5-Hydroxy-1-Butyl-1H-indol-3-yl)ethyl]acetamide or
[0230] N-[2-(5-Hydroxy-1-Pentyl-1H-indol-3-yl)ethyl]acetamide.
[0231] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0232] N-[2-(5-Hydroxy-1H-indol-1-yl)ethyl]acetamide,
[0233] N-[2-(1-Hydroxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0234] N-[2-(1-Methyl-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0235] N-[2-(1-Chloro-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0236] N-[2-(1-Bromo-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide or
[0237] N-[2-(1-Ethoxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide.In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0238] N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0239] N-[2-(5-Hydroxy-3-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0240] N-[2-(5-Hydroxy-3-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0241] N-[2-(5-Hydroxy-3-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0242] N-[2-(5-Hydroxy-3-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0243] N-[2-(5-Hydroxy-3-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0244] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0245] N-[2-(5-Hydroxy-1H-indol-6-yl)ethyl]acetamide,
[0246] N-[2-(5-Hydroxy-6-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0247] N-[2-(5-Hydroxy-6-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0248] N-[2-(5-Hydroxy-6-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0249] N-[2-(5-Hydroxy-6-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0250] N-[2-(5-Hydroxy-6-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0251] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0252] N-[2-(5-Hydroxy-1H-indol-7-yl)ethyl]acetamide,
[0253] N-[2-(5-Hydroxy-7-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0254] N-[2-(5-Hydroxy-7-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0255] N-[2-(5-Hydroxy-7-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0256] N-[2-(5-Hydroxy-7-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0257] N-[2-(5-Hydroxy-7-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0258] In an embodiment, the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:
[0259] N-[2-(5-Hydroxy-1H-indol-8-yl)ethyl]acetamide,
[0260] N-[2-(5-Hydroxy-8-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0261] N-[2-(5-Hydroxy-8-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0262] N-[2-(5-Hydroxy-8-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0263] N-[2-(5-Hydroxy-8-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0264] N-[2-(5-Hydroxy-8-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0265] In an embodiment, the TrkB agonist is a compound of formula (la):
[0266]
[0267] or a pharmaceutically acceptable salt thereof, whereinR1a, R2a, R3a, R4a, R7a, R8a, R9a and R10a are each independently H or C1-6 alkyl optionally substituted with 1-3 fluorine atoms;
[0268] R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;
[0269] wherein n is 0 to 6;
[0270] m is 0 to 6;
[0271] Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;
[0272] Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; and
[0273] R6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
[0274] In an embodiment, the TrkB agonist is a compound of formula (2a):
[0275]
[0276] or a pharmaceutically acceptable salt thereof, wherein
[0277] Rlais H or Ci-6 alkyl optionally substituted with 1-3 fluorine atoms;
[0278] R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;
[0279] wherein n is 0 to 6;
[0280] m is 0 to 6;
[0281] Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;
[0282] Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; and
[0283] R6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
[0284] In an embodiment, the TrkB agonist is a compound of formula (2b):
[0285]
[0286] or a pharmaceutically acceptable salt thereof, wherein
[0287] R1a and R11a are each independently H or C1-6 alkyl optionally substituted with 1-3 fluorine atoms;
[0288] R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;wherein n is 0 to 6;
[0289] m is 0 to 6;
[0290] Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;
[0291] Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; and
[0292] R6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
[0293] In an embodiment, the TrkB agonist is a compound of formula (2c):
[0294]
[0295] or a pharmaceutically acceptable salt thereof, wherein
[0296] R11ais H or C1-6alkyl optionally substituted with 1-3 fluorine atoms;
[0297] R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;
[0298] wherein n is 0 to 6;
[0299] m is 0 to 6;
[0300] Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;
[0301] Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; and
[0302] R6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
[0303] In an embodiment, the TrkB agonist is a compound of formula (3a):
[0304]
[0305] or a pharmaceutically acceptable salt thereof, wherein R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ; wherein n is 0 to 6;
[0306] m is 0 to 6;
[0307] Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO; and
[0308] Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms.
[0309] In an embodiment, the TrkB agonist is a compound of formula (3b), (3c), (3d), (3e), (3f) or (3g):
[0310]
[0311] or a pharmaceutically acceptable salt thereof, wherein X is a group -(CH2)mZ;
[0312] wherein m is 0 to 6; and
[0313] Z is H, OH, C1, 2, 3, 4, 5 or 6alkyl optionally substituted with 1-3 fluorine atoms, C1, 2, 3, 4, 5 or 6alkoxy optionally substituted with 1-3 fluorine atoms, C1, 2, 3, 4, 5 or 6thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3, 4, 5 or 6carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms.
[0314] In an embodiment, the group R1or R1acan be selected from the group consisting of:
[0315]
[0316] In an embodiment, the group R5or R5acan be selected from the group consisting of:
[0317]
[0318]
[0319] In an embodiment, the group R6or R6acan be selected from the group consisting of:
[0320]
[0321] In an embodiment, the group R11acan be selected from the group consisting of:
[0322]
[0323] In an embodiment, the group X can be selected from the group consisting of:
[0324]
[0325]
[0326] In an embodiment, the method of treatment is a method of treatment of:
[0327] one or more neurodegenerative diseases;
[0328] Alzheimer's disease, Parkinson's disease or Huntington's disease;
[0329] one or more mood disorders;
[0330] depression, bipolar disorder or anxiety;
[0331] one or more epilepsy disorders;
[0332] one or more pain disorders;
[0333] one or more inflammatory disorders;
[0334] one or more psychiatric disorders;
[0335] schizophrenia or borderline personality disorder;
[0336] one or more disorders resulting from brain injury;
[0337] one or more addiction disorders;
[0338] one or more neurodevelopmental disorders;
[0339] autism spectrum disorders or attention-deficit / hyperactivity disorder; or
[0340] one or more circadian rhythm disorders.
[0341] In an embodiment, the mTOR inhibitor is rapamycin and the TrkB agonist is:
[0342]
[0343] In an embodiment, the mTOR inhibitor is rapamycin and the TrkB agonist is:
[0344]
[0345] In an embodiment, the mTOR inhibitor is rapamycin and the TrkB agonist is:
[0346]
[0347] In an embodiment, the amount of the mTOR inhibitor administered is an amount which is ineffective in the absence of the co-administration of the TrkB agonist.In an embodiment, the efficacy shown by administering by the (i) TrkB agonist and the (ii) mTOR inhibitor in combination is greater than the efficacy shown by administering either of (i) or (ii) alone.
[0348] A combination pharmaceutical composition comprising: (i) a TrkB agonist; (ii) an inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
[0349] A combination pharmaceutical composition comprising: (i) a compound of formula (II); (ii) an inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
[0350] A combination pharmaceutical composition comprising:
[0351]
[0352] inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
[0353] A combination pharmaceutical composition comprising:
[0354]
[0355] inhibitor
[0356]
[0357] mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
[0358] A combination pharmaceutical composition comprising:
[0359]
[0360] inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
[0361] In an embodiment, the mTOR inhibitor is rapamycin.
[0362] A combination pharmaceutical composition comprising: (i) a TrkB agonist; (ii) an inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
[0363] A combination pharmaceutical composition comprising: (i) a compound of formula (II); (ii) an inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.A combination pharmaceutical composition comprising: (
[0364]
[0365] inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
[0366] A combination pharmaceutical composition comprising:
[0367]
[0368] inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
[0369] A combination pharmaceutical composition comprising: (
[0370]
[0371] inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
[0372] In an embodiment, the mTOR inhibitor is rapamycin.
[0373] In an embodiment, rapamycin is present at a dosage substantially lower than a dosage wherein rapamycin alone is active.
[0374] In an embodiment, rapamycin is present at a dosage that substantially produces none of the known adverse effects of rapamycin.
[0375] A method of treating a disease or condition in a patient in need thereof comprising administering:
[0376] (i) a TrkB agonist; and
[0377] (ii) an inhibitor of mTOR;
[0378] wherein the amount of the mTOR inhibitor administered is an amount which is ineffective in the absence of the co-administration of the TrkB agonist.
[0379] In an embodiment, the efficacy shown by administering by (i) and (ii) in combination is greater than the efficacy shown by administering either of (i) or (ii) alone.
[0380] In an embodiment, the TrkB agonist and / or the mTOR inhibitor is described herein.
[0381] A TrkB agonist for use in treating a disease or condition in a patient in need thereof in combination with an inhibitor of mTOR.
[0382] In an embodiment, the TrkB agonist and / or the mTOR inhibitor is described herein.A kit of pharmaceutical compositions, said kit comprising separate pharmaceutical compositions, one of the pharmaceutical compositions comprising a TrkB agonist and the other pharmaceutical composition comprising an mTOR inhibitor.
[0383] In an embodiment, the kit comprises instructions for use.
[0384] In an embodiment, the TrkB agonist and / or the mTOR inhibitor is described herein.
[0385] A kit of pharmaceutical compositions for use in treating a disease or condition in a patient in need thereof, said kit comprising separate pharmaceutical compositions, one of the pharmaceutical compositions comprising a TrkB agonist and the other pharmaceutical composition comprising an mTOR inhibitor.
[0386] In an embodiment, the pharmaceutical composition comprising the mTOR inhibitor comprises an amount of the mTOR inhibitor which is ineffective in the absence of the co-administration of the TrkB agonist.
[0387] In an embodiment, the kit comprises instructions for use.
[0388] In an embodiment, the TrkB agonist and / or the mTOR inhibitor is described herein.
[0389] In an embodiment, the TrkB agonist, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, selected from the following:
[0390]
[0391]
[0392]
[0393]
[0394]
[0395]
[0396]
[0397]
[0398]
[0399]
[0400]
[0401]
[0402] In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 2. In an embodiment, there is provided a NAS analogue selected from: N-[2-(2-Hydroxy-5-hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Methoxy-5-hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Fluoro-5-hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Hydroxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Methyl-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Chloro-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Bromo-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide or N-[2-(2-Ethoxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide.
[0403] In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 4. In an embodiment, there is provided a NAS analogue selected from:
[0404] N-[2-(5-Hydroxy-4-methoxy-1H-indol-3-yl)ethyl]acetamide
[0405] N-[2-(5-Hydroxy-4-fluoro-1H-indol-3-yl)ethyl]acetamide,
[0406] N-[2-(5-Hydroxy-4-chloro-1H-indol-3-yl)ethyl]acetamide,
[0407] N-[2-(5-Hydroxy-4-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0408] N-[2-(5-Hydroxy-4-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0409] N-[2-(5-Hydroxy-4-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0410] N-[2-(5-Hydroxy-4-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0411] N-[2-(5-Hydroxy-4-Methoxy-1H-indol-3-yl)ethyl]acetamide.In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 5. In an embodiment, there is provided a NAS analogue selected from:
[0412] N-[2-(5-Hydroxy-1-methyl-1H-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-1-ethyl-1H-indol-3-yl)ethyl]acetamide,
[0413] N-[2-(5-Hydroxy-1-propyl-1H-indol-3-yl)ethyl]acetamide,
[0414] N-[2-(5-Hydroxy-1-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0415] N-[2-(5-Hydroxy-1-Ethyl-1H-indol-3-yl)ethyl]acetamide,
[0416] N-[2-(5-Hydroxy-1-Propyl-1H-indol-3-yl)ethyl]acetamide,
[0417] N-[2-(5-Hydroxy-1-Butyl-1H-indol-3-yl)ethyl]acetamide or
[0418] N-[2-(5-Hydroxy-1-Pentyl-1H-indol-3-yl)ethyl]acetamide.
[0419] In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 1. In an embodiment, there is provided a NAS analogue selected from:
[0420] N-[2-(5-Hydroxy-1H-indol-1-yl)ethyl]acetamide,
[0421] N-[2-(1-Hydroxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0422] N-[2-(1-Methyl-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0423] N-[2-(1-Chloro-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0424] N-[2-(1-Bromo-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide or
[0425] N-[2-(1-Ethoxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide.
[0426] In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 3. In an embodiment, there is provided a NAS analogue selected from:
[0427] N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,
[0428] N-[2-(5-Hydroxy-3-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0429] N-[2-(5-Hydroxy-3-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0430] N-[2-(5-Hydroxy-3-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0431] N-[2-(5-Hydroxy-3-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0432] N-[2-(5-Hydroxy-3-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0433] In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 6. In an embodiment, there is provided a NAS analogue selected from:
[0434] N-[2-(5-Hydroxy-1H-indol-6-yl)ethyl]acetamide,
[0435] N-[2-(5-Hydroxy-6-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0436] N-[2-(5-Hydroxy-6-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0437] N-[2-(5-Hydroxy-6-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0438] N-[2-(5-Hydroxy-6-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0439] N-[2-(5-Hydroxy-6-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0440] In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 7. In an embodiment, there is provided a NAS analogue selected from:
[0441] N-[2-(5-Hydroxy-1H-indol-7-yl)ethyl]acetamide,
[0442] N-[2-(5-Hydroxy-7-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0443] N-[2-(5-Hydroxy-7-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0444] N-[2-(5-Hydroxy-7-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0445] N-[2-(5-Hydroxy-7-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0446] N-[2-(5-Hydroxy-7-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0447] In an embodiment, there is provided a TrkB agonist which is an NAS analogue comprising a modification to position 8. In an embodiment, there is provided a NAS analogue selected from:
[0448] N-[2-(5-Hydroxy-1H-indol-8-yl)ethyl]acetamide,N-[2-(5-Hydroxy-8-Methyl-1H-indol-3-yl)ethyl]acetamide,
[0449] N-[2-(5-Hydroxy-8-Fluoro-1H-indol-3-yl)ethyl]acetamide,
[0450] N-[2-(5-Hydroxy-8-Chloro-1H-indol-3-yl)ethyl]acetamide,
[0451] N-[2-(5-Hydroxy-8-Bromo-1H-indol-3-yl)ethyl]acetamide or
[0452] N-[2-(5-Hydroxy-8-Methoxy-1H-indol-3-yl)ethyl]acetamide.
[0453] In an embodiment, the NAS analogue has an enhanced affinity for the melatonin receptor and / or tropomyosin receptor kinase B compared with the unmodified NAS. In an embodiment, NAS analogues possessing modifications to the indole ring have an enhanced affinity for the melatonin receptor and / or tropomyosin receptor kinase B compared with the unmodified NAS. In an embodiment, the NAS analogue has an increased half-life compared with the unmodified NAS. In an embodiment, NAS analogues possessing a modification to the acetamide group have an increased half-life compared with the unmodified NAS. In an embodiment, the NAS analogue comprises a halogen atom. In an embodiment, the NAS analogue comprises a fluorine atom. In an embodiment, the NAS analogue comprises a fluorine atom substituted on the hydroxyl group. In an embodiment, the NAS analogue comprises a fluorine atom and has enhanced metabolic stability and / or lipophilicity compared with the unmodified NAS. In an embodiment, the NAS analogue comprises a chloride atom. In an embodiment, the NAS analogue comprises a chloride atom substituted on the hydroxyl group. In an embodiment, the NAS analogue comprises a chloride atom and has enhanced physiochemical properties compared with the unmodified NAS. In an embodiment, the NAS analogue comprises a bromide atom. In an embodiment, the NAS analogue comprises a bromide atom substituted on the hydroxyl group. In an embodiment, the NAS analogue comprises a bromide atom and has enhanced physiochemical properties compared with the unmodified NAS. In an embodiment, the hydroxy group of the NAS analogue is replaced with an alkyl group. In an embodiment, the hydroxy group of the NAS analogue is replaced with a methyl group. In an embodiment, the hydroxy group of the NAS analogue is replaced with a methyl group and has enhanced physiochemical properties compared with the unmodified NAS analogue. In an embodiment, the hydroxy group of the NAS analogue is replaced with a nitro group. In an embodiment, the hydroxy group of the NAS analogue is replaced with a nitro group and has enhanced physiochemical properties compared with the unmodified NAS analogue. In an embodiment, the indole ring of the NAS analogue is substituted with an amino group. In an embodiment, the indole ring of the NAS analogue is substituted with an amino group enhancing the receptor binding of the NAS analogue compared with unmodified NAS. In an embodiment, the indole ring of the NAS analogue is substituted with a halogen. In an embodiment, the indole ring of the NAS analogue is substituted with a halogen enhancing the receptor selectivity of the NAS analogue compared with unmodified NAS. In an embodiment, the indole ring of the NAS analogue is substituted with an electronwithdrawing group enhancing the chemical stability of the NAS analogue compared with unmodified NAS. In an embodiment, the indole ring of the NAS analogue is substituted with an electron-withdrawing group such as a nitro group or sulfonyl group enhancing the chemical stability of the NAS analogue compared with unmodified NAS. In an embodiment, one or more of the functional groups of the NAS analogue are protected by a protecting group. In an embodiment, one or more of the functional groups of the NAS analogue are protected by a protecting group such as benzyl, tert-butyl or acetyl. In an embodiment, the NAS analogue comprises one or more pH-sensitive functional groups.
[0454] In an embodiment, there is provided a method of selectively activating the tropomyosin receptor kinase B by administering the compound or combination as described herein. In an embodiment, there is provided a method of selectively activating a melatonin receptor by administering the compound or combination as described herein.
[0455] In an embodiment, there is provided a method of treating one or more neurodegenerative diseases by administering the compound or combination as described herein. In an embodiment, there is provided a method of halting / slowing the progression of one or more neurodegenerative diseases by administering thecompound or combination as described herein. In an embodiment, the disease is a disease involving neuronal degeneration. In an embodiment, the disease is selected from amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease.
[0456] In an embodiment, there is provided a method of treating one or more mood disorders by administering the compound or combination as described herein. In an embodiment, the disorder is depression, bipolar disorder or anxiety. In an embodiment, there is provided a method of treating one or more mood disorders resulting from one or more neurotransmitter imbalances, by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more mood disorders resulting from serotonin imbalance by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more mood disorders resulting from dopamine imbalance by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more mood disorders resulting from norepinephrine imbalance by administering the compound or combination as described herein.
[0457] In an embodiment, there is provided a method of treating one or more epilepsy disorders by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more pain disorders by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more inflammatory disorders by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more psychiatric disorders, such as schizophrenia or borderline personality disorder, by administering the compound or combination as described herein.
[0458] In an embodiment, there is provided a method of treating one or more disorders resulting from brain injury by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more addiction disorders by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more neurodevelopmental disorders, such as autism spectrum disorders or attention-deficit / hyperactivity disorder, by administering the compound or combination as described herein. In an embodiment, there is provided a method of treating one or more circadian rhythm disorders by administering the compound or combination as described herein. In an embodiment, there is provided a compound, or pharmaceutically acceptable salt thereof, selected from the following:
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470]
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477] In an embodiment, there is provided the use of the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, or a pharmaceutical composition as described herein, in a method of treatment.In an embodiment, there is provided a method of treatment comprising administering the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, or a pharmaceutical composition as described herein to a patient in need thereof. In an embodiment, there is provided a method of treatment of:
[0478] one or more neurodegenerative diseases;
[0479] Alzheimer's disease, Parkinson's disease or Huntington's disease;
[0480] one or more mood disorders;
[0481] depression, bipolar disorder or anxiety;
[0482] one or more epilepsy disorders;
[0483] one or more pain disorders;
[0484] one or more inflammatory disorders;
[0485] one or more psychiatric disorders;
[0486] schizophrenia or borderline personality disorder;
[0487] one or more disorders resulting from brain injury;
[0488] one or more addiction disorders;
[0489] one or more neurodevelopmental disorders;
[0490] autism spectrum disorders or attention-deficit / hyperactivity disorder; or
[0491] one or more circadian rhythm disorders;
[0492] comprising administering the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, or a pharmaceutical composition as described herein to a patient in need thereof.
[0493] In an embodiment, there is provided a method of treatment of one or more circadian rhythm disorders comprising administering the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, or a pharmaceutical composition as described herein to a patient in need thereof.
[0494] In an embodiment, there is provided the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, or a pharmaceutical composition as described herein, for use in medicine.
[0495] In an embodiment, there is provided the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, or a pharmaceutical composition as described herein, for use in the treatment of:
[0496] one or more neurodegenerative diseases;
[0497] Alzheimer's disease, Parkinson's disease or Huntington's disease;
[0498] one or more mood disorders;
[0499] depression, bipolar disorder or anxiety;
[0500] one or more epilepsy disorders;
[0501] one or more pain disorders;
[0502] one or more inflammatory disorders;
[0503] one or more psychiatric disorders;
[0504] schizophrenia or borderline personality disorder;
[0505] one or more disorders resulting from brain injury;
[0506] one or more addiction disorders;
[0507] one or more neurodevelopmental disorders;
[0508] autism spectrum disorders or attention-deficit / hyperactivity disorder; or
[0509] one or more circadian rhythm disorders.In an embodiment, there is provided the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, or a pharmaceutical composition as described herein, for use in the treatment of one or more circadian rhythm disorders.
[0510] In an embodiment, there is provided the use of the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, as described herein, for the manufacture of a medicament.
[0511] In an embodiment, there is provided the use of the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, as described herein, for the manufacture of a medicament for the treatment of:
[0512] one or more neurodegenerative diseases;
[0513] Alzheimer's disease, Parkinson's disease or Huntington's disease;
[0514] one or more mood disorders;
[0515] depression, bipolar disorder or anxiety;
[0516] one or more epilepsy disorders;
[0517] one or more pain disorders;
[0518] one or more inflammatory disorders;
[0519] one or more psychiatric disorders;
[0520] schizophrenia or borderline personality disorder;
[0521] one or more disorders resulting from brain injury;
[0522] one or more addiction disorders;
[0523] one or more neurodevelopmental disorders;
[0524] autism spectrum disorders or attention-deficit / hyperactivity disorder; or
[0525] one or more circadian rhythm disorders.
[0526] In an embodiment, there is provided the use of a the compound or combination as described herein, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, as described herein, for the manufacture of a medicament for the treatment of one or more circadian rhythm disorders. Salts
[0527] It will be appreciated that for use in medicine the salts of the compound of the invention should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art. Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci.
[0528] 1977, 66, pp. 1-19. Such pharmaceutically acceptable salts include acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Other salts e.g. oxalates or formates may be used, for example in the isolation of the compound of the invention and are included within the scope of this invention. However, salts that are not pharmaceutically acceptable may also be prepared as intermediate forms which may then be converted into pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salts forms, which may be useful, for example, in the purification or separation of the compounds of the invention, also form part of the invention.
[0529] In one embodiment, the / each compound of the invention is present within the pharmaceutical composition as the free base.
[0530] SolvatesThose skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a complex with water is known as a "hydrate". Pharmaceutically acceptable solvates of the compound of the invention are within the scope of the invention. In one embodiment, the pharmaceutically acceptable solvates of the compounds of the invention include the hydrate thereof.
[0531] Pharmaceutical Compositions
[0532] While it is possible for the compound of the invention to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation). In one embodiment this is a sterile pharmaceutical composition.
[0533] Thus, the invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising (e.g. admixing) compound of the invention, together with one or more pharmaceutically acceptable excipients and optionally other therapeutic or prophylactic agents, as described herein.
[0534] The pharmaceutically acceptable excipient(s) can be selected from, for example, carriers (e.g. a solid, liquid or semi-solid carrier), adjuvants, diluents, fillers or bulking agents, granulating agents, coating agents, release-controlling agents, binding agents, disintegrants, lubricating agents, preservatives, antioxidants, buffering agents, suspending agents, thickening agents, flavouring agents, sweeteners, taste masking agents, stabilisers or any other excipients conventionally used in pharmaceutical compositions. Examples of excipients for various types of pharmaceutical compositions are set out in more detail below.
[0535] The term "pharmaceutically acceptable" as used herein pertains to compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
[0536] Pharmaceutical compositions containing compounds of the invention can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
[0537] The pharmaceutical compositions can be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ophthalmic, optic, rectal, intra-vaginal, or transdermal administration. In one embodiment, the compound of the invention may be administered directly to the ear or eye.
[0538] Where the compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery. The delivery can be by bolus injection, short term infusion or longer term infusion and can be via passive delivery or through the utilisation of a suitable infusion pump or syringe driver.
[0539] Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, co-solvents, surface active agents, organic solvent mixtures, cyclodextrin complexation agents, emulsifying agents (for forming and stabilizing emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymeric gels, lyophilisation protectants and combinations of agents for, inter alia, stabilising the active ingredient in a soluble form and rendering the formulation isotonic with the blood of the intended recipient. Pharmaceuticalformulations for parenteral administration may also take the form of aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents (R. G. Strickly, Solubilizing Excipients in oral and injectable formulations, Pharmaceutical Research, Vol 21(2) 2004, p 201-230).
[0540] The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules, vials and prefilled syringes, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. In one embodiment, the formulation is provided as an active pharmaceutical ingredient in a bottle for subsequent reconstitution using an appropriate diluent.
[0541] The pharmaceutical formulation can be prepared by lyophilising compound of the invention. Lyophilisation refers to the procedure of freeze-drying a composition. Freeze-drying and lyophilisation are therefore used herein as synonyms.
[0542] Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
[0543] Pharmaceutical compositions of the present invention for parenteral injection can also comprise pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as sunflower oil, safflower oil, corn oil or olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of thickening or coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0544] The compositions of the present invention may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include agents to adjust tonicity such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
[0545] In one particular embodiment of the invention, the pharmaceutical composition is in a form suitable for i.v. administration, for example by injection or infusion. For intravenous administration, the solution can be dosed as is, or can be injected into an infusion bag (containing a pharmaceutically acceptable excipient, such as 0.9% saline or 5% dextrose), before administration.
[0546] In another particular embodiment, the pharmaceutical composition is in a form suitable for sub-cutaneous (s.c.) administration.
[0547] Pharmaceutical dosage forms suitable for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, liquids such as emulsions, cachets, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers or patches such as buccal patches.
[0548] Thus, tablet compositions can contain a unit dosage of active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, e.g.; lactose, sucrose, sorbitol or mannitol; and / or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof such as microcrystalline cellulose (MCC), methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, andstarches such as corn starch. Tablets may also contain such standard ingredients as binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g. swellable crosslinked polymers such as crosslinked carboxymethylcellulose), lubricating agents (e.g. stearates), preservatives (e.g. parabens), antioxidants (e.g. BHT), buffering agents (for example phosphate or citrate buffers), and effervescent agents such as citrate / bicarbonate mixtures. Such excipients are well known and do not need to be discussed in detail here. Tablets may be designed to release the drug either upon contact with stomach fluids (immediate release tablets) or to release in a controlled manner (i.e. controlled release tablets, such as enteric coated formulations) over a prolonged period of time or with a specific region of the Gl tract.
[0549] Capsule formulations may be of the hard gelatin or soft gelatin variety and can contain the active component in solid, semi-solid, or liquid form. Gelatin capsules can be formed from animal gelatin or synthetic or plant derived equivalents thereof.
[0550] The solid dosage forms (eg; tablets, capsules etc.) can be coated or un-coated. Coatings may act either as a protective film (e.g. a polymer, wax or varnish) or as a mechanism for controlling drug release or for aesthetic or identification purposes. The coating (e.g. a Eudragit ™ type polymer) can be designed to release the active component at a desired location within the gastro-intestinal tract. Thus, the coating can be selected so as to degrade under certain pH conditions within the gastrointestinal tract, thereby selectively release the compound in the stomach or in the ileum, duodenum, jejenum or colon.
[0551] Instead of, or in addition to, a coating, the drug can be presented in a solid matrix comprising a release controlling agent, for example a release delaying agent which may be adapted to release the compound in a controlled manner in the gastrointestinal tract. Alternatively the drug can be presented in a polymer coating e.g. a polymethacrylate polymer coating, which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract. Alternatively, the matrix material or release retarding coating can take the form of an erodible polymer (e.g. a maleic anhydride polymer) which is substantially continuously eroded as the dosage form passes through the gastrointestinal tract. In another alternative, the coating can be designed to disintegrate under microbial action in the gut. As a further alternative, the active compound can be formulated in a delivery system that provides osmotic control of the release of the compound. Osmotic release and other delayed release or sustained release formulations (for example formulations based on ion exchange resins) may be prepared in accordance with methods well known to those skilled in the art.
[0552] The compound of the invention may be formulated with a carrier and administered in the form of nanoparticles, the increased surface area of the nanoparticles assisting their absorption. In addition, nanoparticles offer the possibility of direct penetration into the cell. Nanoparticle drug delivery systems are described in " Nanoparticle Technology for Drug Delivery", edited by Ram B Gupta and Uday B. Kompella, Informa Healthcare, ISBN 9781574448573, published 13thMarch 2006. Nanoparticles for drug delivery are also described in J. Control. Release, 2003, 91 (1-2), 167-172, and in Sinha et al., Mol. Cancer Ther. August 1, (2006) 5, 1909.
[0553] The pharmaceutical compositions typically comprise from approximately 1% (w / w) to approximately 95% (w / w) active ingredient and from 99% (w / w) to 5% (w / w) of a pharmaceutically acceptable excipient or combination of excipients. Particularly, the compositions comprise from approximately 20% (w / w) to approximately 90%,% (w / w) active ingredient and from 80% (w / w) to 10% of a pharmaceutically acceptable excipient or combination of excipients. The pharmaceutical compositions comprise from approximately 1% to approximately 95%, particularly from approximately 20% to approximately 90%, active ingredient.
[0554] Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, pre-filled syringes, dragees, tablets or capsules.The pharmaceutically acceptable excipient(s) can be selected according to the desired physical form of the formulation and can, for example, be selected from diluents (e.g solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and co-solvents), disintegrants, buffering agents, lubricants, flow aids, release controlling (e.g. release retarding or delaying polymers or waxes) agents, binders, granulating agents, pigments, plasticizers, antioxidants, preservatives, flavouring agents, taste masking agents, tonicity adjusting agents and coating agents.
[0555] The skilled person will have the expertise to select the appropriate amounts of ingredients for use in the formulations. For example tablets and capsules typically contain 0-20% disintegrants, 0-5% lubricants, 0-5% flow aids and / or 0-99% (w / w) fillers / or bulking agents (depending on drug dose). They may also contain 0-10% (w / w) polymer binders, 0-5% (w / w) antioxidants, 0-5% (w / w) pigments. Slow release tablets would in addition contain 0-99% (w / w) release-controlling (e.g. delaying) polymers (depending on dose). The film coats of the tablet or capsule typically contain 0-10% (w / w) polymers, 0-3% (w / w) pigments, and / or 0-2% (w / w) plasticizers.
[0556] Parenteral formulations typically contain 0-20% (w / w) buffers, 0-50% (w / w) cosolvents, and / or 0-99% (w / w) Water for Injection (WFI) (depending on dose and if freeze dried). Formulations for intramuscular depots may also contain 0-99% (w / w) oils.
[0557] Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. It is also possible for them to be incorporated into a polymer or waxy matrix that allow the active ingredients to diffuse or be released in measured amounts.
[0558] The compounds of the invention can also be formulated as solid dispersions. Solid dispersions are homogeneous extremely fine disperse phases of two or more solids. Solid solutions (molecularly disperse systems), one type of solid dispersion, are well known for use in pharmaceutical technology (see (Chiou and Riegelman, J. Pharm. Sci., 60, 1281-1300 (1971)) and are useful in increasing dissolution rates and increasing the bioavailability of poorly water-soluble drugs.
[0559] This invention also provides solid dosage forms comprising the solid solution described above. Solid dosage forms include tablets, capsules, chewable tablets and dispersible or effervescent tablets. Known excipients can be blended with the solid solution to provide the desired dosage form. For example, a capsule can contain the solid solution blended with (a) a disintegrant and a lubricant, or (b) a disintegrant, a lubricant and a surfactant. In addition a capsule can contain a bulking agent, such as lactose or microcrystalline cellulose. A tablet can contain the solid solution blended with at least one disintegrant, a lubricant, a surfactant, a bulking agent and a glidant. A chewable tablet can contain the solid solution blended with a bulking agent, a lubricant, and if desired an additional sweetening agent (such as an artificial sweetener), and suitable flavours. Solid solutions may also be formed by spraying solutions of drug and a suitable polymer onto the surface of inert carriers such as sugar beads ('non-pareils'). These beads can subsequently be filled into capsules or compressed into tablets.
[0560] The pharmaceutical formulations may be presented to a patient in "patient packs" containing an entire course of treatment in a single package, usually a blister pack. Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in patient prescriptions. The inclusion of a package insert has been shown to improve patient compliance with the physician's instructions.Compositions for topical use and nasal delivery include ointments, creams, sprays, transdermal via patches, gels, liquid drops and inserts (for example intraocular inserts). Such compositions can be formulated in accordance with known methods.
[0561] Examples of formulations for rectal or intra-vaginal administration include pessaries and suppositories which may be, for example, formed from a shaped moldable or waxy material containing the active compound. Solutions of the active compound may also be used for rectal administration.
[0562] Compositions for administration by inhalation may take the form of inhalable powder compositions or liquid or powder sprays, and can be administrated in standard form using powder inhaler devices or aerosol dispensing devices. Such devices are well known. For administration by inhalation, the powdered formulations typically comprise the active compound together with an inert solid powdered diluent such as lactose.
[0563] The compound of the invention will generally be presented in unit dosage form and, as such, will typically contain sufficient compound to provide a desired level of biological activity. For example, a formulation may contain from 1 nanogram to 2 grams of active ingredient, e.g. from 1 nanogram to 2 milligrams of active ingredient. Within these ranges, particular sub-ranges of compound are 0.1 milligrams to 2 grams of active ingredient (more usually from 10 milligrams to 1 gram, e.g. 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (for example 1 microgram to 10 milligrams, e.g. 0.1 milligrams to 2 milligrams of active ingredient).
[0564] For oral compositions, a unit dosage form may contain from 1 milligram to 2 grams, more typically 10 milligrams to 1 gram, for example 50 milligrams to 1 gram, e.g. 100 miligrams to 1 gram, of active compound. The compound of the invention will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect.
[0565] Parenteral administration, including subcutaneous, intravenous, intramuscular and infusions includes both sterile injectable aqueous or oleaginous suspensions.
[0566] Combination Therapy
[0567] The compound of the invention can be administered as the sole therapeutic agent or can be administered in combination therapy with one of more other compounds (or therapies) for treatment of a particular disease state.
[0568] In some embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof and (b) an agent are sequentially administered, concurrently administered or simultaneously administered. In certain embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof and (b) an agent are administered with a time separation of about 15 minutes or less, such as about any of 10, 5, or 1 minutes or less. In certain embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof and (b) an agent are administered with a time separation of about 15 minutes or more, such as about any of 20, 30, 40, 50, 60, or more minutes. Either of (a) a compound described herein, or a pharmaceutically acceptable salt thereof and (b) an agent may be administered first. In certain embodiments, (a) a compound described herein, or a pharmaceutically acceptable salt thereof and (b) an agent are administered simultaneously.
[0569] Methods Of Synthesis
[0570] In an embodiment, there is provided a method of synthesis of the compound or combination as described herein. The method of synthesis may comprise any one of the synthetic routes, steps or transformationsdescribed in the following examples. The methods of synthesis are not only limited to the conditions, solvents and reagents described in the following examples. The synthetic routes disclosed herein, and therefore the methods of synthesis, may be applicable to numerous compounds, including compounds which themselves are not disclosed herein.
[0571] Further Definitions
[0572] The term "treatment", in relation to the uses of any of the compounds described herein is used to describe any form of intervention where a compound is administered to a subject suffering from, or at risk of suffering from, or potentially at risk of suffering from the disease or disorder in question. Thus, the term "treatment" covers both preventative (prophylactic) treatment and treatment where measurable or detectable symptoms of the disease or disorder are being displayed.
[0573] The term "therapeutically effective amount" (for example in relation to methods of treatment of a disease or condition) refers to an amount of the compound which is effective to produce a desired therapeutic effect. For example, if the condition is pain, then the effective therapeutic amount is an amount sufficient to provide a desired level of pain relief. The desired level of pain relief may be, for example, complete removal of the pain or a reduction in the severity of the pain.
[0574] Chemical terms are all used in their conventional sense (e.g. as defined in the IUPAC Gold Book), unless indicated otherwise.
[0575] The term "alkyl" as used herein, refers to a straight or branched chain, saturated alkyl group.
[0576] The term "alkoxy" as used herein, refers to a straight or branched chain, saturated alkoxy (-O-alkyl) group. The term "thioalkyl" as used herein, refers to a straight or branched chain, saturated thioalkyl (-S-alkyl) group. The term "alkenyl" as used herein, refers to a straight or branched chain alkyl group which is fully or partially unsaturated.
[0577] The term "carbocyclic" as used herein, refers to a saturated or unsaturated carbocyclic group containing the indicated number of carbon atoms.
[0578] The term "heterocyclic" as used herein, refers to a saturated or unsaturated ring containing the indicated number of total ring member atoms in which one or more of the ring members is a heteroatom selected from O, S and N, and oxidised forms thereof and the remaining atoms are C.
[0579] Where heteroatoms are mentioned without further attachment in a Markush definition, e.g. nitrogen, oxygen, sulphur, it should be understood that the valencies of these atoms would be satisfied, e.g. by one or more bonds / groups.
[0580] The number of carbon atoms that are possible in the referenced groups herein may be indicated by subscript " Cni-n2". Thus, for example, the term " C1-3 alkyl" represents an alkyl group having 1, 2 or 3 carbon atoms and includes methyl, ethyl, n-propyl and iso-propyl.
[0581] The term "optionally substituted" as applied to any group means that the said group may if desired be substituted with one or more substituents, which may be the same or different. Thus, for example, the term "optionally substituted with 1-6 fluorine atoms" as applied to a group means that the said group may if desired be substituted with 1, 2, 3, 4, 5 or 6 fluorine atoms.To the extent that any of the compounds described have chiral centres, the present invention extends to all optical isomers of such compounds, whether in the form of racemates or resolved enantiomers. The invention described herein relates to all crystal forms, solvates and hydrates of any of the disclosed compounds however so prepared. To the extent that any of the compounds disclosed herein have acid or basic centres such as carboxylates or amino groups, then all salt forms of said compounds are included herein. In the case of pharmaceutical uses, the salt should be seen as being a pharmaceutically acceptable salt.
[0582] The compounds of the invention may contain one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element. For example, a reference to hydrogen includes within its scope1H,2H (D), and3H (T). Similarly, references to carbon and oxygen include within their scope respectively12C,13C and14C and16O and18O. In an analogous manner, a reference to a particular functional group also includes within its scope isotopic variations, unless the context indicates otherwise. For example, a reference to an alkyl group such as an ethyl group or an alkoxy group such as a methoxy group also covers variations in which one or more of the hydrogen atoms in the group is in the form of a deuterium or tritium isotope, e.g. as in an ethyl group in which all five hydrogen atoms are in the deuterium isotopic form (a perdeuteroethyl group) or a methoxy group in which all three hydrogen atoms are in the deuterium isotopic form (a trideuteromethoxy group). The isotopes may be radioactive or non-radioactive.
[0583] Examples
[0584] Example 1 - Synthesis Routes
[0585] A general route of synthesis for compounds 2-1 to 2-7 is as follows:
[0586] Start with 5-hydroxyindole as the base compound. Protect the indole nitrogen with a suitable protecting group (e.g., tert-butyloxycarbonyl, Boc). Perform an aminomethylation to introduce the 2-aminoethyl side chain at the 3-position. For compounds with alkoxy substituents at the 5-position: perform a nucleophilic substitution of phenol ether synthesis using the appropriate alkyl halide and base. For compounds with unsaturated substituents (e.g., allyl, propargyl): use the corresponding unsaturated alkyl halide in the nucleophilic substitution of phenol ether synthesis. Deprotect the indole nitrogen. Acetylate the primary amine to form the final acetamide.
[0587] A general route of synthesis for compounds 2-8 to 2-13 is as follows:
[0588] As above, see the general route for compound 2-1 to 2-7. For compounds with alkynyl substituents: use propargyl bromide or similar alkynyl halides in the nucleophilic substitution of phenol ether synthesis. For compounds with cycloalkyl substituents: use cycloalkyl halides or cycloalkyl methyl halides in the nucleophilic substitution of phenol ether synthesis.
[0589] A general route of synthesis for compounds 2-14 to 2-21 is as follows:
[0590] As above, see the general route for compound 2-1 to 2-7. For compounds with cycloalkyloxy substituents: use cycloalkyl halides in the nucleophilic substitution of phenol ether synthesis. For compounds with aryloxy or benzyloxy substituents: use aryl halides or benzyl halides in the nucleophilic substitution of phenol ether synthesis. For compounds with fluorinated substituents:
[0591] use fluorinated alkyl halides in the nucleophilic substitution of phenol ether synthesis.
[0592] A general route of synthesis for compounds 2-22 to 2-31 is as follows:
[0593] As above, see the general route for compound 2-1 to 2-7. For compounds with heterocyclic substituents: use appropriate heterocyclic halides in the nucleophilic substitution of phenol ether synthesis. For compounds with amine-containing substituents: use halides containing protected amines in the nucleophilic substitution of phenol ether synthesis. Deprotect the amine after the ether formation. For compounds with trifluoromethoxy or halomethoxy substituents: use trifluoromethyl triflate or appropriate halomethyl halides in the ether synthesis.A general route of synthesis for compounds 2-32 to 2-41 is as follows:
[0594] As above, see the general route for compound 2-1 to 2-7. For compounds with halogenated alkoxy substituents: use appropriately halogenated alkyl halides in the nucleophilic substitution of phenol ether synthesis. For compounds with branched alkoxy substituents: use branched alkyl halides in the nucleophilic substitution of phenol ether synthesis. For compounds with alkoxymethoxy substituents: first form the chloromethyl ether at the 5-position, then perform a second ether synthesis with the appropriate alkoxide.
[0595] A general route of synthesis for compounds 2-42 to 2-49 is as follows:
[0596] As above, see the general route for compound 2-1 to 2-7. For compounds with alkoxymethoxy and alkoxyethoxy substituents: first form the chloromethyl or chloroethyl ether at the 5-position, then perform a second ether synthesis with the appropriate alkoxide.
[0597] For compounds with hydroxy or amino substituents: these can be obtained by deprotection of appropriate precursors (e.g., benzyl ether for hydroxy, carbamate for amino). For compounds with amine-containing substituents: use halides containing protected amines in the nucleophilic substitution of phenol ether synthesis. Deprotect the amine after the ether formation.
[0598] A general route of synthesis for compounds 2-50 to 2-58 is as follows:
[0599] As above, see the general route for compound 2-1 to 2-7. For compounds with amine-containing substituents: use halides containing protected amines in the nucleophilic substitution of phenol ether synthesis. Deprotect the amine after the ether formation. For compounds with ester-containing substituents: use halides containing protected esters in the nucleophilic substitution of phenol ether synthesis. Deprotect the ester after the ether formation if necessary. For compounds with thioether substituents: use sodium thioethoxide or similar reagents instead of alkoxides in the ether synthesis step.
[0600] A general route of synthesis for compounds 2-59 to 2-62 is as follows:
[0601] As above, see the general route for compound 2-1 to 2-7. For compounds with alkyl substituents: start with appropriately substituted indoles or introduce the alkyl group via Friedel-Crafts alkylation. For compounds with halogenated alkyl substituents: introduce the halogenated alkyl group via electrophilic aromatic substitution or start with appropriately substituted indoles. For compounds with amino substituents: start with nitro-substituted indoles and reduce to the corresponding amines.
[0602] A general route of synthesis for compounds 2-63 to 2-69 is as follows:
[0603] As above, see the general route for compound 2-1 to 2-7. For compounds with halogenated alkyl substituents: introduce the halogenated alkyl group via electrophilic aromatic substitution or start with appropriately substituted indoles. For compounds with amino substituents: start with nitro-substituted indoles and reduce to the corresponding amines. For alkylated amines, perform reductive amination on the amino group. For compounds with cycloalkyl substituents: introduce the cycloalkyl group via Friedel-Crafts alkylation or start with appropriately substituted indoles.
[0604] A general route of synthesis for compounds 2-70 to 2-74 is as follows:
[0605] As above, see the general route for compound 2-1 to 2-7. For compounds with cycloalkyl substituents: introduce the cycloalkyl group via Friedel-Crafts alkylation or start with appropriately substituted indoles. For compounds with aryl or benzyl substituents: introduce these groups via Suzuki coupling or similar crosscoupling reactions. For compounds with heteroarylmethoxy substituents: perform nucleophilic substitution of phenol ether synthesis using the appropriate heteroarylmethyl halide.
[0606] Example 2 - Synthesis Routes
[0607] N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide (NAS1) may be prepared as follows:Step 1: Begin with 5-Methoxyindole. Step 2: React 5-Methoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent known to the person skilled in the art. Conditions: Typical ly, this reaction is performed under mild conditions with an appropriate solvent such as DMF (Dimethylformamide) or THF (Tetrahydrofuran). The potassium carbonate acts as a base to facilitate the reaction.
[0608] N-[2-(5-Fluoro-1H-indol-3-yl)ethyl]acetamide (NAS2) may be prepared as follows:
[0609] Step 1: Start with 5-Fluoroindole. Step 2: React 5-Fluoroindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Similar to the previous synthesis, this reaction can be performed under mild conditions using a suitable solvent and potassium carbonate as the base.
[0610] N-[2-(5-Chloro-1H-indol-3-yl)ethyl]acetamide (NAS3) may be prepared as follows:
[0611] Step 1: Begin with 5-Chloroindole. Step 2: React 5-Chloroindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: The reaction conditions are similar to the synthesis of the previous compounds, employing a mild base and a suitable solvent.
[0612] N-[2-(5-Bromo-1H-indol-3-yl)ethyl]acetamide (NAS4) may be prepared as follows:
[0613] Step 1: Start with 5-Bromoindole. Step 2: React 5-Bromoindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: The synthesis is conducted under conditions similar to the previous steps, using potassium carbonate as a base and a suitable solvent.
[0614] N-[2-(5-Methyl-1H-indol-3-yl)ethyl]acetamide (NAS5) may be prepared as follows:
[0615] Step 1: Begin with 5-Methylindole. Step 2: React 5-Methylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Like the previous compounds, this synthesis involves the use of potassium carbonate as a base and a suitable solvent.
[0616] N-[2-(5-Nitro-1H-indol-3-yl)ethyl]acetamide (NAS6) may be prepared as follows:
[0617] Step 1: Start with 5-Nitroindole. Step 2: Reduce 5-Nitroindole to 5-Aminoindole, typically using hydrogen gas in the presence of a catalyst like palladium on carbon (Pd / C). Step 3: React 5-Aminoindole with 2-(chloroethyl)acetamide. Reagents: Hydrogen gas, palladium on carbon (Pd / C), potassium carbonate, appropriate solvent. Conditions: The reduction of 5-Nitroindole to 5-Aminoindole requires specialized conditions with hydrogen gas and a catalyst. Subsequent steps follow conditions similar to the previous syntheses.
[0618] N-[2-(5-Amino-1H-indol-3-yl)ethyl]acetamide (NAS7) may be prepared as follows:
[0619] Step 1: Begin with 5-Aminoindole. Step 2: React 5-Aminoindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: This synthesis is similar to the previous ones, using potassium carbonate as a base and an appropriate solvent.
[0620] N-[2-(5-Methylthio-1H-indol-3-yl)ethyl]acetamide (NAS8) may be prepared as follows:
[0621] Step 1: Start with 5-Methylthioindole. Step 2: React 5-Methylthioindole with 2-(chloroethyl)acetamide.
[0622] Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0623] N-[2-(5-Isopropoxy-1H-indol-3-yl)ethyl]acetamide (NAS9) may be prepared as follows:
[0624] Step 1: Begin with 5-Isopropoxyindole. Step 2: React 5-Isopropoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0625] N-[2-(5-Ethoxy-1H-indol-3-yl)ethyl]acetamide (NAS10) may be prepared as follows:Step 1: Start with 5-Ethoxyindole. Step 2: React 5-Ethoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions similar to the previous syntheses, using potassium carbonate as a base and a suitable solvent.
[0626] N-[2-(5-Hydroxy-2-methyl-1H-indol-3-yl)ethyl]acetamide (NAS11) may be prepared as follows:
[0627] Step 1: Begin with 5-Hydroxy-2-methylindole. Step 2: React 5-Hydroxy-2-methylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Follow conditions similar to the previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0628] N-[2-(5-Cyano-1H-indol-3-yl)ethyl]acetamide (NAS12) may be prepared as follows:
[0629] Step 1: Start with 5-Cyanoindole. Step 2: React 5-Cyanoindole with 2-(chloroethyl)acetamide.
[0630] Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions similar to the previous syntheses, using potassium carbonate as a base and a suitable solvent.
[0631] N-[2-(5-Propoxy-1H-indol-3-yl)ethyl]acetamide (NAS13) may be prepared as follows:
[0632] Step 1: Begin with 5-Propoxyindole. Step 2: React 5-Propoxyindole with 2-(chloroethyl)acetamide.
[0633] Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and a suitable solvent.
[0634] N-[2-(5-Benzyloxy-1H-indol-3-yl)ethyl]acetamide (NAS14) may be prepared as follows:
[0635] Step 1: Start with 5-Benzyloxyindole. Step 2: React 5-Benzyloxyindole with 2-(chloroethyl)acetamide.
[0636] Reagents: Potassium carbonate, appropriate solvent. Conditions: Follow conditions similar to the previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0637] N-[2-(5-Formyl-1H-indol-3-yl)ethyl]acetamide (NAS15) may be prepared as follows:
[0638] Step 1: Start with 5-Formylindole. Step 2: React 5-Formylindole with 2-(chloroethyl)acetamide.
[0639] Reagents: Potassium carbonate, appropriate solvent. Conditions: This synthesis follows a pattern similar to the previously described compounds. Begin with 5-Formylindole and react it with 2-(chloroethyl)acetamide using potassium carbonate as a base and an appropriate solvent.
[0640] N-[2-(5-Formyl-1H-indol-3-yl)ethyl]acetamide (NAS16) may be prepared as follows:
[0641] Step 1: Start with 5-Formylindole. Step 2: React 5-Formylindole with 2-(chloroethyl)acetamide.
[0642] Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0643] N-[2-(5-Methylsulfonyl-1H-indol-3-yl)ethyl]acetamide (NAS17) may be prepared as follows:
[0644] Step 1: Begin with 5-Methylsulfonylindole. Step 2: React 5-Methylsulfonylindole with 2-(chloroethyl)acetamide.
[0645] Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0646] N-[2-(5-Ethylthio-1H-indol-3-yl)ethyl]acetamide (NAS18) may be prepared as follows:
[0647] Step 1: Commence with 5-Ethylthioindole. Step 2: React 5-Ethylthioindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0648] N-[2-(5-Methylamino-1H-indol-3-yl)ethyl]acetamide (NAS19) may be prepared as follows:
[0649] Step 1: Begin with 5-Methylaminoindole. Step 2: React 5-Methylaminoindole with 2-(chloroethyl)acetamide.Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0650] N-[2-(5-Ethyl-lH-indol-3-yl)ethyl]acetamide (NAS20) may be prepared as follows:
[0651] Synthesis: Step 1: Begin with 5-Ethylindole. Step 2: React 5-Ethylindole with 2-(chloroethyl)acetamide.
[0652] Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0653] N-[2-(5-Isobutoxy-1H-indol-3-yl)ethyl]acetamide (NAS21) may be prepared as follows:
[0654] Synthesis: Step 1: Start with 5-Isobutoxyindole. Step 2: React 5-Isobutoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0655] N-[2-(5-Carboxy-1H-indol-3-yl)ethyl]acetamide (NAS22) may be prepared as follows:
[0656] Synthesis: Step 1: Begin with 5-Carboxyindole. Step 2: React 5-Carboxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0657] N-[2-(5-Methylthiomethyl-1H-indol-3-yl)ethyl]acetamide (NAS23) may be prepared as follows:
[0658] Synthesis: Step 1: Begin with 5-Methylthiomethylindole. Step 2: React 5-Methylthiomethylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to previous syntheses, using potassium carbonate as a base and an appropriate solvent.
[0659] N-[2-(5-Isobutyl-1H-indol-3-yl)ethyl]acetamide (NAS24) may be prepared as follows:
[0660] Synthesis: Step 1: Start with 5-Isobutylindole. Step 2: React 5-Isobutylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0661] N-[2-(5-Cyclopropyl-1H-indol-3-yl)ethyl]acetamide (NAS25) may be prepared as follows:
[0662] Synthesis: Step 1: Begin with 5-Cyclopropylindole. Step 2: React 5-Cyclopropylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0663] N-[2-(5-Methoxy-2-methyl-1H-indol-3-yl)ethyl]acetamide (NAS26) may be prepared as follows:
[0664] Step 1: Start with 5-Methoxy-2-methylindole. Step 2: React 5-Methoxy-2-methylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0665] N-[2-(5-Fluoromethyl-1H-indol-3-yl)ethyl]acetamide (NAS27) may be prepared as follows:
[0666] Step 1: Begin with 5-Fluoromethylindole. Step 2: React 5-Fluoromethylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0667] N-[2-(5-Ethylsulfonyl-1H-indol-3-yl)ethyl]acetamide (NAS28) may be prepared as follows:
[0668] Step 1: Start with 5-Ethylsulfonylindole. Step 2: React 5-Ethylsulfonylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0669] N-[2-(5-Butylthio-1H-indol-3-yl)ethyl]acetamide (NAS29) may be prepared as follows:Step 1: Begin with 5-Butylthioindole. Step 2: React 5-Butylthioindole with 2-(chloroethyl)acetamide.
[0670] Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0671] N-[2-(5-Hvdroxy-lH-indol-2-yl)ethyl]acetamide (NAS30) may be prepared as follows:
[0672] Step 1: Start with 5-Hydroxy-lH-indole. Step 2: React 5-Hydroxy-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0673] N-[2-(5-lsopropylthio-lH-indol-3-yl)ethyl]acetamide (NAS31) may be prepared as follows:
[0674] Step 1: Begin with 5-lsopropylthioindole. Step 2: React 5-lsopropylthioindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0675] N-[2-(5-Hvdroxy-3-methyl-lH-indol-3-yl)ethyl]acetamide (NAS32) may be prepared as follows:
[0676] Step 1: Start with 5-Hydroxy-3-methyl-lH-indole. Step 2: React 5-Hydroxy-3-methyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0677] N-[2-(5-Cvclohexyl-lH-indol-3-yl)ethyl]acetamide (NAS33) may be prepared as follows:
[0678] Step 1: Begin with 5-Cyclohexylindole. Step 2: React 5-Cyclohexylindole with 2-(chloroethyl)acetamide.
[0679] Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0680] N-[2-(5-Methylthiomethoxy-lH-indol-3-yl)ethyl]acetamide (NAS34) may be prepared as follows:
[0681] Step 1: Start with 5-Methylthiomethoxyindole. Step 2: React 5-Methylthiomethoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0682] N-[2-(5-lsobutylthio-lH-indol-3-yl)ethyl]acetamide (NAS35) may be prepared as follows:
[0683] Step 1: Begin with 5-lsobutylthioindole. Step 2: React 5-lsobutylthioindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0684] N-[2-(5-Hvdroxy-4-methyl-lH-indol-3-yl)ethyl]acetamide (NAS36) may be prepared as follows:
[0685] Step 1: Start with 5-Hydroxy-4-methyl-lH-indole. Step 2: React 5-Hydroxy-4-methyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0686] N-[2-(5-Phenoxy-lH-indol-3-yl)ethyl]acetamide (NAS37) may be prepared as follows:
[0687] Step 1: Begin with 5-Phenoxyindole. Step 2: React 5-Phenoxyindole with 2-(chloroethyl)acetamide.
[0688] Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0689] N-[2-(5-Butylsulfonyl-lH-indol-3-yl)ethyl]acetamide (NAS38) may be prepared as follows:
[0690] Step 1: Start with 5-Butylsulfonylindole. Step 2: React 5-Butylsulfonylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.N-[2-(5-Fluoro-2-methyl-lH-indol-3-yl)ethyl]acetamide (NAS39) may be prepared as follows:
[0691] Step 1: Begin with 5-Fluoro-2-methylindole. Step 2: React 5-Fluoro-2-methylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0692] N-[2-(5-Hvdroxy-2-propyl-lH-indol-3-yl)ethyl]acetamide (NAS40) may be prepared as follows:
[0693] Step 1: Start with 5-Hydroxy-2-propylindole. Step 2: React 5-Hydroxy-2-propylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0694] N-[2-(5-Butyl-lH-indol-3-yl)ethyl]acetamide (NAS41) may be prepared as follows:
[0695] Step 1: Begin with 5-Butylindole. Step 2: React 5-Butylindole with 2-(chloroethyl)acetamide.
[0696] Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0697] N-[2-(5-Ethylthiomethoxy-lH-indol-3-yl)ethyl]acetamide (NAS42) may be prepared as follows:
[0698] Step 1: Start with 5-Ethylthiomethoxyindole. Step 2: React 5-Ethylthiomethoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0699] N-[2-(5-Propylthio-lH-indol-3-yl)ethyl]acetamide (NAS43) may be prepared as follows:
[0700] Step 1: Begin with 5-Propylthioindole. Step 2: React 5-Propylthioindole with 2-(chloroethyl)acetamide.
[0701] Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0702] N-[2-(5-Methylthioethoxy-lH-indol-3-yl)ethyl]acetamide (NAS44) may be prepared as follows:
[0703] Step 1: Start with 5-Methylthioethoxyindole. Step 2: React 5-Methylthioethoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0704] N-[2-(5-lsobutylsulfonyl-lH-indol-3-yl)ethyl]acetamide (NAS45) may be prepared as follows:
[0705] Step 1: Begin with 5-lsobutylsulfonylindole. Step 2: React 5-lsobutylsulfonylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0706] N-[2-(5-Hvdroxy-3-ethyl-lH-indol-3-yl)ethyl]acetamide (NAS46) may be prepared as follows:
[0707] Step 1: Start with 5-Hydroxy-3-ethyl-lH-indole. Step 2: React 5-Hydroxy-3-ethyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0708] N-[2-(5-Butylthiomethoxy-lH-indol-3-yl)ethyl]acetamide (NAS47) may be prepared as follows:
[0709] Step 1: Begin with 5-Butylthiomethoxyindole. Step 2: React 5-Butylthiomethoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0710] N-[2-(5-Fluoro-3-methyl-lH-indol-3-yl)ethyl]acetamide (NAS48) may be prepared as follows:
[0711] Step 1: Start with 5-Fluoro-3-methyl-lH-indole. Step 2: React 5-Fluoro-3-methyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.N-[2-(5-Hvdroxy-2-butyl-lH-indol-3-yl)ethyl]acetamide (NAS49) may be prepared as follows:
[0712] Step 1: Start with 5-Hydroxy-2-butyl-lH-indole. Step 2: React 5-Hydroxy-2-butyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0713] N-[2-(5-Propylsulfonyl-lH-indol-3-yl)ethyl]acetamide (NAS50) may be prepared as follows:
[0714] Step 1: Begin with 5-Propylsulfonylindole. Step 2: React 5-Propylsulfonylindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0715] N-[2-(5-Methylthiopropoxy-lH-indol-3-yl)ethyl]acetamide (NAS51) may be prepared as follows:
[0716] Step 1: Start with 5-Methylthiopropoxyindole. Step 2: React 5-Methylthiopropoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0717] N-[2-(5-lsopropylthiomethoxy-lH-indol-3-yl)ethyl]acetamide (NAS52) may be prepared as follows:
[0718] Step 1: Begin with 5-lsopropylthiomethoxyindole. Step 2: React 5-lsopropylthiomethoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0719] N-[2-(5-Hvdroxy-4-ethyl-lH-indol-3-yl)ethyl]acetamide (NAS53) may be prepared as follows:
[0720] Step 1: Start with 5-Hydroxy-4-ethyl-lH-indole. Step 2: React 5-Hydroxy-4-ethyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Utilize conditions analogous to previous syntheses, employing potassium carbonate as a base and a suitable solvent.
[0721] N-[2-(5-Hvdroxy-3-propyl-lH-indol-3-yl)ethyl]acetamide (NAS54) may be prepared as follows:
[0722] Step 1: Begin with 5-Hydroxy-3-propyl-lH-indole. Step 2: React 5-Hydroxy-3-propyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.
[0723] N-[2-(5-Butylthioethoxy-lH-indol-3-yl)ethyl]acetamide (NAS55) may be prepared as follows:
[0724] Step 1: Start with 5-Butylthioethoxyindole. Step 2: React 5-Butylthioethoxyindole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Employ conditions similar to the previous syntheses, utilizing potassium carbonate as a base and an appropriate solvent.
[0725] N-[2-(5-Fluoro-4-methyl-lH-indol-3-yl)ethyl]acetamide (NAS56) may be prepared as follows:
[0726] Step 1: Begin with 5-Fluoro-4-methyl-lH-indole. Step 2: React 5-Fluoro-4-methyl-lH-indole with 2-(chloroethyl)acetamide. Reagents: Potassium carbonate, appropriate solvent. Conditions: Use conditions similar to the prior syntheses, with potassium carbonate as the base and a suitable solvent.Example 3 - Further Synthesis Routes
[0727] Further synthetic routes for compounds within the scope of the invention are set out below.
[0728] In an embodiment, there is provided a method of synthesis of one or more compounds as disclosed herein according to one or more of the synthesis routes as disclosed herein. In an embodiment, there is provided one or more compounds, intermediates or products as disclosed herein. In an embodiment, there is provided one or more pharmaceutical compositions or formulations, comprising one or more compounds, intermediates or products as disclosed herein, and one or more pharmaceutically acceptable excipients. The uses of said compounds, intermediates, products or pharmaceutical compositions or formulations thereof, may be as disclosed elsewhere herein.
[0729] Group 1 - Phenolic Derivatives
[0730]
[0731]
[0732]
[0733]
[0734]
[0735]
[0736]
[0737] Group 2 - Alkyl Derivatives
[0738]
[0739] MeOH / H2O reflux
[0740]
[0741]
[0742]
[0743] Alternative:
[0744]
[0745] THF 4 RT...65 °C
[0746]
[0747] Group 3 - Thiophenolic Derivatives
[0748]
[0749]
[0750]
[0751]
[0752]
[0753]
[0754]
[0755] R2= H or Boc
[0756]
[0757]
[0758]
[0759]
[0760]
[0761]
[0762]
[0763] Group 4 - 2-Alkyl-substituted Derivatives
[0764] NHAc NHAc TES / TFA
[0765] CH2Cl2, RT
[0766] NHAc
[0767] 63 %
[0768]
[0769]
[0770] General synthesis schemes for NAS40 and NAS49:
[0771]
[0772] Group 5 - Miscellaneous
[0773]
[0774]
[0775]
[0776]
[0777] General synthesis schemes for NAS16:
[0778]
[0779] EM: 274.13 EM: 232.12 EM: 230.11 MW: 274.32 MW: 232.28 MW: 230.27
[0780] General synthesis schemes for NAS59:Paraformaldehyde Morpholine EtOH, reflux
[0781]
[0782]
[0783]
[0784] EM: 317.17
[0785] MW: 317.39
[0786] General synthesis schemes for NAS60:
[0787]
[0788] General synthesis schemes for NAS58a:
[0789]
[0790]
[0791]
[0792] EM: 317.17
[0793] MW (free base): 317.39 MW (salt): 353.85General synthesis schemes for NAS59a:
[0794]
[0795] MW: 258.32:.
[0796] Group 6 - Alkylated analogues
[0797] General synthesis schemes for NAS48:
[0798]
[0799] Alternative routes:
[0800]
[0801] General synthesis schemes towards NAS32, NAS46 and NAS54:
[0802]
[0803] Example 4 - Further Synthesis Routes
[0804] Further synthetic routes for compounds within the scope of the invention are set out below.
[0805] Example 4a - N-(2-(5-lsopropoxy-lH-indol-3-yl)ethyl)acetamide (NAS9)
[0806] Product summary
[0807]
[0808] Synthetic scheme
[0809]
[0810] 260.33 g / mol
[0811] Experimental
[0812] Step 1 N-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0813] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and themixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford N-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0814] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0815] Step 2 N-(2-(5-lsopropoxy-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-10)
[0816] To N-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (100 mg, 0.46 mmol) and potassium carbonate (317 mg, 2.29 mmol) in anhydrous acetonitrile (3.3 mL) under nitrogen was added 2-iodopropane (233 mg, 137 pL, 1.37 mmol). The reaction mixture was stirred at 80 °C for 20 h. The reaction was filtered and the solids washed with acetonitrile (2 x 10 mL). The combined filtrates were concentrated under reduced pressure. The residue was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford N-(2-(5-isopropoxy-lH-indol-3-yl)ethyl)acetamide (64 mg, 53 %) as a pale-yellow oil.
[0817] LC-MS (+ve mode): m / z = 261.20 [M+H]+.
[0818] Example 4b - N-(2-(5-hvdroxy-2-methyl-lH-indol-3-yl)ethyl)acetamide (NASH)
[0819] Product summary
[0820]
[0821] Synthetic scheme
[0822]
[0823] Experimental
[0824] Step 12-(5-Methoxy-2-methyl-lH-indol-3-yl)-2-oxoacetyl chloride (BP-AZ-1-60)
[0825] A solution of 5-methoxy-2-methylindole (1.27 g, 7.88 mmol) in methyl tert-butyl ether (9 mL) was added to a solution of oxalyl chloride (1.20 g, 9.46 mmol) in methyl tert-butyl ether (8 mL) dropwise at 0 °C under nitrogen. After the addition was complete, the reaction mixture was warmed to room temperature and stirred for 30 min. Petrol (10 mL) was added and stirring was continued for 5 min. The precipitate was collected by Buchner filtration, washed with petrol and air-dried to give 2-(5-methoxy-2-methyl-lH-indol-3-yl)-2-oxoacetyl chloride (1.85 g, 93 %) as a yellow solid which was used in the next step without further purification.
[0826] Step 22-(5-Methoxy-2-methyl-lH-indol-3-yl)-2-oxoacetamide (BP-AZ-1-61)
[0827] A mixture of 35 % aqueous NH3 (5 mL) and tetrahydrofuran (10 mL) was cooled to 0 °C and a solution of 2-(5-methoxy-2-methyl-lH-indol-3-yl)-2-oxoacetyl chloride (1.83 g, 7.28 mmol) in tetrahydrofuran (30 mL) was added dropwise. After the addition was complete, the reaction mixture was warmed to room temperature and stirred for 30 min. The reaction mixture was cooled to 0 °C and cautiously acidified to pH 2 with concentrated hydrochloric acid. Water (30 mL) was added and the layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with satd. brine (50 mL), dried (MgSO₄) and concentrated to afford 2-(5-methoxy-2-methyl-lH-indol-3-yl)-2-oxoacetamide (0.89 g, 53 %) as a yellow solid which was used in the next step without further purification.
[0828] Step 32-(5-Methoxy-2-methyl-lH-indol-3-yl)ethan-l-amine (BP-AZ-1-62)
[0829] Lithium aluminium hydride (2.4 M in tetrahydrofuran, 6.0 mL, 14.4 mmol) was added to a suspension of 2-(5-methoxy-2-methyl-lH-indol-3-yl)-2-oxoacetamide (0.89 g, 3.83 mmol) in anhydrous 2-methyltetrahydrofuran (30 mL) dropwise over 5 min. After the addition was complete, the reaction mixture was stirred at 80 °C for 3 h under nitrogen. The flask was cooled to 0 °C and the reaction was quenched with a mixture of water: tetrahydrofuran (1:3, 4 mL). Silica (1.8 g) and Na2SO4 (1.8 g) were introduced to the flask; the contents were stirred at room temperature for 5 min, filtered through a plug of Celite and washed with a mixture of methanol: dichloromethane (1:9, 100 mL). The combined filtrates were concentrated to give 2-(5-methoxy-2-methyl-lH-indol-3-yl)ethan-l-amine (0.79 g, quant.) as a yellow-green oil which was used in the next step without further purification.LC-MS (+ve mode): m / z = 205.20 [M+H]+.
[0830] Step 4 / V-(2-(5-Methoxy-2-methyl-lH-indol-3-yl)ethyl)acetamide (BP-AZ-1-64)
[0831] Pyridine (0.74 g, 0.75 mL, 9.29 mmol) was added to a solution of 2-(5-methoxy-2-methyl-lH-indol-3-yl)ethan-1-amine (0.78 g, 3.83 mmol) in anhydrous dichloromethane (10 mL), followed by acetic anhydride (474 mg, 438 pL, 4.64 mmol) dropwise. The reaction mixture was stirred at room temperature for 1 h. The contents of the flask were poured into dichloromethane (100 mL) and washed with 0.5 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL). The organic layer was dried (MgSC ) and the solvent was removed under reduced pressure. The residue was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to give / V-(2-(5-methoxy-2-methyl-lH-indol-3-yl)ethyl)acetamide (474 mg, 50 %) as a beige gum.
[0832] Step 5 / V-(2-(5-Hydroxy-2-methyl-lH-indol-3-yl)ethyl)acetamide (BP-AZ-1-66)
[0833] Boron tribromide (1 M in dichloromethane, 7.5 mL, 7.50 mmol) was added to a solution of / V-(2-(5-methoxy-2-methyl-lH-indol-3-yl)ethyl)acetamide (462 mg, 1.88 mmol) in anhydrous dichloromethane (15 mL) dropwise at 0 °C under nitrogen. The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with ice-water (10 mL) and the liquid layers were decanted from the resultant semi-solid precipitate. The semi-solid was dissolved in a mixture of 0.1 % formic acid: acetonitrile (1:1, 5 mL) and purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous formic acid to give N-(2-(5-hydroxy-2-methyl-lH-indol-3-yl)ethyl)acetamide (110 mg, 25 %) as a pale-brown solid. The decanted liquid layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 25 mL) and the organic extracts were combined with the dichloromethane layer, dried (MgSCh) and concentrated. The residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous formic acid to give an additional portion of / V-(2-(5-hydroxy-2-methyl-lH-indol-3-yl)ethyl)acetamide (100 mg, 23 %) as a beige solid.
[0834] LC-MS (+ve mode): m / z = 233.20 [M+H]+.
[0835] Example 4c - N-(2-(5-Formyl-lH-indol-3-yl)ethyl)acetamide (NAS16)
[0836] Product summary
[0837]
[0838]
[0839] Synthetic scheme
[0840]
[0841] 232.28 g / mol 230.27 g / mol
[0842] Experimental
[0843] Step 1 Ethyl 4-hydrazinylbenzoate (BP-AB-1-82)
[0844] 4-Hydrazinobenzoic acid (3.04 g, 20.0 mmol) was suspended in anhydrous ethanol (40 mL) under nitrogen. Concentrated sulfuric acid (2 mL) was added dropwise and the suspension was heated at 80 °C overnight. The reaction mixture was cooled to room temperature and concentrated to give an orange residue. The residue was partitioned between satd. aqueous sodium hydrogen carbonate (40 mL) and ethyl acetate (80 mL) and the layers were separated. The organic layer was washed with sat. aqueous sodium hydrogen carbonate (40 mL) and satd. brine (40 mL), dried (MgSCU) and concentrated to afford ethyl 4-hydrazinylbenzoate (2.71 g, 75 %) as an orange solid.
[0845] Step 2 Ethyl 3-(2-aminoethyl)-l / 7-indole-5-carboxylate (BP-AB-1-86)
[0846] Ethyl 4-hydrazinylbenzoate (2.71 g, 15.0 mmol) was dissolved in ethanol (50 mL), sulfuric acid (0.16 M, 108 mL) was added and the solution was heated to 55 °C and degassed with nitrogen. 4-Chlorobutanal dimethyl acetal (2.52 g, 2.42 mL, 16.5 mmol) was added dropwise and the reaction was heated at 100 °C for 3 h. The reaction was cooled to room temperature and satd. aqueous sodium hydrogen carbonate (80 mL) was added. The reaction was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were washed with satd. brine (100 mL), dried (MgSO₄) and concentrated to afford ethyl 3-(2-aminoethyl)-l / 7-indole-5-carboxylate (3.75 g, quant.) as an orange solid.
[0847] Step 3 Ethyl 3-(2-acetamidoethyl)-l / 7-indole-5-carboxylate (BP-AB-1-88)Ethyl 3-(2-aminoethyl)-lH-indole-5-carboxylate (3.57 g, 15.4 mmol) was suspended in anhydrous dichloromethane (150 mL) under nitrogen and triethylamine (7.77 g, 10.7 mL, 76.8 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (1.81 g, 1.64 mL, 23.0 mmol) was added dropwise. The reaction was warmed to room temperature and stirred for 2 h. The reaction mixture was washed with 1 M hydrochloric acid (60 mL), water (60 mL), satd. aqueous sodium hydrogen carbonate (60 mL) and satd. brine (60 mL), dried (MgSC ) and concentrated to give a pale-brown foam. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford ethyl 3-(2-acetamidoethyl)-lH-indole-5-carboxylate (1.28 g, 30 %) as a pale-brown solid.
[0848] LC-MS (+ve mode): m / z = 275.15 [M+H]+.
[0849] Step 4 / V-(2-(5-(Hydroxymethyl)-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-92)
[0850] Ethyl 3-(2-acetamidoethyl)-lH-indole-5-carboxylate (1.28 g, 4.67 mmol) was dissolved in anhydrous tetrahydrofuran (25 mL) and the solution was cooled to 0 °C. Lithium aluminium hydride (2.4 M in tetrahydrofuran, 7.78 mL, 18.7 mmol) was added dropwise and the reaction was warmed to room temperature and stirred overnight. The solution was cooled to 0 °C, diluted with tetrahydrofuran (30 mL) and quenched by dropwise addition of a mixture of water: tetrahydrofuran (1:4, 25 mL). Ethyl acetate (60 mL) and satd. aqueous potassium sodium tartrate solution (60 mL) were added and the mixture was stirred for 15 min at room temperature. The layers were separated and the aqueous phase was extracted with ethyl acetate (2 x 60 mL). The combined organic extracts were washed with satd. brine (100 mL), dried (MgSC ) and concentrated to give an off-white solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to give / V-(2-(5-(hydroxymethyl)-lH-indol-3-yl)ethyl)acetamide (773 mg, 71 %) as a white solid.
[0851] LC-MS (+ve mode): m / z = 215.20, [benzyl cation]+.
[0852] Step 5 / V-(2-(5-Formyl-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-84)
[0853] / V-(2-(5-(Hydroxymethyl)-lH-indol-3-yl)ethyl)acetamide (100 mg, 0.43 mmol) was dissolved in anhydrous acetonitrile (9 mL) under nitrogen. Manganese dioxide (374 mg, 4.30 mmol) was added and the reaction was stirred at room temperature for 6 h. The reaction mixture was filtered through Celite and washed with acetonitrile (3 x 10 mL). The filtrate was concentrated to afford a colourless film. The material was combined with crude / V-(2-(5-formyl-lH-indol-3-yl)ethyl)acetamide (27 mg, BP-AB-1-76-1) which was previously synthesised and purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford / V-(2-(5-formyl-lH-indol-3-yl)ethyl)acetamide (95 mg, 72 % combined yield) as a white solid.
[0854] LC-MS (+ve mode): m / z = 231.20 [M+H]+.
[0855] Example 4d - N-(2-(5-lsobutyl-lH-indol-3-yl)ethyl)acetamide (NAS21)
[0856] Product Summary
[0857]
[0858]
[0859] Synthetic scheme
[0860]
[0861] 274.36 g / mol
[0862] Experimental
[0863] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0864] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-l / 7-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL), potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-l / 7-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0865] Step 2 / V-(2-(5-lsobutyl-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-46)
[0866] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (220 mg, 1.01 mmol), potassium carbonate (698 mg, 5.05 mmol) and potassium iodide (25 mg, 0.15 mmol) were dissolved in anhydrous acetonitrile (6.5 mL) under nitrogen. l-Bromo-2-methyl propane (430 mg, 341 pL, 3.13 mmol) was added and the mixture was heated at 80 °C for 72 h. The reaction was cooled to room temperature and filtered through a plug of Celite, washing with acetonitrile (2 x 5 mL). The combined filtrates were concentrated to give a brown residue. This material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford / V-(2-(5-isobutyl-lH-indol-3-yl)ethyl)acetamide (29 mg, 10 %) as a yellow oil.
[0867] LC-MS (+ve mode): m / z = 275.15 [M+H]+.
[0868] Example 4e - N-(2-(5-lsobutyl-lH-indol-3-yl)ethyl)acetamide (NAS24)
[0869] Product summary
[0870]
[0871] Synthetic scheme
[0872]
[0873]
[0874] oc 281.15 g / mol 381.27 g / mol
[0875]
[0876] Experimental
[0877] Step 15-Bromo-3-(2-nitrovinyl)-lH-indole (BP-AZ-1-71)
[0878] Ammonium acetate (0.65 g, 8.43 mmol) was added to a solution of 5-bromoindole-3-carboxaldehyde (1.89 g, 8.43 mmol) in nitromethane (15 mL) and the reaction mixture was heated at reflux for 1 h. The mixture was cooled to room temperature; ethyl acetate (120 mL) was added and the mixture was washed with water (30 mL) and satd. brine (30 mL). The organic layer was dried (MgSCU) and concentrated to give 5-bromo-3-(2-nitrovinyl)-lH-indole (2.37 g, quant.) as an orange solid.
[0879] Step 22-(5-Bromo-lH-indol-3-yl)ethan-l-amine (BP-AZ-1-75)
[0880] Lithium aluminium hydride (2.4 M in tetrahydrofuran, 19.8 mL, 47.4 mmol) was added dropwise to a solution of 5-bromo-3-(2-nitrovinyl)-lH-indole (2.11 g, 7.90 mmol) in anhydrous tetrahydrofuran (80 mL) at 0 °C over 20 min. The reaction mixture was stirred at 0 °C until evolution of H2ceased and then slowly warmed to room temperature and stirred for 16 h. The reaction mixture was cooled to 0 °C and diethyl ether (100 mL) was added. Water (1.8 mL), 15 % (w / w) aqueous NaOH solution (1.8 mL) and water (5.4 mL) were added dropwise and the mixture was stirred for 30 min. The ethereal layer was dried (MgSCU) and concentrated to give 2-(5-bromo-lH-indol-3-yl)ethan-l-amine (1.58 g, 84 %) as a brown oil, which was used without further purification. LC-MS (+ve mode): m / z = 239.05 [M+H]+.
[0881] Step 3 / V-(2-(5-Bromo-l / - / -indol-3-yl)ethyl)acetamide (BP-AZ-1-76)
[0882] Pyridine (1.25 g, 1.28 mL, 15.9 mmol) was added to a solution of 2-(5-bromo-lH-indol-3-yl)ethan-l-amine (1.58 g, 6.61 mmol) in anhydrous dichloromethane (20 mL), followed by acetic anhydride (0.81 g, 0.75 mL, 7.93 mmol) dropwise. The mixture was stirred at room temperature for 1 h. The volatiles were removed under reduced pressure and the residue was purified by normal phase chromatography, eluting with a gradient ofmethanol in dichloromethane to give / V-(2-(5-bromo-lH-indol-3-yl)ethyl)acetamide (1.51 g) as a brown oil which contained pyridine. The oil was dissolved in ethyl acetate (100 mL), washed with 0.5 M hydrochloric acid (2 x 20 mL), water (30 mL) and satd. brine (30 mL). The organic layer was dried (MgSCh) and concentrated to afford / V-(2-(5-bromo-lH-indol-3-yl)ethyl)acetamide (1.30 g, 70 %) as a brown gum.
[0883] LC-MS (+ve mode): m / z = 281.05 [M+H]+.
[0884] Step 4 tert-Butyl 3-(2-acetamidoethyl)-5-bromo-lH-indole-l-carboxylate (BP-AZ-1-87)
[0885] Di-tert-butyl dicarbonate (1.03 g, 4.74 mmol) was added to a solution of / V-(2-(5-bromo-lH-indol-3-yl)ethyl)acetamide (1.11 g, 3.95 mmol) in anhydrous dichloromethane (40 mL) followed by triethylamine (480 mg, 0.66 mL, 4.74 mmol) and 4-(dimethylamino)pyridine (24 mg, 198 pmol). The reaction mixture was stirred at room temperature under nitrogen for 3 h. The volatiles were removed under reduced pressure and the residue was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford tert-butyl 3-(2-acetamidoethyl)-5-bromo-lH-indole-l-carboxylate (1.27 g, 84 %) as a pale-yellow solid.
[0886] LC-MS (+ve mode): m / z = 383.10 [M+H]+.
[0887] Step 5 tert-Butyl 3-(2-acetamidoethyl)-5-isobutyl-lH-indole-l-carboxylate (BP-AZ-1-94)
[0888] A 20 mL microwave vial was charged with tert-butyl 3-(2-acetamidoethyl)-5-bromo-lH-indole-l-carboxylate (167 mg, 0.44 mmol), 2-methyl-l-propylboronic acid (58 mg, 0.57 mmol), palladium(II) acetate (4.9 mg, 0.02 mmol), tripotassium phosphate (325 mg, 1.53 mmol), xantphos (25.3 mg, 0.04 mmol), water (112 mg, 112 pL, 6.22 mmol) and toluene (2.3 mL). The reaction vessel was evacuated and back-filled with nitrogen (3 cycles). The reaction mixture was heated at 120 °C for 20 h. The vial was cooled to room temperature; water (20 mL) was added and the mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with satd. brine (20 mL), dried (MgSO₄) and concentrated. The residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous formic acid to afford tert-butyl 3-(2-acetamidoethyl)-5-isobutyl-lH-indole-l-carboxylate (33 mg, 21 %) as a white gum.
[0889] LC-MS (+ve mode): m / z = 359.30 [M+H]+.
[0890] Step 6 / V-(2-(5-lsobutyl-lH-indol-3-yl)ethyl)acetamide (BP-AZ-1-96)
[0891] Trifluoroacetic acid (500 pL) was added to a solution of tert-butyl 3-(2-acetamidoethyl)-5-isobutyl-lH-indole-l-carboxylate (33 mg, 0.09 mmol) in anhydrous dichloromethane (1 mL) and the reaction mixture was stirred at room temperature for 3 h. The volatiles were removed under reduced pressure and the residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-isobutyl-lH-indol-3-yl)ethyl)acetamide (9.9 mg, 42 %) as a brown oil.
[0892] LC-MS (+ve mode): m / z = 259.20 [M+H]+.
[0893] Example 4f - N-(2-(5-(Ethylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (NAS28)
[0894] Product summary
[0895]
[0896]
[0897] Synthetic scheme
[0898]
[0899] Experimental
[0900] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0901] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residuewhich was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0902] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0903] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[0904] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSC ) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[0905] Step 3 / V-(2-(5-(ethylthio)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-108)
[0906] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (500 mg, 1.43 mmol) was dissolved in anhydrous 1,4-dioxane (5 mL) and Hunig's base (369 mg, 0.50 mL, 2.86 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (33 mg, 0.036 mmol) and xantphos (41 mg, 0.071 mmol) under nitrogen. 1-Ethanethiol (89 mg, 110 pL, 1.43 mmol) was added and the reaction was stirred at reflux for 20 h. The reaction mixture was cooled to room temperature and concentrated. The resultant material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(ethylthio)-lH-indol-3-yl)ethyl)acetamide (372 mg, 99 %) as a pale-orange oil.
[0907] LC-MS (+ve mode): m / z = 263.15 [M+H]+.
[0908] Step 4 tert-Butyl 3-(2-acetamidoethyl)-5-(ethylthio)-lH-indole-l-carboxylate (BP-GA-1-110)
[0909] / V-(2-(5-(Butylthio)-lH-indol-3-yl)ethyl)acetamide (247 mg, 0.94 mmol) was dissolved in anhydrous dichloromethane (8.0 mL) under nitrogen. A solution of di-tert-butyl dicarbonate (226 mg, 1.04 mmol) in anhydrous dichloromethane (1.0 mL) was added followed by a solution of 4-(dimethylamino)pyridine (12 mg, 0.094 mmol) in anhydrous dichloromethane (1.0 mL). The reaction was stirred at room temperature for 5 h then concentrated. The residue was purified by normal phase chromatography, eluting with a gradient of ethyl acetate in dichloromethane to afford tert-butyl 3-(2-acetamidoethyl)-5-(ethylthio)-lH-indole-l-carboxylate (276 mg, 81 %) as a colourless oil.
[0910] LC-MS (+ve mode): m / z = 363.25 [M+H]+.
[0911] Step 5 / V-(2-(5-(Ethylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-122)
[0912] tert-Butyl 3-(2-acetamidoethyl)-5-(ethylthio)-lH-indole-l-carboxylate (276 mg, 0.76 mmol) was dissolved in anhydrous dichloromethane (12.7 mL) under nitrogen. m-Chloroperbenzoic acid (276 mg, 1.60 mmol) was added portion-wise and the reaction stirred at 0 °C for 1 h. The reaction was quenched with satd. aqueous sodium bicarbonate (20 mL) and the layers separated. The aqueous phase was extracted with dichloromethane (2 x 15 mL). The combined organic layers were washed with satd. brine (20 mL), dried(MgSC ) and concentrated. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford tert-butyl 3-(2-acetamidoethyl)-5-(ethylsulfonyl)-lH-indole-1-carboxylate (298 mg, 98 %) as a colourless oil. This was dissolved in dichloromethane (3.0 mL), trifluoroacetic acid (3.0 mL) was added and the mixture was stirred at room temperature for 3 h. The reaction was concentrated and purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(ethylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (182 mg, 83 %) as an orange oily solid.
[0913] LC-MS (+ve mode): m / z = 295.15 [M+H]+.
[0914] Example 4g - N-(2-(5-(Ethylthio)-lH-indol-3-yl)ethyl)acetamide (NAS28b)
[0915] Product summary
[0916]
[0917] Synthetic scheme
[0918]
[0919] .
[0920] Experimental
[0921] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0922] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0923] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0924] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[0925] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSC ) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[0926] Step 3 / V-(2-(5-(ethylthio)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-108)
[0927] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (500 mg, 1.43 mmol) was dissolved in anhydrous 1,4-dioxane (5 mL) and Hunig's base (369 mg, 0.50 mL, 2.86 mmol) was added. The vessel wasevacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (33 mg, 0.04 mmol) and xantphos (41 mg, 0.07 mmol) under nitrogen. 1-Ethanethiol (89 mg, 110 pL, 1.43 mmol) was added and the reaction mixture was stirred at reflux for 20 h. The reaction mixture was cooled to room temperature and concentrated. The resultant material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(ethylthio)-lH-indol-3-yl)ethyl)acetamide (372 mg, 99 %) as an orange oil.
[0928] LC-MS (+ve mode): m / z = 263.15 [M+H]+.
[0929] Example 4h - N-(2-(5-(Butylthio)-lH-indol-3-yl)ethyl)acetamide (NAS29)
[0930] Product summary
[0931]
[0932] Synthetic scheme
[0933]
[0934] Experimental
[0935] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0936] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0937] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0938] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[0939] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSC ) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.Step 3 / V-(2-(5-(Butylthio)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-082)
[0940] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (165 mg, 0.47 mmol) was dissolved in 1,4-dioxane (1.65 mL) and Hunig's base (122 mg, 164 pL, 0.94 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tetrakis(triphenylphosphine)palladium(0) (14 mg, 0.01 mmol) and xantphos (14 mg, 0.02 mmol) under nitrogen. 1-Butanethiol (43 mg, 51 pL, 0.47 mmol) was added and the reaction was stirred at reflux for 20 h. The reaction mixture was cooled to room temperature and concentrated to give a brown oil. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford / V-(2-(5-(butylthio)-lH-indol-3-yl)ethyl)acetamide (121 mg, 88 %) as a yellow oil.
[0941] LC-MS (+ve mode): m / z = 291.15 [M+H]+.
[0942] Example 4i - N-(2-(5-(lsopropylthio)-lH-indol-3-yl)ethyl)acetamide (NAS31)
[0943] Product summary
[0944]
[0945] Synthetic scheme
[0946]
[0947] Experimental
[0948] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0949] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0950] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0951] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[0952] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSC ) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[0953] Step 3 / V-(2-(5-(lsopropylthio)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-102)3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (100 mg, 0.29 mmol) was dissolved in anhydrous 1,4-dioxane (1 mL) and Hunig's base (74 mg, 100 pL, 0.57 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (7 mg, 0.01 mmol) and xantphos (8 mg, 0.01 mmol) under nitrogen. 2-Propanethiol (22 mg, 27 pL, 0.29 mmol) was added and the mixture was stirred at reflux for 20 h. The solvent was removed under reduced pressure and the material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(isopropylthio)-lH-indol-3-yl)ethyl)acetamide (54 mg, 71 %) as a yellow oil.
[0954] LC-MS (+ve mode): m / z = 277.15 [M+H]+.
[0955] Example 4j - N-(2-(5-(lsobutylthio)-lH-indol-3-yl)ethyl)acetamide (NAS35)
[0956] Product summary
[0957]
[0958] Synthetic scheme
[0959]
[0960] 212.68 g / mol 218.25 g / mol
[0961]
[0962] , - oxane 350.31 g / mol 290.42 g / mol Experimental
[0963] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0964] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0965] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0966] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[0967] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSO₄) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.Step 3 / V-(2-(5-(lsobutylthio)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-26)
[0968] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (200 mg, 0.57 mmol) was dissolved in anhydrous 1,4-dioxane (2.0 mL) and Hunig's base (147 mg, 199 pL, 1.14 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (13 mg, 0.01 mmol) and xantphos (17 mg, 0.03 mmol) under nitrogen. 2-Methyl-l-propanethiol (51 mg, 62 pL, 0.57 mmol) was added and the reaction was stirred at reflux for 20 h. The reaction mixture was cooled and concentrated to give a brown oil. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(isobutylthio)-lH-indol-3-yl)ethyl)acetamide (145 mg, 88 %) as a colourless oil.
[0969] LC-MS (+ve mode): m / z = 291.15 [M+H]+.
[0970] Example 4k - N-(2-(5-Hvdroxy-4-methyl-lH-indol-3-yl)ethyl)acetamide (NAS36)
[0971] Product summary
[0972]
[0973] Synthetic scheme
[0974]
[0975] Experimental
[0976] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0977] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3- yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0978] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0979] Step 2 / V-(2-(4-((Dimethylamino)methyl)-5-hydroxy-lH-indol-3-yl)ethyl) acetamide (BP-AB-1-28) Formaldehyde (37 % in water, 101 mg, 94 pL, 1.25 mmol) and dimethylamine (2 M in methanol, 0.69 mL, 1.37 mmol) were dissolved in anhydrous ethanol (4.6 mL) under nitrogen. The reaction was heated at 80 °C for 30 min. The reaction mixture was cooled to room temperature and was added to a solution of / V-(2-(5-hydroxy- lH-indol-3-yl)ethyl)acetamide (300 mg, 1.37 mmol) in ethanol (1.9 mL). The reaction was heated at 80 °C for 2 h. The reaction was cooled to room temperature and concentrated to give a dark-red residue. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1% aqueous formic acid to afford / V-(2-(4-((dimethylamino)methyl)-5-hydroxy-lH-indol-3-yl)ethyl)acetamide (187 mg, 50 %) as a pale-pink film.
[0980] LC-MS (+ve mode): m / z = 276.20 [M+H]+.Step 3 / V-(2-(5-Hydroxy-4-methyl-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-40)
[0981] A solution of / V-(2-(4-((dimethylamino)methyl)-5-hydroxy-l / - / -indol-3-yl)ethyl)acetamide (137 mg, 0.50 mmol) in anhydrous ethanol (6.5 mL) was added to a flask containing 10 % palladium on carbon (68.5 mg, 5 mol % Pd) under nitrogen. A condenser was added to the vessel and the solution was degassed under vacuum and backfilled with hydrogen (3 cycles). The suspension was heated at 65 °C for 2 h. The reaction was cooled to room temperature and filtered through Celite, washing with ethanol (3 x 5 mL). The filtrate was concentrated to afford / V-(2-(5-hydroxy-4-methyl-lH-indol-3-yl)ethyl)acetamide (85 mg, 73 %) a pale-brown oil which solidified upon standing.
[0982] LC-MS (+ve mode): m / z = 233.20 [M+H]+.
[0983] Example 41 - N-(2-(5-(Butylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (NAS38)
[0984] Product summary
[0985]
[0986] Synthetic scheme
[0987]
[0988] 390.54 g / mol 322.42 g / mol Experimental
[0989] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[0990] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3- yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[0991] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[0992] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[0993] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl- bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSO₄) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[0994] Step 3 / V-(2-(5-(Butylthio)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-088)
[0995] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (165 mg, 0.47 mmol) was dissolved in 1,4-dioxane (1.65 mL) and Hunig's base (122 mg, 164 pL, 0.94 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tetrakis(triphenylphosphine)palladium(0) (14 mg, 0.01 mmol) and xantphos (14 mg, 0.02 mmol) under nitrogen. 1-Butanethiol (43 mg, 51 pL, 0.47 mmol) was added and the reaction stirred at reflux for 20 h. The reaction mixture was cooled to room temperature and concentrated to give a brown oil. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford / V-(2-(5-(butylthio)-lH-indol-3-yl)ethyl)acetamide (121 mg, 88 %) as a yellow oil.
[0996] LC-MS (+ve mode): m / z = 291.15 [M+H]+.
[0997] Step 4 tert-Butyl 3-(2-acetamidoethyl)-5-(butylthio)-lH-indole-l-carboxylate (BP-GA-1-092)
[0998] / V-(2-(5-(Butylthio)-lH-indol-3-yl)ethyl)acetamide (207 mg, 0.71 mmol) was dissolved in anhydrous dichloromethane (4.4 mL) under nitrogen. A solution of di-tert-butyl dicarbonate (171 mg, 0.79 mmol) in anhydrous dichloromethane (0.9 mL) was added followed by a solution of 4-(dimethylamino)pyridine (9 mg, 0.07 mmol) in anhydrous dichloromethane (0.9 mL). The reaction was stirred at room temperature for 3 h then concentrated. The residue was purified by normal phase chromatography, eluting with a gradient of ethyl acetate in dichloromethane to afford tert-butyl 3-(2-acetamidoethyl)-5-(butylthio)-lH-indole-l-carboxylate (250 mg, 90 %) as a colourless oil.
[0999] LC-MS (+ve mode): m / z = 391.25 [M+H]+.
[1000] Step 5 / V-(2-(5-(Butylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-104)
[1001] tert-Butyl 3-(2-acetamidoethyl)-5-(butylthio)-lH-indole-l-carboxylate (250 mg, 0.64 mmol) was dissolved in anhydrous dichloromethane (10 mL) under nitrogen. m-Chloroperbenzoic acid (232 mg, 1.34 mmol) was added portion-wise and the mixture was stirred at 0 °C for 1 h. The reaction was quenched with satd. aqueous sodium bicarbonate (15 mL) and the layers separated. The aqueous phase was extracted with dichloromethane (2 x 10 mL). The combined organic layers were washed with satd. brine (15 mL), dried (MgSO₄) and concentrated. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to give tert-butyl 3-(2-acetamidoethyl)-5-(butylsulfonyl)-lH-indole-l-carboxylate (222 mg, 82 %) as a colourless oil. This was dissolved in dichloromethane (2.5 mL), trifluoroacetic acid (2.5 mL) was added and the reaction mixture was stirred at room temperature for 5 h. The reaction was concentrated and purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(butylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (118 mg, 70 %) as a yellow oil.
[1002] LC-MS (+ve mode): m / z = 323.15 [M+H]+.
[1003] Example 4m - N-(2-(5-Hvdroxy-2-propyl-lH-indol-3-yl)ethyl)acetamide (NAS40)
[1004] 1.1 Product summary
[1005]
[1006] Synthetic scheme
[1007]
[1008] Norbornene 274.36 g / mol 260.34 g / mol Experimental
[1009] Step 1 / V-(2-(5-Methoxy-2-propyl-lH-indol-3-yl)ethyl)acetamide (BP-AZ-1-78)
[1010] A 20 mL microwave vial was charged with melatonin (195 mg, 0.84 mmol), 1-propyl bromide (207 mg, 153 pL, 1.68 mmol), palladium^ I) acetate (7.5 mg, 0.03 mmol), 2-norbornene (158 mg, 1.68 mmol), potassium carbonate (232 mg, 1.68 mmol), water (38 mg, 38 pL, 2.10 mmol) and dimethylacetamide (3 mL). The reaction vessel was evacuated and back-filled with nitrogen (3 cycles). The reaction mixture was heated at 70 °C for 20 h. The vial was cooled to room temperature; ethyl acetate (20 mL) was added, and the suspension was filtered through a plug of Celite, washing with ethyl acetate (3 x 2 mL) and the combined filtrates were concentrated. The residue was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to give impure / V-(2-(5-methoxy-2-propyl-lH-indol-3-yl)ethyl)acetamide (71 mg) as a palebrown oil. The oil was further purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.02 % hydrochloric acid to afford / V-(2-(5-methoxy-2-propyl-lH-indol-3-yl)ethyl)acetamide (30 mg, 13 %) as an off-white solid.LC-MS (+ve mode): m / z = 275.20 [M+H]+.
[1011] Step 2 / V-(2-(5-hydroxy-2-propyl-lH-indol-3-yl)ethyl)acetamide (BP-AZ-1-86)
[1012] Boron tribromide (1 M in dichloromethane, 1.08 mL, 1.08 mmol) was added dropwise to a solution of A / -(2-(5-methoxy-2-propyl-lH-indol-3-yl)ethyl)acetamide (74 mg, 0.27 mmol) in anhydrous dichloromethane (2 mL) at 0 °C under nitrogen. The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with methanol (15 mL) and concentrated. The residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.02 % hydrochloric acid to afford / V-(2-(5-hydroxy-2-propyl-lH-indol-3-yl)ethyl)acetamide (42 mg, 60 %) as a beige solid.
[1013] LC-MS (+ve mode): m / z = 261.25 [M+H]+.
[1014] Example 4n - N-(2-(5-Butyl-lH-indol-3-yl)ethyl)acetamide (NAS41)
[1015] Product summary
[1016]
[1017] Synthetic scheme
[1018]
[1019]
[1020]
[1021] Experimental
[1022] Step 15-Bromo-3-(2-nitrovinyl)-lH-indole (BP-AZ-1-71)
[1023] Ammonium acetate (0.65 g, 8.43 mmol) was added to a solution of 5-bromoindole-3-carboxaldehyde (1.89 g, 8.43 mmol) in nitromethane (15 mL) and the reaction mixture was heated at reflux for 1 h. The mixture was cooled to room temperature; ethyl acetate (120 mL) was added, and the mixture was washed with water (30 mL) and satd. brine (30 mL). The organic layer was dried (MgSO₄) and concentrated to afford 5-bromo-3-(2-nitrovinyl)-lH-indole (2.37 g, quant.) as an orange solid.
[1024] Step 22-(5-Bromo-lH-indol-3-yl)ethan-l-amine (BP-AZ-1-75)
[1025] Lithium aluminium hydride (2.4 M in tetrahydrofuran, 19.8 mL, 47.4 mmol) was added dropwise to a solution of 5-bromo-3-(2-nitrovinyl)-lH-indole (2.11 g, 7.9 mmol) in anhydrous tetrahydrofuran (80 mL) at 0 °C over 20 min. The reaction mixture was stirred at 0 °C until evolution of H2ceased and then slowly warmed to room temperature and stirred for 16 h. The reaction mixture was cooled to 0 °C and diethyl ether (100 mL) was added. Water (1.8 mL), 15 % (w / w) aqueous NaOH solution (1.8 mL) followed by water (5.4 mL) were added dropwise, and the mixture was stirred for 30 min. The ethereal layer was dried (MgSO₄) and concentrated to afford 2-(5-bromo-lH-indol-3-yl)ethan-l-amine (1.58 g, 84 %) as a brown oil, which was used without further purification.
[1026] LC-MS (+ve mode): m / z = 239.05 [M+H]+.
[1027] Step 3 / V-(2-(5-Bromo-lH-indol-3-yl)ethyl)acetamide (BP-AZ-1-76)
[1028] Pyridine (1.25 g, 1.28 mL, 15.9 mmol) was added to a solution of 2-(5-bromo-lH-indol-3-yl)ethan-l-amine (1.58 g, 6.6 mmol) in anhydrous dichloromethane (20 mL) followed by addition of acetic anhydride (0.81 g, 0.75 mL, 7.9 mmol) dropwise The mixture was stirred at room temperature for 1 h. The volatiles were removed under reduced pressure and the residue was purified by normal phase chromatography, eluting witha gradient of methanol in dichloromethane to afford / V-(2-(5-bromo-lH-indol-3-yl)ethyl)acetamide (1.51 g) as a brown oil containing pyridine. The oil was dissolved in ethyl acetate (100 mL), washed with 0.5 M hydrochloric acid (2 x 20 mL), water (30 mL) and satd. brine (30 mL). The organic layer was dried (MgSO₄) and concentrated to afford / V-(2-(5-bromo-lH-indol-3-yl)ethyl)acetamide (1.30 g, 70 %) as a brown gum.
[1029] LC-MS (+ve mode): m / z = 281.05 [M+H]+.
[1030] Step tert-Butyl 3-(2-acetamidoethyl)-5-bromo-lH-indole-l-carboxylate4 (BP-AZ-1-87)
[1031] Di-tert-butyl dicarbonate (1.03 g, 4.74 mmol) was added to a solution of / V-(2-(5-bromo-lH-indol-3-yl)ethyl)acetamide (1.11 g, 3.95 mmol) in anhydrous dichloromethane (40 mL) followed by triethylamine (480 mg, 0.661 mL, 4.74 mmol) and 4-(dimethylamino)pyridine (24 mg, 0.20 mmol). The reaction mixture was stirred at room temperature under nitrogen for 3 h. The volatiles were removed under reduced pressure and the residue was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to give tert-butyl 3-(2-acetamidoethyl)-5-bromo-lH-indole-l-carboxylate (1.27 g, 84 %) as a pale-yellow solid.
[1032] Step 5 tert-Butyl 3-(2-acetamidoethyl)-5-butyl-lH-indole-l-carboxylate (BP-AZ-1-88)
[1033] A 20 mL microwave vial was charged with tert-butyl 3-(2-acetamidoethyl)-5-bromo-lH-indole-l-carboxylate (142 mg, 0.37 mmol), butylboronic acid (49 mg, 0.48 mmol), palladium(ll) acetate (4.2 mg, 0.02 mmol), tripotassium phosphate (279 mg, 1.31 mmol), xantphos (21.5 mg, 0.04 mmol) water (96 mg, 96 pL, 5.33 mmol) and toluene (2 mL). The reaction vessel was evacuated and back-filled with nitrogen (3 cycles). The reaction mixture was heated at 100 °C for 24 h followed by 120 °C for 20 h. The vial was cooled to room temperature; water (20 mL) was added, and the mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with satd. brine (20 mL), dried (MgSO₄) and concentrated. The residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous formic acid to afford tert-butyl 3-(2-acetamidoethyl)-5-butyl-lH-indole-l-carboxylate (51 mg, 38 %) as a colourless oil.
[1034] LC-MS (+ve mode): m / z = 359.30 [M+H]+.
[1035] Step 6 / V-(2-(5-Butyl-lH-indol-3-yl)ethyl)acetamide (BP-AZ-1-92)
[1036] Trifluoroacetic acid (300 pL) was added to a solution of tert-butyl 3-(2-acetamidoethyl)-5-butyl-lH-indole-l-carboxylate (51 mg, 0.14 mmol) in anhydrous dichloromethane (2 mL) and the reaction mixture was stirred at room temperature for 3 h. The volatiles were removed under reduced pressure and the residue was purified by reversed phase-chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-butyl-lH-indol-3-yl)ethyl)acetamide (25 mg, 68 %) as a dark-brown oil.
[1037] LC-MS (+ve mode): m / z = 259.20 [M+H]+.
[1038] Example 4o - N-(2-(5-(Propylthio)-lH-indol-3-yl)ethyl)acetamide (NAS43)
[1039] Product summary
[1040]
[1041]
[1042] Synthetic scheme
[1043]
[1044] Experimental
[1045] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[1046] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed withwater (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1047] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1048] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[1049] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSO₄) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[1050] Step 3 / V-(2-(5-(propylthio)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-36)
[1051] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (300 mg, 0.86 mmol) was dissolved in anhydrous 1,4-dioxane (3 mL) and Hunig's base (221 mg, 298 pL, 1.71 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (20 mg, 0.02 mmol) and xantphos (25 mg, 0.04 mmol) under nitrogen. 1-Propanethiol (65 mg, 78 pL, 0.86 mmol) was added and the reaction was stirred at reflux for 20 h. The solvent was removed under reduced pressure to give a yellow oil. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(propylthio)-lH-indol-3-yl)ethyl)acetamide (239 mg, quant.) as a yellow oil.
[1052] LC-MS (+ve mode): m / z = 277.15 [M+H]+.
[1053] Example 4p - N-(2-(5-(Propylsulfinyl)-lH-indol-3-yl)ethyl)acetamide (NAS43b)
[1054] Product summary
[1055]
[1056] Physical form Pale-yellow oil
[1057]
[1058] Synthetic scheme
[1059]
[1060] 212
[1061]
[1062] ,
[1063] 350.31 g / mol 276.40 g / mol
[1064]
[1065] 292.40 g / mol
[1066] Experimental
[1067] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[1068] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1069] LC-MS (+ve mode): m / z = 219.15 [M+H]+.Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24) / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSC ) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[1070] Step 3 / V-(2-(5-(Propylthio)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-36)
[1071] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (300 mg, 0.86 mmol) was dissolved in anhydrous 1,4-dioxane (3 mL) and Hunig's base (221 mg, 298 pL, 1.71 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (20 mg, 0.02 mmol) and xantphos (25 mg, 0.04 mmol) under nitrogen. 1-Propanethiol (65 mg, 78 pL, 0.86 mmol) was added and the reaction was stirred at reflux for 20 h. The solvent was removed under reduced pressure to give a yellow oil. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(propylthio)-lH-indol-3-yl)ethyl)acetamide (239 mg, quant.) as a yellow oil.
[1072] LC-MS (+ve mode): m / z = 277.15 [M+H]+.
[1073] Step 4 / V-(2-(5-(Propylsulfinyl)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-56)
[1074] / V-(2-(5-(Propylthio)-lH-indol-3-yl)ethyl)acetamide (111 mg, 0.40 mmol) was dissolved in ethanol (2 mL) and hydrogen peroxide aqueous solution (27 % w / w, 27 mg, 83 pL, 0.80 mmol) was added followed by trifluoromethanesulfonic acid (30 mg, 18 pL, 0.20 mmol). The reaction was stirred at room temperature for 30 min. Water (10 mL) was added and the aqueous phase was extracted with dichloromethane (3 x 5 mL). The combined organic layers were dried (MgSO₄) and concentrated to give a yellow oil. The residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(propylsulfinyl)-lH-indol-3-yl)ethyl)acetamide (99 mg, 85 %) as a pale-yellow oil.
[1075] LC-MS (+ve mode): m / z = 293.15 [M+H]+.
[1076] Example 4q - N-(2-(5-(2-(Methylthio)ethoxy)-lH-indol-3-yl)ethyl)acetamide (NAS44)
[1077] Product summary
[1078]
[1079]
[1080] 292,40 g / mol
[1081] Experimental
[1082] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[1083] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1084] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1085] Step 2 / V-(2-(5-(2-(Methylthio)ethoxy)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-078)To / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (200 mg, 0.92 mmol) and potassium carbonate (0.63 g, 4.58 mmol) in anhydrous acetonitrile (6.6 mL) under nitrogen was added 2-chloroethyl methyl sulfide (304 mg, 274 pL, 2.75 mmol) dropwise. The reaction mixture was stirred at 80 °C for 2 h. The reaction was cooled to room temperature and concentrated. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(2-(methylthio)ethoxy)-lH-indol-3-yl)ethyl)acetamide (140 mg, 52 %) as a pale-pink solid.
[1086] LC-MS (+ve mode): m / z = 293.20 [M+H]+.
[1087] Example 4r - N-(2-(5-(lsobutylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (NAS45)
[1088] Product summary
[1089]
[1090] Synthetic scheme
[1091]
[1092] Experimental
[1093] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[1094] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1095] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1096] Step 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[1097] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSO₄) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[1098] Step 3 / V-(2-(5-(lsobutylthio)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-26)
[1099] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (200 mg, 0.57 mmol) was dissolved in anhydrous 1,4-dioxane (2.0 mL) and Hunig's base (147 mg, 199 pL, 1.14 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (13 mg, 0.01 mmol) and xantphos (17 mg, 0.03 mmol) under nitrogen. 2-Methyl-l-propanethiol (51 mg, 62 pL, 0.57 mmol) was added and the reaction was stirred at reflux for 20 h. The reaction mixture was cooled and concentrated to give a brown oil. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(isobutylthio)-lH-indol-3-yl)ethyl)acetamide (145 mg, 88 %) as a colourless oil.
[1100] LC-MS (+ve mode): m / z = 291.15 [M+H]+.
[1101] Step 4 / V-(2-(5-(lsobutylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-30)
[1102] / V-(2-(5-(lsobutylthio)-lH-indol-3-yl)ethyl)acetamide (152 mg, 0.52 mmol) was dissolved in anhydrous dichloromethane (8.5 mL) and cooled to 0 °C. To this was added meta-chloroperbenzoic acid (190 mg, 1.10 mmol) and the reaction was slowly warmed to room temperature over 1 h. The reaction was quenched with satd. aqueous sodium bicarbonate (10 mL) and the layers separated. The aqueous phase was extracted with dichloromethane (2 x 5 mL). The combined organic layers were washed with satd. brine (10 mL), dried (MgSO₄) and concentrated. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(isobutylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (114 mg, 68 %) as a colourless oil.
[1103] LC-MS (+ve mode): m / z = 323.15 [M+H]+.
[1104] Example 4s - N-(2-(5-Hvdroxy-2-butyl-lH-indol-3-yl)ethyl)acetamide (NAS49)
[1105] Product summary
[1106]
[1107]
[1108] Synthetic scheme
[1109]
[1110] Experimental
[1111] Step 1 / V-(2-(5-Methoxy-2-butyl-l / 7-indol-3-yl)ethyl)acetamide (BP-AZ-1-84)
[1112] A 20 mL microwave vial was charged with melatonin (0.55 mg, 2.35 mmol), n-butyl bromide (0.64 g, 0.51 mL, 4.69 mmol), bis(acetonitrile)palladium dichloride (61 mg, 0.24 mmol), 2-norbornene (442 mg, 4.69 mmol), potassium carbonate (0.65 g, 4.69 mmol), water (106 mg, 106 pL, 5.88 mmol) and dimethylacetamide (7 mL). The reaction vessel was evacuated and back-filled with nitrogen (3 cycles). The reaction mixture was heated at 70 °C for 40 h. The vial was cooled to room temperature; ethyl acetate (5 mL) was added, and the suspension was filtered through a plug of Celite, washing with ethyl acetate (3 x 2 mL) and the combined filtrates were concentrated. The residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.02 % hydrochloric acid to afford impure / V-(2-(5-methoxy-2-butyl-l / 7-indol-3-yl)ethyl)acetamide (325 mg) as a pale-brown oil. The oil was further purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford / V-(2-(5-methoxy-2-butyl-l / 7-indol-3-yl)ethyl)acetamide (146 mg, 22 %) as a pale-brown gum.
[1113] LC-MS (+ve mode): m / z = 289.25 [M+H]+.
[1114] Step 2 / V-(2-(5-Hydroxy-2-butyl-l / 7-indol-3-yl)ethyl)acetamide (BP-AZ-1-91)
[1115] Boron tribromide (1 M in dichloromethane, 1.94 mL, 1.94 mmol) was added dropwise to a solution of A / -(2-(5-methoxy-2-butyl-l / 7-indol-3-yl)ethyl)acetamide (140 mg, 0.49 mmol) in anhydrous dichloromethane (4 mL) at 0 °C under nitrogen. The reaction mixture was stirred at room temperature for 3 h. The reaction was cooled to 0 °C and quenched with methanol (5 mL) dropwise. The volatiles were removed under reduced pressure and the residue was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.02 % hydrochloric acid to afford / V-(2-(5-hydroxy-2-butyl-l / 7-indol-3-yl)ethyl)acetamide (85 mg, 64 %) as a beige solid.
[1116] LC-MS (+ve mode): m / z = 275.25 [M+H]+.
[1117] Example 4t - N-(2-(5-(Propylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (NAS50)
[1118] Product summary
[1119]
[1120] Synthetic scheme
[1121]
[1122]
[1123] 376.51 g / mol 308.40 g / mol
[1124] Experimental
[1125] Step 1 / V-(2-(5-Hydroxy-l / 7-indol-3-yl)ethyl)acetamide (BP-AB-1-74)Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1126] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1127] Step 23-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (BP-AB-1-24)
[1128] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (2.00 g, 9.16 mmol) was dissolved in anhydrous dichloromethane (100 mL) and anhydrous acetonitrile (50 mL) under nitrogen. Triethylamine (1.85 g, 2.55 mL, 18.33 mmol) was added followed by potassium carbonate (6.33 g, 45.80 mmol) and / V-phenyl-bis(trifluoromethanesulfonimide) (3.93 g, 11.00 mmol) and the reaction was heated at 50 °C for 2 h. The mixture was cooled to room temperature and filtered through cotton wool. The filtrate was washed with 1 M hydrochloric acid (100 mL), water (100 mL) and satd. brine (100 mL), dried (MgSC ) and concentrated to give a red solid. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford 3-(2-acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (2.52 g, 79 %) as a pale-yellow solid.
[1129] Step 3 / V-(2-(5-(Propylthio)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-36)
[1130] 3-(2-Acetamidoethyl)-lH-indol-5-yl trifluoromethanesulfonate (300 mg, 0.86 mmol) was dissolved in anhydrous 1,4-dioxane (3 mL) and Hunig's base (221 mg, 298 pL, 1.71 mmol) was added. The vessel was evacuated and back-filled with nitrogen. To this was added tris(dibenzylideneacetone)dipalladium (20 mg, 0.02 mmol) and xantphos (25 mg, 0.04 mmol) under nitrogen. 1-Propanethiol (65 mg, 78 pL, 0.86 mmol) was added and the reaction was stirred at reflux for 20 h. The solvent was removed under reduced pressure to give a yellow oil. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(propylthio)-lH-indol-3-yl)ethyl)acetamide (239 mg, quant.) as a yellow oil.
[1131] LC-MS (+ve mode): m / z = 277.15 [M+H]+.
[1132] Step 4 tert-Butyl 3-(2-acetamidoethyl)-5-(propylthio)-lH-indole-l-carboxylate (BP-RR-1-44) / V-(2-(5-(Propylthio)-lH-indol-3-yl)ethyl)acetamide (129 mg, 0.47 mmol) was dissolved in anhydrous dichloromethane (2.5 mL) under nitrogen. A solution of di-tert-butyl dicarbonate (111 mg, 0.51 mmol) in dichloromethane (0.5 mL) was added followed by a solution of 4-(dimethylamino)pyridine (6 mg, 0.05 mmol) in dichloromethane (0.5 mL). The reaction was stirred at room temperature for 18 h. The reaction was concentrated to give tert-butyl 3-(2-acetamidoethyl)-5-(propylthio)-lH-indole-l-carboxylate (196 mg, quant) as a pale-yellow solid, which was used directly in the next step without further purification.
[1133] LC-MS (+ve mode): m / z = 377.20 [M+H]+.Step 5 / V-(2-(5-(Propylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (BP-RR-1-53)
[1134] To tert-butyl 3-(2-acetamidoethyl)-5-(propylthio)-lH-indole-l-carboxylate (194 mg, 0.52 mmol) in anhydrous dichloromethane (8.5 mL) at 0 °C was added meta-chloroperbenzoic acid (187 mg, 1.08 mmol) and the reaction was slowly warmed to room temperature over 1 h. The reaction was quenched with satd. aqueous sodium bicarbonate (8 mL) and the layers separated. The aqueous phase was extracted with dichloromethane (2 x 5 mL). The combined organic layers were washed with satd. brine (5 mL), dried (MgSCU) and concentrated to give tert-butyl 3-(2-acetamidoethyl)-5-(propylsulfonyl)-lH-indole-l-carboxylate (246 mg) as a pale-yellow oil. The resultant material was dissolved in a mixture of dichloromethane (2.5 mL) and trifluoroacetic acid (2.5 mL) and stirred at room temperature for 2.5 h. The reaction was concentrated to give a pale-orange solid. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(propylsulfonyl)-lH-indol-3-yl)ethyl)acetamide (124 mg, 77 %) as a pale-yellow oil.
[1135] LC-MS (+ve mode): m / z = 309.15 [M+H]+.
[1136] Example 4u - N-(2-(5-(3-(Methylthio)propoxy)-lH-indol-3-yl)ethyl)acetamide (NAS51)
[1137] Product summary
[1138]
[1139] Synthetic scheme
[1140]
[1141] 306.42 g / mol
[1142] Experimental
[1143] (3-Chloropropyl)(methyl)sulfane (BP-GA-1-124)
[1144] A solution of thionyl chloride (0.67 g, 410 pL, 5.65 mmol) in anhydrous chloroform (3 mL) was added dropwise over 10 min to a solution of 3-(methylthio)-l-propanol (500 mg, 490 pL, 4.71 mmol) in anhydrous chloroform (5 mL) under nitrogen. The reaction mixture was stirred at reflux for 3 h. The reaction was cooled to room temperature and diluted with water (15 mL). The layers were separated, and the aqueous phase was extracted with chloroform (2 x 15 mL). The combined organic extracts were washed with satd. aqueous sodium bicarbonate (15 mL) and satd. brine (15 mL), dried (MgSCU) and concentrated. The material was purified by normal phase chromatography, eluting with a gradient of ethyl acetate in petrol to afford (3- chloropropyl)(methyl)sulfane (250 mg, 43 %) as a pale-yellow oil.
[1145] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[1146] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3- yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1147] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1148] Step 2 / V-(2-(5-(3-(Methylthio)propoxy)-lH-indol-3-yl)ethyl)acetamide (BP-GA-1-130, BP-AB-1-83-2) To a solution of / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (220 mg, 1.01 mmol) in anhydrous acetonitrile (7.2 mL) was added potassium carbonate (0.70 g, 5.04 mmol) followed by (3-chloropropyl)(methyl)sulfane (251mg, 2.01 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 2 d, sodium iodide (181 mg, 1.21 mmol) was added, and the reaction was stirred for a further 4 d at reflux. The reaction mixture was cooled to room temperature and concentrated. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.02 % hydrochloric acid to afford / V-(2-(5-(3-(methylthio)propoxy)-lH-indol-3-yl)ethyl)acetamide (15 mg, 5 %) as a pale-brown oil.
[1149] LC-MS (+ve mode): m / z = 307.20 [M+H]+.
[1150] Example 4v - N-(2-(5-(2-(Butylthio)ethoxy)-lH-indol-3-yl)ethyl)acetamide (NAS55)
[1151] Product summary
[1152]
[1153]
[1154] 334.48 g / molExperimental
[1155] Butyl (2-chloroethyl)sulfane (BP-GA-1-106)
[1156] 1-Butanethiol (200 mg, 240 pL, 2.22 mmol), l-bromo-2-chloroethane (318 mg, 180 pL, 2.22 mmol) and potassium carbonate (460 mg, 3.33 mmol) were stirred in anhydrous acetonitrile (9 mL) at room temperature under nitrogen for 20 h. The reaction mixture was diluted with water (15 mL) and extracted with diethyl ether (3 x 15 mL). The combined organic extracts were washed with water (2 x 10 mL), dried (MgSCU) and concentrated. The material was purified by normal phase chromatography, eluting with a gradient of ethyl acetate in petrol to afford butyl(2-chloroethyl)sulfane (128 mg, 43 %) as a colourless oil.
[1157] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[1158] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1159] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1160] Step 2 / V-(2-(5-(2-(butylthio)ethoxy)-lH-indol-3-yl)ethyl)acetamide (GA-BP-1-112)
[1161] To a solution of butyl(2-chloroethyl)sulfane (128 mg, 0.95 mmol) in anhydrous acetonitrile (4.5 mL) was added a solution of / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (139 mg, 0.64 mmol) in anhydrous acetonitrile (0.7 mL) followed by potassium carbonate (439 mg, 3.18 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 4 h. The mixture was cooled to room temperature and concentrated. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.1 % aqueous trifluoroacetic acid to afford / V-(2-(5-(2-(butylthio)ethoxy)-lH-indol-3-yl)ethyl)acetamide (144 mg, 81 %) as a brown oil.
[1162] LC-MS (+ve mode): m / z = 335.20 [M+H]+.
[1163] Example 4w - Ethyl 3-(2-acetamidoethyl)-lH-indole-5-carboxylate (NAS57a)
[1164] Product summary
[1165]
[1166]
[1167] Synthetic scheme
[1168]
[1169] Step 1 Ethyl 4-hydrazinylbenzoate (BP-AB-1-82)
[1170] 4-Hydrazinobenzoic acid (3.04 g, 20.0 mmol) was suspended in anhydrous ethanol (40 mL) under nitrogen. Concentrated sulfuric acid (2 mL) was added dropwise and the suspension was heated at 80 °C overnight. The solution was cooled to room temperature and concentrated to give an orange residue. The residue was partitioned between satd. aqueous sodium hydrogen carbonate (40 mL) and ethyl acetate (80 mL), and the layers were separated. The organic layer was washed with satd. aqueous sodium hydrogen carbonate (40 mL) and satd. brine (40 mL), dried (MgSCU) and concentrated to afford ethyl 4-hydrazinylbenzoate (2.71 g, 75 %) as an orange solid.
[1171] Step 2 Ethyl 3-(2-aminoethyl)-lH-indole-5-carboxylate (BP-AB-1-86)
[1172] Ethyl 4-hydrazinylbenzoate (2.71 g, 15.0 mmol) was dissolved in ethanol (50 mL) sulfuric acid (0.16 M, 108 mL) was added and the solution was heated to 55 °C and degassed with nitrogen. 4-Chlorobutanal dimethyl acetal (2.52 g, 2.42 mL, 16.5 mmol) was added dropwise and the reaction was heated at 100 °C for 3 h. The reaction was cooled to room temperature and satd. aqueous sodium hydrogen carbonate (80 mL) was added. Thereaction was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were washed with satd. brine (100 mL), dried (MgSO₄) and concentrated to afford ethyl 3-(2-aminoethyl)-lH-indole-5-carboxylate (3.75 g, quant.) as an orange solid which was used directly in the next step without further purification.
[1173] Step 3 Ethyl 3-(2-acetamidoethyl)-lH-indole-5-carboxylate (BP-AB-1-48)
[1174] Ethyl 3-(2-aminoethyl)-lH-indole-5-carboxylate (530 mg, 2.28 mmol) was suspended in anhydrous dichloromethane (20 mL) under nitrogen and triethylamine (1.16 g, 1.59 mL, 11.40 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (268 mg, 243 pL, 3.42 mmol) was added dropwise. The reaction was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (20 mL) and washed with 1 M hydrochloric acid (2 x 20 mL), water (20 mL), satd. aqueous sodium hydrogen carbonate (2 x 20 mL) and satd. brine (20 mL), dried (MgSCU) and concentrated to give an orange oil. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford ethyl 3-(2-acetamidoethyl)-lH-indole-5-carboxylate (171 mg, 27 %) as a pale-brown solid.
[1175] LC-MS (+ve mode): m / z = 275.15 [M+H]+.
[1176] Example 4x - N-(2-(5-Hvdroxy-4-(morpholinomethyl)-lH-indol-3-yl)ethyl)acetamide hydrochloride (NAS58a) Product summary
[1177]
[1178] Synthetic scheme
[1179]
[1180] 353.85 g / mol
[1181] Experimental
[1182] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)
[1183] Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1184] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1185] Step 2 / V-(2-(5-Hydroxy-4-(morpholinomethyl)-lH-indol-3-yl)ethyl)acetamide hydrochloride (BP-AB-1-68)
[1186] Paraformaldehyde (33 mg, 1.08 mmol) was suspended in anhydrous ethanol (2 mL) under nitrogen and morpholine (94 mg, 94 pL, 1.08 mmol) was added. The suspension was stirred for 30 min at room temperature and a solution of / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (206 mg, 0.94 mmol) in ethanol (3 mL) was added. The reaction was heated at 80 °C overnight. The reaction was cooled to room temperature and concentrated to give a dark-red foam. The material was purified by reversed-phase chromatography, eluting with a gradient of acetonitrile in 0.02 % hydrochloric acid to afford / V-(2-(5-hydroxy-4-(morpholinomethyl)-lH-indol-3-yl)ethyl)acetamide hydrochloride (94 mg, 24 %) as a white solid.
[1187] LC-MS (+ve mode): m / z = 318.25 [M+H]+.
[1188] Example 4y - N-(2-(5-Hvdroxy-4-propyl-lH-indol-3-yl)ethyl)acetamide (NAS59a)
[1189] Product summary
[1190]
[1191] Synthetic scheme
[1192]
[1193] Experimental
[1194] Step 1 / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-74)Serotonin hydrochloride (3.00 g, 14.1 mmol) was suspended in anhydrous dichloromethane (90 mL) under nitrogen and triethylamine (7.13 g, 9.84 mL, 70.5 mmol) was added. The suspension was cooled to 0 °C and acetyl chloride (3.54 g, 3.21 mL, 45.1 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction was diluted with dichloromethane (30 mL) and washed with water (50 mL), 1 M hydrochloric acid (50 mL), water (50 mL) and satd. brine (50 mL), dried (MgSO₄) and concentrated to give impure 3-(2-acetamidoethyl)-lH-indol-5-yl acetate (3.96 g) as an orange foam. The material was dissolved in methanol (60 mL) and potassium carbonate (1.95 g, 14.1 mmol) was added and the mixture was stirred at room temperature for 18 h. The mixture was concentrated to give a brown residue which was partitioned between water (20 mL) and ethyl acetate (60 mL). The layers were separated, and the aqueous phase was extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water (30 mL), satd. brine (30 mL), dried (MgSO₄) and concentrated to afford / V-(2-(5-hydroxy-lH-indol-3-yl)ethyl)acetamide (2.84 g, 92 %) as a brown sticky foam.
[1195] LC-MS (+ve mode): m / z = 219.15 [M+H]+.
[1196] Step 2 / V-(2-(5-(Allyloxy)-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-64)
[1197] / V-(2-(5-Hydroxy-lH-indol-3-yl)ethyl)acetamide (212 mg, 0.97 mmol) and caesium carbonate (332 mg, 1.05 mmol) were suspended in anhydrous acetonitrile (10 mL) under nitrogen, and allyl bromide (124 mg, 88 pL, 1.02 mmol) was added. The reaction was heated at 60 °C for 4 h. The reaction was cooled to room temperature and filtered through Celite, washing with acetonitrile (3 x 10 mL). The combined filtrates were concentrated to give a dark-brown residue. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford / V-(2-(5-(allyloxy)-lH-indol-3-yl)ethyl)acetamide (142 mg, 57 %) as a brown oil.
[1198] LC-MS (+ve mode): m / z = 259.15 [M+H]+.
[1199] Step 3 / V-(2-(4-Allyl-5-hydroxy-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-72)
[1200] / V-(2-(5-(Allyloxy)-lH-indol-3-yl)ethyl)acetamide (110 mg, 0.50 mmol) was dissolved in diglyme (1 mL) in a microwave vessel. The vessel was degassed under vacuum and back-filled with nitrogen (3 cycles) and the vessel was sealed and heated at 180 °C under microwave irradiation for 2 h. The reaction was shown to be incomplete by LC-MS and the reaction was further heated at 190 °C under microwave irradiation for 1 h. The solution was concentrated under high vacuum to give a dark-brown residue. The material was purified by normal phase chromatography, eluting with a gradient of methanol in dichloromethane to afford N-(2-(4-allyl-5-hydroxy-1H-indol-3-yl)ethyl)acetamide (48 mg, 43 %) as a yellow semi-solid.
[1201] Step 4 / V-(2-(5-Hydroxy-4-propyl-lH-indol-3-yl)ethyl)acetamide (BP-AB-1-80)
[1202] A solution of / V-(2-(4-allyl-5-hydroxy-lH-indol-3-yl)ethyl)acetamide (48 mg, 0.19 mmol) in anhydrous methanol (2 mL) was added to a flask containing 10 % palladium on carbon (24 mg, 5 mol % Pd) under nitrogen. The suspension was evacuated and back-filled with hydrogen (3 cycles) and the reaction was stirred under hydrogen at room temperature for 1 h. The suspension was filtered through Celite, washing with methanol (3 x 5 mL) and the combined filtrates were concentrated to afford / V-(2-(5-hydroxy-4-propyl-lH-indol-3-yl)ethyl)acetamide as a brown semi-solid (44 mg, 89 %).
[1203] LC-MS (+ve mode): m / z = 261.20 [M+H]+.
[1204] Example 5: Effects of New Chemical Entities (several concentrations) in a primary culture of cortical neuronsNeuronal plasticity corresponds to the ability of the nervous system to reorganise itself by making new connections through neurogenesis, neuritogenesis and synaptogenesis. Disrupted, abnormal and / or malfunctioning neuronal plasticity is found in neurodegenerative diseases, neurological disorders and during biological ageing, or senescence. Low neuronal plasticity is associated with cognitive decline, depression and psychiatric diseases.
[1205] The aim of this study was to assess the effect of several test compounds (2-4 concentrations) on the number of neurons, the outgrowth of neurite network of cortical neurons, as well as the number of roots and extremities after 3 days of treatment (from D1-D3). The treatment was applied on day 1 of culture.
[1206] All experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and followed current European Union regulations (Directive 2010 / 63 / EU).
[1207] Rat cortical neurons were cultured as described by Callizot et al., 2021 (Callizot N, Campanari ML, Rouvière L, Jacquemot G, Henriques A, Garayev E, Poindron P. Huperzia serrata Extract 'NSP01' With Neuroprotective Effects-Potential Synergies of Huperzine A and Polyphenols. Front Pharmacol. 2021 Aug 30;12:681532) with modifications.
[1208] Briefly pregnant female rat (Wistar) of 15 days of gestation was killed using a deep anaesthesia with CO2 chamber and a cervical dislocation. Foetuses were collected and immediately placed in ice-cold L15 Leibovitz medium with a 2 % penicillin (10,000 U / mL) and streptomycin (10 mg / mL) solution (PS) and 1 % bovine serum albumin (BSA).
[1209] Cortex were specifically dissected and then were treated for 20 min at 37 °C with a trypsin-EDTA solution at a final concentration of 0.05 % trypsin and 0.02 % EDTA. The dissociation was stopped by addition of Dulbecco's modified Eagle's medium (DMEM) with 4.5 g / L of glucose, containing DNAse I grade II (final concentration 0.5 mg / mL) and 10 % foetal calf serum (FCS). Cells were mechanically dissociated by three forced passages through the tip of a 10-mL pipette. Cells were then centrifuged at 515 x g for 10 min at 4 °C. The supernatant was discarded, and the pellet was resuspended in a defined culture medium consisting of Neurobasal medium with a 2 % solution of B27 supplement, 2 mmol / litre of L-glutamine, 2 % of PS solution, and 10 ng / mL of brain-derived neurotrophic factor (BDNF). Viable cells were counted in a Neubauer cytometer, using the trypan blue exclusion test. The cells were seeded at a density of 25,000 per well in a 96-well plate precoated with poly-L-lysine and were cultured at 37 °C in an air (95 %) - CO2 (5 %) incubator. For 96 well-plates, only 60 wells were used. The wells of first and last lines and columns were not used (to avoid any edge effect) and were filled with sterile water.
[1210] Vehicle: Culture medium, 0.1% or 0.2% DMSO or 0.1 % Methanol.
[1211] Treatment: On day 1 (day of seeding), compounds were applied on the culture and left for 3 days (72h). For plate 0 and Obis, ANA-12 (antagonist of TrkB) was added first and lh after ANA-12 application, test compounds, as well as negative or positive controls, were added. All compounds were left for 72h on cells. 3 days after the treatment (and after seeding), the supernatant was removed, and kept frozen. Cells were then fixed by a cold solution of ethanol (95 %) and acetic acid (5 %) for 5 min at -20 °C and washed twice in PBS. Cell membranes were permeabilized and non-specific sites were blocked with a solution of PBS containing 0.1 % of saponin and 1 % FCS for 15 min at room temperature. Cells were incubated for 2 hours at room temperature with a primary chicken polyclonal antibody anti-MAP-2 (microtubule-associated protein 2), at a dilution of 1 / 400 in PBS containing 1 % FCS and 0.1 % of saponin. This antibody binds specifically neurons and neurites, allowing study of neuronal cell survival and neurite network.The anti-MAP-2 antibody was revealed with a secondary Alexa Fluor 488 coupled goat anti-chicken antibody diluted at 1 / 400 in PBS containing 1 % FCS, 0.1 % saponin, for 1 hour at room temperature. Cell nuclei were counterstained with the fluorescent dye Hoechst.
[1212] For each condition, 30 pictures (representing the whole well area) are automatically taken using ImageXpress® (Molecular Devices) or Operetta® (Perkin Elmer) at 20x magnification using the same acquisition parameters. The following read-outs were automatically assessed:
[1213] Total neuron survival (number of MAP-2 positive neuron)
[1214] Total neurite network (length of MAP-2 positive neurite in pm)
[1215] Number of roots (of MAP-2 positive neuron)
[1216] Number of extremities (of MAP-2 positive neurons)
[1217] All values are expressed as mean + / - SEM (standard error of the mean). Normality was verified and outliers were identified with Grubb's test. Statistical analysis was performed by one-way ANOVA followed by Fisher's LSD test. p< 0.05 will be considered significant.
[1218] Example 5a: BPL-NAS36
[1219]
[1220] BPL-NAS36 was tested and the results can be seen in Fig.l alongside a range of other compounds and controls. It is readily apparent that BPL-NAS36 performed exceptionally well. This positive effect was evident in all 4 parameters tested. The results indicate that BPL-NAS36s effects are mediated by the tropomyosin receptor kinase B (TrkB) receptor (co-administration of BPL-NAS36 alongside the TrkB antagonist ANA-12 attenuates the effects of BPL-NAS36).
[1221]
[1222] BPL-NAS11, 36 and 21 were tested and the results can be seen in Fig.2. All compounds performed well compared with control, at all of the concentrations tested. The standout compounds of those tested were BPL-NAS36 and 21.
[1223] Example 5c: BPL-NAS28b, 28 and 29
[1224]
[1225] BPL-NAS28b, 28 and 29 were tested and the results can be seen in Fig.3. All compounds performed well compared with control, at the majority of concentrations tested. The effect of NAS38 was mostly evident in increasing neuronal survival, this is advantageous for use as an intervention at early stages of a neurodegenerative, or similar, condition. A reduction in the number of neurons dying may delay or halt the progression of the condition.
[1226] Example 5d: BPL-NAS9, 44 and 55
[1227]
[1228] BPL-NAS9, 44 and 55 were tested and the results can be seen in Fig.4. All compounds performed relatively well at most concentrations compared with control, with the exception of a specific concentration of BPL-NAS9 (Fig.3 C and D). The standout compound of those tested is BPL-NAS55, particularly in terms of (i) number of MAP-2 neurons in a primary culture of cortical neurons; and (ii) neurite network of MAP-2 neurons in a primary culture of cortical neurons.
[1229]
[1230] BPL-NAS45, 43 and 50 were tested and the results can be seen in Fig.5. It is readily apparent that all compounds performed well compared with control, at all of the concentrations tested. The standout compounds of those tested were BPL-NAS43 and 50. The effects of NAS50 were mostly evident in increasing branching points and extremities; this is advantageous for use as a treatment in the latter stages of a neurodegenerative, or similar, condition. A reduction in the number of neurons dying may delay or halt the progression of the condition. Maturation of the surviving population of neurons may be beneficial for symptom management.
[1231] Example 5f: BPL-NAS38, 31 and 35
[1232]
[1233] BPL-NAS38, 31 and 35 were tested and the results can be seen in Fig.6. The standout compounds of those tested were BPL-NAS31 and 35.
[1234] Example 5g: BPL-NAS51, 24 and 41
[1235]
[1236] BPL-NAS51, 24 and 41 were tested and the results can be seen in Fig.7. The standout compounds of those tested were BPL-NAS24 and 41. NAS41 was mostly effective in neuronal survival, and potentially efficacious in earlier stages of a pathology.
[1237]
[1238] BPL-NAS43b, 40 and 49 were tested and the results can be seen in Fig.8. The standout compound of those tested was BPL-NAS40, with effect on all parameters tested.
[1239] Example 5i: BPL-NAS16, 57a and 58a
[1240]
[1241] BPL-NAS16, 57a and 58a were tested and the results can be seen in Fig.9. The standout compound of those tested was BPL-NAS58a.
[1242] Example 5j: Further Embodiments
[1243] Herein disclosed is there is provided a method of increasing neuronal survival and plasticity. The method may comprise contacting a neuronal cell with an NAS analogue, in an amount sufficient to increase neural plasticity of the neuronal cell.
[1244] Herein disclosed is there is provided a method of treating a brain disorder. The method may comprise administering to a subject in need thereof a therapeutically effective amount of an NAS analogue, thereby treating the brain disorder, wherein the NAS analogue increases neural plasticity of the neuronal cell.
[1245] The neuronal cells can be any type of neuron cells. In some embodiments, the neuron cell is a cortical neuron cell. In some embodiments, the neuron cell is a cortical pyramidal neuron cell.
[1246] In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of neuroprotection. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of treating a condition wherein said condition would benefit from neuroprotection. In an embodiment, there is provided any one of the compounds as disclosed herein, or apharmaceutical composition comprising any said compound, for use in a method of preventing a condition wherein said condition may be prevented and / or lessened by neuroprotection.
[1247] In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of increasing neural plasticity. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of treating a condition wherein said condition would benefit from increasing neural plasticity. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of preventing a condition wherein said condition may be prevented and / or lessened by increasing neural plasticity.
[1248] In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of increasing neurogenesis. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of treating a condition wherein said condition would benefit from increasing neurogenesis. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of preventing a condition wherein said condition may be prevented and / or lessened by increasing neurogenesis. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of increasing neurite outgrowth. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of treating a condition wherein said condition would benefit from increasing neurite outgrowth. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of preventing a condition wherein said condition may be prevented and / or lessened by increasing neurite outgrowth.
[1249] In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of increasing neural plasticity. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of treating a condition wherein said condition would benefit from increasing neural plasticity. In an embodiment, there is provided any one of the compounds as disclosed herein, or a pharmaceutical composition comprising any said compound, for use in a method of preventing a condition wherein said condition may be prevented and / or lessened by increasing neural plasticity.
[1250] In an embodiment, there is provided a compound, or a pharmaceutical composition comprising said compound, for use in a method of one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity, wherein the compound is selected from:
[1251]
[1252]
[1253] In an embodiment, there is provided a compound, or a pharmaceutical composition comprising said compound, for use in a method of treating a condition wherein said condition would benefit from one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity, wherein the compound is selected from:
[1254]
[1255] In an embodiment, there is provided BPL-NAS29, or a pharmaceutical composition comprising said compound, for use in a method of one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity.
[1256] In an embodiment, there is provided BPL-NAS36, or a pharmaceutical composition comprising said compound, for use in a method of one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity.In an embodiment, there is provided BPL-NAS50, or a pharmaceutical composition comprising said compound, for use in a method of one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity.
[1257] In an embodiment, there is provided BPL-NAS55, or a pharmaceutical composition comprising said compound, for use in a method of one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity.
[1258] In an embodiment, there is provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in a method of one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity.
[1259] In an embodiment, there is provided BPL-NAS43, or a pharmaceutical composition comprising said compound, for use in a method of one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity.
[1260] In an embodiment, there is provided BPL-NAS29, or a pharmaceutical composition comprising said compound, for use in a method of treating a condition wherein said condition would benefit from one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity. In an embodiment, there is provided BPL-NAS36, or a pharmaceutical composition comprising said compound, for use in a method of treating a condition wherein said condition would benefit from one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity. In an embodiment, there is provided BPL-NAS50, or a pharmaceutical composition comprising said compound, for use in a method of treating a condition wherein said condition would benefit from one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity. In an embodiment, there is provided BPL-NAS55, or a pharmaceutical composition comprising said compound, for use in a method of treating a condition wherein said condition would benefit from one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity. In an embodiment, there is provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in a method of treating a condition wherein said condition would benefit from one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity. In an embodiment, there is provided BPL-NAS43, or a pharmaceutical composition comprising said compound, for use in a method of treating a condition wherein said condition would benefit from one or more of: neuroprotection, increasing neurogenesis, increasing neurite outgrowth and / or increasing neural plasticity. Another embodiment described herein is a method of treating or preventing serotonin (5-hydroxytryptamine, 5-HT) receptor disorders, neuronal injuries, neurodegeneration, neurological diseases, congenital or organic cognitive impairment, learning disabilities, autism spectrum disorder, psychiatric and mood disorders, cognitive enhancement, physical or motor neuron enhancement, or general improvement of mental health in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an NAS analogue as described herein, or a composition thereof.
[1261] In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of promoting longevity.In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of delaying ageing.
[1262] In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of treatment of one or more age-related conditions. In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of treatment of gulf war syndrome.
[1263] In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of treatment of one or more womens health conditions. In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of treatment of premenstrual syndrome (PMS).
[1264] In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of treatment of premenstrual dysphoric disorder (PMDD). In an embodiment, there is provided the use of a compound as disclosed herein, or a pharmaceutical composition comprising said compound in a method of treatment of metabolic syndrome and disorders. For the purpose of this disclosure, "neural plasticity" may be understood as structural and functional changes in the nervous system occurring at any time during the life span, including neurogenesis, modulation of neuron or astrocyte soma or neurite size, shape and length, synaptic plasticity, including synaptogenesis, synaptic strengthening, spinogenesis, loss of synaptic spines, "pruning", changes in synaptic spine volume, changes in synaptic densities, including changes in specific synaptic proteins and pathways, including especially mRNA coding for synaptic density protein and receptor subunits, including especially protein subunits of the AMPAR and NMDAR, and including modulation of the mTOR pathway and TrkB pathway and changes in neurotrophic factors' pathways, including especially BDNF. " Neuroprotection" may be understood as the mechanisms and strategies employed to defend the central nervous system (CNS) against injury due to both acute (e.g. trauma or stroke) and chronic neurodegenerative disorders (e.g. Dementia, Parkinson's, Alzheimer's, Epilepsy etc.), inflammatory conditions (ALS), genetic disorders (e.g. Rett, fragile-X), mitochondrial dysfunction, other insults (toxicity, e.g. Gulf War Syndrome), age- or sex- related pathologies, metabolic syndrome.
[1265] Example 6: Effect of certain compounds on dopaminergic tyrosine hydroxylase (TH)-positive neurons injured with a-syn pre-formed fibrils (PFF) and conduritol B epoxide (CBE)
[1266] Parkinson's disease (PD) is a common neurodegenerative movement disorder that affects around 1% of the population over the age of 70. It is the second most common neurodegenerative disease after Alzheimer's disease. The patients suffering PD display symptoms of motor instabilities with resting tremor as the first symptom in 70 % of the cases. Other clinical symptoms are rigidity, bradykinesia and postural instability and often include cognitive impairment, depression and sleep disorders.
[1267] Although the pathological mechanisms leading to substantia nigra (SN) degeneration might be multiple, several pathways are considered to be central: protein aggregation linked to proteasomal impairments, mitochondrial dysfunction (also caused by specific DA-toxins), and impairment in dopamine (DA) release. All these pathways are believed to converge and generate reactive oxygen species (ROS) and massive oxidative stress resulting in cell death.a-syn oligomers and fibrils mediate toxicity that occurs via several intracellular mechanisms such as mitochondrial and endoplasmic reticulum (ER) stress and an impaired autophagy-lysosomal pathway. In addition, emerging evidence suggests that a-syn spreads from neuron to neuron or glia via self amplification and propagates in a stereotypical and topographical pattern among neighbouring cells.
[1268] Mutations on the gene coding for the lysosomal protein glucocerebrosidase (GBA) is present in a small subpopulation of patients with Parkinson's disease and represent a strong risk factor for this disease. GBA represents a therapeutic target for Parkinson's disease. Loss of GBA activity induces lysosomal dysfunction, impaired alpha-synuclein recycling, and later, mitochondrial stress and cell death.
[1269] This study was performed on therapeutic agents developed by the applicant that could display neuroprotective effect on TH neurons injured with a-syn PFF in presence of conduritol B epoxide, CBE, a covalent inhibitor of GBA. Treatment with compounds was performed in a pre-treatment format (lh before the injury).
[1270] All experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and follow current European Union regulations (Directive 2010 / 63 / EU).
[1271] Rat dopaminergic neurons were cultured as described by Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM and Rees DD. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008; 22(7):2488-97 and Callizot N, Combes M, Henriques A, Poindron P. Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins. Pios One. 2019. / doi.org / 10.1371 / journal. pone.0215277. Briefly, pregnant female rat (Wistar) of 15 days of gestation were killed using a deep anesthesia with CO2 chamber and a cervical dislocation.
[1272] The midbrains obtained from 15-day-old rat embryos (Janvier, France) were dissected under a microscope. The embryonic midbrains were removed and placed in ice-cold medium of Leibovitz (L15) containing 2% of Penicillin-Streptomycin (PS) and 1% of bovine serum albumin (BSA). The ventral portion of the mesencephalic flexure, a region of the developing brain rich in dopaminergic neurons, were used for the cell preparations. The midbrains were dissociated by trypsinization for 20 min at 37°C (solution at a final concentration of 0.05% trypsin and 0.02% EDTA). The reaction was stopped by the addition of Dulbecco's modified Eagle's medium (DMEM) containing DNAase I grade II (0.5 mg / mL) and 10% of foetal calf serum (FCS). Cells were then mechanically dissociated by 3 passages through a 10 mL pipette. Cells were then centrifuged at 180 x g for 10 min at +4°C on a layer of BSA (3.5%) in L15 medium. The supernatant was discarded and the cell pellets were re-suspended in a defined culture medium consisting of Neurobasal supplemented with B27 (2%), L-glutamine (2 mM) and 2% of PS solution and 10 ng / mL of Brain-derived neurotrophic factor (BDNF) and 1 ng / mL of Glial-Derived Neurotrophic Factor (GDNF). Viable cells were counted in a Neubauer cytometer using the trypan blue exclusion test. The cells were seeded at a density of 40,000 cel Is / we 11 in 96 well-plates (pre-coated with poly-L-lysine) and maintained in a humidified incubator at 37°C in 5% CO2 / 95% air atmosphere. Half of the medium was changed every 2 days with fresh medium.
[1273] For 96 wells plates, only 60 wells were used. The wells of first and last lines and columns will not be used (to avoid any edge effect) and were filled with sterile water.
[1274] Vehicle: Culture medium (0.1 % DMSO).
[1275] Pre-incubation: On day 6 of culture, the test compounds were dissolved in DMSO and in culture medium and pre-incubated with primary dopaminergic neurons for lh before CBE exposure (and 2 hours before a-syn PFF injury).CBE-mediated GBA inhibition: On day 6 of culture, conduritol B epoxide (CBE, 20 pM) was added to the culture for 1 h before asyn injury. CBE was re-applied on day 8 for an additional 48 hours (see below).
[1276] a-syn PFF injury: Three day before the injury, human a-syn peptide was reconstituted in define culture medium at 4 pM (mother solution) and was slowly shacked at +37 °C for 3 days in dark to generate the a-syn (for details see Henriques, A.; Rouviere, L.; Gloria, E.; Farrugia, C.; El Waly, B.; Poindron, P.; Callizot, N.
[1277] AlphaSynuclein: The Spark That Flames Dopaminergic Neurons, In Vitro and In Vivo Evidence. Int. J. Mol. Sci.
[1278] 2022, 23, 9864). The control medium was prepared in the same conditions. On day 6, a-syn (250 nM) was applied on cells, in presence of CBE (20 pM) in presence or absence of test compounds. The injury was renewed on day 8 for an additional 48h still in presence of test compounds and CBE.
[1279] 96 hours after injury, the cell culture supernatant was discarded. Live cells were incubated with MitoSOX™ Red (marker of ROS generated by the mitochondria) for 10 min at 37°C. Cells were fixed by a solution of 4% paraformaldehyde in PBS, pH =7.3 for 20 min at room temperature. The cells were washed twice in PBS, and then permeabilized. Non-specific sites were blocked with a solution of PBS containing 0.1% of saponin and 1% FBS for 15 min at room temperature. The cultures were incubated with:
[1280] TH neurons: Mouse monoclonal anti-Tyrosine Hydroxylase antibody at dilution of 1 / 10000 in PBS containing 1% FCS, 0.1 % saponin.
[1281] a-syn accumulation: polyclonal anti-alpha synuclein (a-syn, cell signalling, 2642S) antibody produced in rabbit at dilution of 1 / 200 in PBS containing 1% FCS, 0.1 % saponin, for 2 h at room temperature.
[1282] Nuclei were counterstained with the fluorescent dye Hoechst (sigma, 1 / 1000): marker of cell number.
[1283] For each condition, 30 pictures (representative of the all well area) per well were automatically taken using Operetta® (Perkin Elmer) with 20x magnification, using the same acquisition parameters. From images, analyses were directly and automatically performed by Harmony® (Perkin Elmer). The following readouts were investigated:
[1284] Analysis of total number of TH neurons (TH positive neurons)
[1285] Total neurite network of TH positive neurons (in pm)
[1286] a-syn aggregation (overlapping between TH and a-syn staining in pm2)
[1287] Mitochondrial ROS in TH (overlap between TH and MitoSox signal, pm2)
[1288] All values are expressed as mean + / - SEM (standard error of the mean). Statistical analysis was performed by one-way ANOVA, followed by a Fisher's LSD test. p<0.05 was considered significant. The results can be seen in Figure 10 and Figure 11. The "control" refers to cells which have not received treatment with a-syn and CBE treatment.
[1289] Example 6a: BPL-NAS21
[1290]
[1291] It can be seen from Figure 10 that BPL-NAS21 administration led to an increase in neuronal survival and neurite network with a decrease in a-syn area and a decrease in ROS production, all desirable effects. These effects were present at both 1 and lOnM concentration.There is therefore provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in a method of preventing one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in a method of halting or slowing the progression of one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in a method of treating one or more neurodegenerative disorders or conditions.
[1292] Example 6b: BPL-NAS50
[1293]
[1294] It can be seen from Figure 10 that BPL-NAS50 administration led to a decrease in both a-syn area and ROS production, all desirable effects. These effects were present at the InM concentration.
[1295] There is therefore provided BPL-NAS50, or a pharmaceutical composition comprising said compound, for use in a method of halting or slowing the progression of one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS50, or a pharmaceutical composition comprising said compound, for use in a method of treating one or more neurodegenerative disorders or conditions.
[1296] Example 6c: BPL-NAS28
[1297]
[1298] It can be seen from Figure 11 that BPL-NAS28 administration led to an increase in neuronal survival and a decrease in both a-syn area and ROS production, all desirable effects. These effects were present at the lOOnM concentration.
[1299] There is therefore provided BPL-NAS28, or a pharmaceutical composition comprising said compound, for use in a method of preventing one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS28, or a pharmaceutical composition comprising said compound, for use in a method of halting or slowing the progression of one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS28, or a pharmaceutical composition comprising said compound, for use in a method of treating one or more neurodegenerative disorders or conditions.
[1300] Example 7: Evaluation of synergistic effects, with different concentrations, between N-Acetylserotonin (NAS) compounds and Rapamycin on dopaminergic tyrosine hydroxylase (TH)-positive neurons injured with a-syn pre-formed fibrils (PFF)
[1301] Parkinson's disease (PD) is a common neurodegenerative movement disorder that affects around 1% of the population over the age of 70. It is the second most common neurodegenerative disease after Alzheimer's disease. The patients suffering PD display symptoms of motor instabilities with resting tremor as the firstsymptom in 70 % of the cases. Other clinical symptoms are rigidity, bradykinesia and postural instability and often include cognitive impairment, depression and sleep disorders.
[1302] Although the pathological mechanisms leading to substantia nigra (SN) degeneration might be multiple, several pathways are considered to be central: protein aggregation linked to proteasomal impairments, mitochondrial dysfunction (also caused by specific DA-toxins), and impairment in dopamine (DA) release. All these pathways are believed to converge and generate reactive oxygen species (ROS) and massive oxidative stress resulting in cell death.
[1303] The present study investigated the synergy between inactive doses of rapamycin (an mTor inhibitor) and certain NAS compounds, using different ratios of the two compounds, in an in vitro model of PD disease. Treatment with the NAS compounds was performed as a pre-treatment (lh before a-syn injury) and rapamycin was applied 24h post injury.
[1304] All experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and follow current European Union regulations (Directive 2010 / 63 / EU).
[1305] Rat dopaminergic neurons were cultured as described by Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM and Rees DD. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008; 22(7):2488-97 and Callizot N, Combes M, Henriques A, Poindron P. Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins. Pios One. 2019. / doi.org / 10.1371 / journal. pone.0215277. Briefly, pregnant female rat (Wistar) of 15 days of gestation were killed using a deep anesthesia with CO2 chamber and a cervical dislocation.
[1306] The midbrains obtained from 15-day-old rat embryos (Janvier, France) were dissected under a microscope. The embryonic midbrains were removed and placed in ice-cold medium of Leibovitz (L15) containing 2% of Penicillin-Streptomycin (PS) and 1% of bovine serum albumin (BSA). The ventral portion of the mesencephalic flexure, a region of the developing brain rich in dopaminergic neurons, were used for the cell preparations. The midbrains were dissociated by trypsinization for 20 min at 37°C (solution at a final concentration of 0.05% trypsin and 0.02% EDTA). The reaction was stopped by the addition of Dulbecco's modified Eagle's medium (DMEM) containing DNAase I grade II (0.5 mg / mL) and 10% of foetal calf serum (FCS). Cells were then mechanically dissociated by 3 passages through a 10 mL pipette. Cells were then centrifuged at 180 x g for 10 min at +4°C on a layer of BSA (3.5%) in L15 medium. The supernatant was discarded and the cell pellets were re-suspended in a defined culture medium consisting of Neurobasal supplemented with B27 (2%), L-glutamine (2 mM) and 2% of PS solution and 10 ng / mL of Brain-derived neurotrophic factor (BDNF) and 1 ng / mL of Glial-Derived Neurotrophic Factor (GDNF). Viable cells were counted in a Neubauer cytometer using the trypan blue exclusion test. The cells were seeded at a density of 40,000 cel Is / we 11 in 96 well-plates (pre-coated with poly-L-lysine) and maintained in a humidified incubator at 37°C in 5% CO2 / 95% air atmosphere. Half of the medium was changed every 2 days with fresh medium.
[1307] For 96 wells plates, only 60 wells were used. The wells of first and last lines and columns will not be used (to avoid any edge effect) and were filled with sterile water.
[1308] Vehicle: Culture medium (0.1 % DMSO).
[1309] Pre-incubation: On day 6 of culture, the test compounds were dissolved in DMSO and in culture medium and pre-incubated with primary dopaminergic neurons for lh before a-syn PFF injury (for NAS compounds).a-syn PFF injury: Three days before the injury, human a-syn peptide was reconstituted in a defined culture medium at 4 pM (mother solution) and was slowly shacked at +37 °C for 3 days in the dark to generate the a-syn (for details see Henriques, A.; Rouviere, L.; Gloria, E.; Farrugia, C.; El Waly, B.; Poindron, P.; Callizot, N. AlphaSynuclein: The Spark That Flames Dopaminergic Neurons, In Vitro and In Vivo Evidence. Int. J. Mol. Sci.
[1310] 2022, 23, 9864). The control medium was prepared in the same conditions. On day 6, a-syn (250 nM) was applied to the cells, in the presence or absence of test compounds. The injury was renewed on day 8 for an additional 48h still in presence of test compounds.
[1311] Rapamycin application: On day 7, 24 hours after a-syn PFF injury, the rapamycin was dissolved in DMSO and in cell culture and applied to the cell cultures for the following 72 hours. The amount of rapamycin used is not known to be associated with any clinically desirable effect.
[1312] 96 hours after injury, the cell culture supernatant was discarded. Live cells were incubated with MitoSOX™ Red (marker of ROS generated by the mitochondria) for 10 min at 37°C. Cells were fixed by a solution of 4% paraformaldehyde in PBS, pH =7.3 for 20 min at room temperature. The cells were washed twice in PBS, and then permeabilized. Non-specific sites were blocked with a solution of PBS containing 0.1% of saponin and 1% FBS for 15 min at room temperature. The cultures were incubated with:
[1313] TH neurons: Mouse monoclonal anti-Tyrosine Hydroxylase antibody at dilution of 1 / 10000 in PBS containing 1% FCS, 0.1 % saponin.
[1314] a-syn accumulation: polyclonal anti-alpha synuclein (a-syn, cell signaling, 2642S) antibody produced in rabbit at dilution of 1 / 200 in PBS containing 1% FCS, 0.1 % saponin, for 2 h at room temperature.
[1315] Nuclei were counterstained with the fluorescent dye Hoechst (sigma, 1 / 1000): marker of cell number.
[1316] For each condition, 30 pictures (representative of the all well area) per well were automatically taken using Operetta® (Perkin Elmer) with 20x magnification, using the same acquisition parameters. From images, analyses were directly and automatically performed by Harmony® (Perkin Elmer). The following readouts were investigated:
[1317] Analysis of total number of TH neurons (TH positive neurons)
[1318] Total neurite network of TH positive neurons (in pm)
[1319] a-syn aggregation (overlapping between TH and a-syn staining in pm2)
[1320] Mitochondrial ROS in TH (overlap between TH and MitoSox signal, pm2)
[1321] All values are expressed as mean + / - SEM (standard error of the mean). Statistical analysis was performed by one-way ANOVA, followed by a Fisher's LSD test. p<0.05 was considered significant.
[1322] The combination of BPL-NAS21, O.lnM, and rapamycin, 0.05pM, displayed no effect in all readouts. The combination of BPL-NAS28, InM, and rapamycin, 0.05pM, displayed no effect in all readouts. The combination of BPL-NAS50, O.lnM, and rapamycin, 0.05pM, displayed no effect in all readouts.
[1323] The results can be seen in Figures 12 to 15, the Tables below and the following Examples 7a, 7b and 7c.
[1324]
[1325]
[1326]
[1327]
[1328]
[1329] mTOR, also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 (FRAP1), is a protein kinase that in humans is encoded by the MTOR gene. mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF- 2), and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue, and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers.
[1330] Rapamycin is a naturally occurring macrolide compound, produced by the bacterium Streptomyces hygroscopicus, and inhibitor of mTOR kinase. Rapamycin is approved in the EU for use in the prophylaxis of organ rejection and also for use in the treatment of facial angiofibroma with tuberous sclerosis complex. Rapamycin has also been investigated for possible use as a longevity-promoting drug. However, rapamycin has complex effects on the immune system and produces adverse effects (such as sepsis, venous thromboembolism, diabetes, bone necrosis and melanoma), which impose limits on its clinical utility.
[1331] There is therefore a need in the art for improved methods of treatment incorporating rapamycin at dose levels and dosing regimens which avoid such adverse effects, and pharmaceutical combinations thereof. Such dose levels, dosing regiments and pharmaceutical combinations are advantageously provided herein.
[1332] Example 7a: BPL-NAS21
[1333]
[1334] It can be seen from Figure 12 that BPL-NAS21 (active dose, InM) and rapamycin (at an inactive dose, 0.05pM) co-administration exhibited desirable, significant, changes on the % of both a-syn aggregation and mitochondrial ROS in TH. This effect was greater than that observed for BPL-NAS21 alone.
[1335] There is therefore provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of preventing one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of halting or slowing the progression of one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS21, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of treating one or more neurodegenerative disorders or conditions.
[1336] Example 7b: BPL-NAS28
[1337]
[1338] It can be seen from Figure 13 that BPL-NAS28 (at an inactive dose, InM) and rapamycin (at active dose, lpM) co-administration exhibited desirable, large and significant, changes on all readouts. The data also showed thatthe combination of BPL-NAS28 (at an active dose, lOnM) and rapamycin (at an inactive dose, 0.05pM) exhibited desirable, significant, changes on all readouts. This effect was stronger than that observed for BPL-NAS28 alone.
[1339] There is therefore provided BPL-NAS28, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of preventing one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS28, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of halting or slowing the progression of one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS28, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of treating one or more neurodegenerative disorders or conditions.
[1340] Example 7c: BPL-NAS50
[1341]
[1342] It can be seen from Figure 14 that BPL-NAS50 (at an active dose, InM) and rapamycin (at an inactive dose, 0.05pM) co-administration exhibited desirable, and significant, changes on all readouts. This effect was stronger than the effect of BPL-NAS50 alone.
[1343] Please note that the active and inactive dose levels for the BPL-NAS compounds were determined previously (see Example 6).
[1344] There is therefore provided BPL-NAS50, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of preventing one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS50, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of halting or slowing the progression of one or more neurodegenerative disorders or conditions. In an embodiment, there is provided BPL-NAS50, or a pharmaceutical composition comprising said compound, for use in combination with an mTOR inhibitor, such as rapamycin, in a method of treating one or more neurodegenerative disorders or conditions.
Claims
CLAIMS1. A compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein of Ri is selected from: Ci, 2, 3, 4, 5, 6, 7, s, 9 or 10 optionally substituted straight or branched chain alkyl, C3, 4, 5, 6, 7, s, 9 or 10 optionally substituted cycloalkyl, C3, 4, 5, 6, 7, 8, 9 or 10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron, wherein the compound is not N-Acetylserotonin.
2. The compound of claim 1, wherein R1is an Ci, 2, 3, 4, 5, 6, 7, s, 9or-io substituted straight or branched chain alkyl, wherein said alkyl group is substituted with one or more of: deuterium, Ci, 2, 3, 4, 5, 6, 7, s, 9 or-10 optionally substituted straight or branched chain alkyl, C3, 4, 5, 6, 7, s, 9 or -10 optionally substituted cycloalkyl, C3, 4, 5, 6, 7, 8, 9 or -10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
3. The compound of claim 1, wherein R1is a C3, 4, 5, 6, 7, s, 9 or -10 substituted cycloalkyl or a C3, 4, 5, 6, 7, s, 9 or -10 substituted aromatic ring, wherein said C3, 4, 5, 6, 7, s, 9 or -10 substituted cycloalkyl or a C3, 4, 5, 6, 7, 8, 9 or -10 substituted aromatic ring is substituted with one or more of: deuterium, C1, 2, 3, 4, 5, 6, 7, 8, 9 or -10 optionally substituted straight or branched chain alkyl, C3, 4, 5, 6, 7, 8, 9 or -10 optionally substituted cycloalkyl, C3, 4, 5, 6, 7, 8, 9 or -10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
4. The compound of claim 1, wherein R1is selected from:
5. The compound of claim 1, wherein R1is selected from:OCH2F, OCH(F2), OC(F3), OCH2CI, OCH2Br, OCH2F, OCH2CH2F, OCH2CH2Br, OCH2CH2CI, OCH2C(F3), OCH2C(F3), OCH2CH(F2), OCH2CH2C(F3) or OCH2CH2CH2F.
6. The compound of claim 1, wherein R1is selected from:OCH2X, OCH(X2), OC(X3), OCH2CH2X, OCH2C(X3), OCH2CH(X2), OCH2CH2C(X3) or OCH2CH2CH2X, wherein X is a halogen.
7. The compound of claim 1, wherein R1is selected from:OCH2X, OCH(X2), OC(X3), OCH2CH2X, OCH2C(X3), OCH2CH(X2), OCH2CH2C(X3) or OCH2CH2CH2X, wherein X is fluorine, bromine, chlorine or iodine.
8. The compound of claim 1, wherein R1is selected from:OCH(CH3)3, OCH2CH(CH3)CH2CH3, OCH(CH3)CH2CH3 or OCH2CH(CH2CH3)2.
9. The compound of claim 1, wherein R1is selected from:OCH2OCH3, OCH2OCH2CH3, OCH2OCH2CH2CH3, OCH2CH2OCH3 or OCH2CH2OCH2CH3.
10. The compound of claim 1, wherein R1is selected from:OCH2CH2N(CH3)2, OCH2CH2CH2N(CH3)2, OCH2CH2SCH3, OCH2CH2C(O)OCH3, OCH2CH2CH2C(O)OCH3, OCH2CH2CH2C(O)OCH2CH3, OCH2CH2CH2OH or OCH2CH2OH.
11. The compound of claim 1, wherein R1is selected from:SC(CH3)3, SCH(CH3)2 or SCH2CH3.
12. The compound of claim 1, wherein R1is selected from:CH2CH2CH3 or C(CH3)3.
13. The compound of claim 1, wherein R1is selected from:CH2CI, CH2Br, CH2F, CH2I, C(Cl3), C(F3), C(Br3) or C(I3).
14. The compound of claim 1, wherein R1is selected from:NHCH2CH3or N(CH3).
15. A compound, or a pharmaceutically acceptable salt thereof, selected from: N-[2-(5-Butoxy-lH-indol-3- yl)ethyl]acetamideN-[2-(5-Pentoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Hexoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methylpropan-2-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Butan-2-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2,2-Dimethylpropoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Prop-2-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Prop-2-yn-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(But-3-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(Pent-4-enyloxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Cyclopropylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclobutylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclopentylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclohexylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclopropyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclobutyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclopentyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclohexyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(4-Methylbenzyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Phenylethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-((4-Fluorophenyl)methoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(2-Fluoroethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Thienylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Pyrrolylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Tetrahydrofuran-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-(5-(Tetrahydrothiophen-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-[5-[2-(Piperidin-l-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Morpholin-4-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(Oxetan-3-yloxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(Oxetan-3-ylmethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Trifluoromethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Chloromethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Bromomethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Fluoroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Chloroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2,2,2-Trifluoroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(2,2-Difluoroethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3,3,3-Trifluoropropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3-Fluoropropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-tert-Butoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methylbutoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(l-Methylpropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3-Methylbutoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(2-Ethylbutoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Methoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Ethoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Propoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methoxyethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Ethoxyethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-(Dimethylamino)ethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-(Pyrrolidin-l-yl)ethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-[3-(Dimethylamino)propoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Methoxycarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[3-(Ethoxycarbonyl)propoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Aminocarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3-Hydroxypropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(2-Hydroxyethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-(2-(Methylthio)ethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Propyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-tert-Butyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-tert-Butylthio-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Chloromethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Bromomethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Trifluoromethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Ethylamino-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Dimethylamino-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclobutyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclopentyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Benzyl-lH-indol-3-yl)ethyl]acetamideN-[2-[5-[2-(Pyridin-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Pyridin-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Pyridin-4-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Thiophen-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Thiophen-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide 16. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Butoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Pentoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Hexoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methylpropan-2-yloxy)-lH-indol-3-yl)ethyl]acetamide N-[2-(5-(Butan-2-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2,2-Dimethylpropoxy)-lH-indol-3-yl)ethyl]acetamide17. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-(Prop-2-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Prop-2-yn-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(But-3-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(Pent-4-enyloxy)-lH-indol-3-yl]ethyl]acetamide18. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Cyclopropylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclobutylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclopentylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclohexylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclopropyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclobutyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclopentyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclohexyloxy)-lH-indol-3-yl)ethyl]acetamide19. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-(4-Methylbenzyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Phenylethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-((4-Fluorophenyl)methoxy)-lH-indol-3-yl)ethyl]acetamide 20. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-[5-(2-Fluoroethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Thienylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Pyrrolylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Tetrahydrofuran-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-(5-(Tetrahydrothiophen-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-[5-[2-(Piperidin-l-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Morpholin-4-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-(Oxetan-3-yloxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(Oxetan-3-ylmethoxy)-lH-indol-3-yl]ethyl]acetamide21. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Trifluoromethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Chloromethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Bromomethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Fluoroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Chloroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2,2,2-Trifluoroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(2,2-Difluoroethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3,3,3-Trifluoropropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3-Fluoropropoxy)-lH-indol-3-yl]ethyl]acetamide22. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-tert-Butoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methylbutoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(l-Methylpropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3-Methylbutoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(2-Ethylbutoxy)-lH-indol-3-yl]ethyl]acetamide23. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Methoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Ethoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Propoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methoxyethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Ethoxyethoxy)-lH-indol-3-yl)ethyl]acetamide24. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-(2-(Dimethylamino)ethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-(5-(2-(Pyrrolidin-l-yl)ethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-[5-[3-(Dimethylamino)propoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Methoxycarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[3-(Ethoxycarbonyl)propoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Aminocarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-(3-Hydroxypropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(2-Hydroxyethoxy)-lH-indol-3-yl]ethyl]acetamide25. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-(2-(Methylthio)ethoxy)-lH-indol-3-yl)ethyl]acetamide26. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Propyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-tert-Butyl-lH-indol-3-yl)ethyl]acetamide27. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Chloromethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Bromomethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Trifluoromethyl-lH-indol-3-yl)ethyl]acetamide28. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Ethylamino-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Dimethylamino-lH-indol-3-yl)ethyl]acetamide29. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Cyclobutyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclopentyl-lH-indol-3-yl)ethyl]acetamide30. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-(5-Benzyl-lH-indol-3-yl)ethyl]acetamide31. A compound, or pharmaceutically acceptable salt thereof, selected from:N-[2-[5-[2-(Pyridin-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Pyridin-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Pyridin-4-yl)methoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Thiophen-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Thiophen-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide32. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or excipients and a compound, or pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 31.
33. The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 31 or a pharmaceutical composition as claimed in claim 21, in a method of treatment.
34. The use of claim 33, wherein the method of treatment is a method of treatment of:one or more neurodegenerative diseases;amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease or Huntington's disease;one or more mood disorders;depression, bipolar disorder or anxiety;one or more epilepsy disorders;one or more pain disorders;one or more inflammatory disorders;one or more psychiatric disorders;schizophrenia or borderline personality disorder;one or more disorders resulting from brain injury;one or more addiction disorders;one or more neurodevelopmental disorders;autism spectrum disorders or attention-deficit / hyperactivity disorder; orone or more circadian rhythm disorders.
35. The use of claim 34, wherein the method of treatment is a method of treatment of one or more circadian rhythm disorders.
36. A method of synthesis of a compound, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 31.
37. A method of preparing a pharmaceutical composition as claimed in claim 32.
38. An agonist of tropomyosin receptor kinase B (TrkB) and an inhibitor of mammalian target of rapamycin (mTOR) for use in a method of treatment of a disease or condition in a patient in need thereof, wherein the method of treatment comprises the co-administration of the TrkB agonist and the mTOR inhibitor to the patient.
39. The TrkB agonist and the mTOR inhibitor for use of claim 38, wherein the mTOR inhibitor is administered at a dose which is substantially lower than a dose at which said mTOR inhibitor is active when administered alone.
40. The TrkB agonist and the mTOR inhibitor for use of claim 38 or claim 39, wherein the mTOR inhibitor is administered at a dose which does not produce known adverse effects of said mTOR inhibitor.
41. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 40, wherein the mTOR inhibitor is administered at a dose of 0.1 to 1mg / kg or below of body weight of a patient.
42. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 41, wherein the TrkB agonist and the mTOR inhibitor are administered at the same time.
43. The TrkB agonist and the mTOR inhibitor for use of claim 42, wherein the TrkB agonist and the mTOR inhibitor are administered at the same time in the same dosage form.
44. The TrkB agonist and the mTOR inhibitor for use of claim 42, wherein the TrkB agonist and the mTOR inhibitor are administered at the same time in the same single dosage form.
45. The TrkB agonist and the mTOR inhibitor for use of claim 42, wherein the TrkB agonist and the mTOR inhibitor are administered at the same time via the same administration route.
46. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 41, wherein the TrkB agonist and the mTOR inhibitor are administered within 1 to 180 minutes of one another.
47. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 41, wherein the TrkB agonist and the mTOR inhibitor are administered within 1 to 24 hours of one another.
48. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 41, wherein the TrkB agonist and the mTOR inhibitor are administered within 1 to 28 days of one another.
49. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 41, wherein the TrkB agonist and the mTOR inhibitor are administered within 1 to 28 weeks of one another.
50. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 49, wherein the TrkB agonist is administered one or more times every 1 to 28 days.
51. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 49, wherein the TrkB agonist is administered one or more times every 1 to 26 weeks.
52. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 49, wherein the TrkB agonist is administered one or more times every 1 to 12 months.
53. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 49, wherein the mTOR inhibitor is administered one or more times every 1 to 28 days.
54. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 49, wherein the mTOR inhibitor is administered one or more times every 1 to 26 weeks.
55. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 49, wherein the mTOR inhibitor is administered one or more times every 1 to 12 months.
56. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 55, wherein the TrkB agonist is administered followed by administration of the mTOR inhibitor.
57. The TrkB agonist and the mTOR inhibitor for use of any one of claim 38 to 55, wherein the mTOR inhibitor is administered followed by administration of the TrkB agonist.
58. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 57, wherein the TrkB agonist and the mTOR inhibitor are administered as the same dosage form.
59. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 57, wherein the TrkB agonist and the mTOR inhibitor are administered as different dosage forms.
60. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 57, wherein the TrkB agonist and the mTOR inhibitor are administered via the same administration route.
61. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 57, wherein the TrkB agonist and the mTOR inhibitor are administered via different administration routes.
62. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 61, wherein the mTOR inhibitor is selected from: rapamycin, temsirolimus, everolimus, ridaforolimus, ridaforolimus, umirolimus, zotarolimus, quinoxaline, torin-1, torin-2 or vistusertib, or derivatives thereof.
63. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 62, wherein the mTOR inhibitor is rapamycin.
64. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 63, wherein the TrkB agonist is selected from: BDNF, NT-4, NT-3, 7,8-dihydroxyflavone, N-Acetylserotonin or derivatives thereof.
65. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 64, wherein the TrkB agonist is a compound of formula (II):or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, wherein each of R1-R10 is independently selected from: hydrogen, deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
66. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound of formula (II), wherein R1-R5 and R7-R10 are hydrogen and R6 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
67. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound of formula (II), wherein R2-R10 are hydrogen and Ri is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
68. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound of formula (II), wherein Riand R3-R10 are hydrogen and R2 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid,methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
69. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound of formula (II), wherein Ri, R2 and R4-R10 are hydrogen and R3 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
70. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein R1-R3 and R5-R10 are hydrogen and R4 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
71. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein R1-R4 and R6-R10 are hydrogen and R5 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
72. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein R1-R5 and R7-R10 are hydrogen and R6 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
73. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein R1-R6 and R8-R10 are hydrogen and R7 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
74. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein R1-R7 and R9 and R10 are hydrogen and R8 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
75. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein R1-R8 and R10 are hydrogen and R9 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
76. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein R1-R9 are hydrogen and R10 is deuterium, C1-10 optionally substituted straight or branched chain alkyl, C3-10 optionally substituted cycloalkyl, C3-10 optionally substituted aromatic ring, methyl, ethyl, propyl, butyl, isopropyl, alkoxy, hydroxy, methoxy, ethoxy, a halogen, fluoro, chloro, bromo, nitrogen, oxygen, sulphur, phosphate, phenyl, amino, cyano, carboxylic acid, methylthiomethyl, isobutyl, methylsulfonyl, benzyl, formyl, benzyloxy, ethylthio, butylthioethoxy, isopropylthiomethoxy, methylthiopropoxy, propylsulfonyl, butylthiomethoxy, isobutylsulfonyl, ethylthioethoxy, methylthioethoxy, propylthio, ethylthiomethoxy, butylsulfonyl, phenoxy, isobutylthio, methylthiomethoxy, cyclohexyl, isopropylthio, butylthio, flouromethyl, chloromethyl, bromomethyl, ethylsulfonyl, cyclopropyl, benzyloxy, propoxy, acetyl or boron.
77. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound of formula (II):or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, whereinR1-R4 are hydrogen;R5 is OH, S-C4alkyl, S-C3alkyl, SO2-C3alkyl, O-CH2CH(CH3)2or O-CH2CH2-S-C4alkyl;R6 is hydrogen or methyl; andR7-R10 are hydrogen.
78. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound of formula (II):or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof, whereinRi is hydrogen, methyl, ethyl, propyl or butyl;R2-R4 are hydrogen;Rs is OH, C4alkyl, CH2CH(CH3)2, S(O)-C3alkyl, C(O)H, COOC2 alkyl, S-C2 alkyl, S-C3alkyl, S-C4alkyl, S- CH(CH3), S-CH2CH(CH3)2, SO2-C2 alkyl, SO2-C3alkyl, SO2-CH2CH(CH3)2, O-CH(CH3), O-CH2CH(CH3)2, O- CH2CH2-S-C1 alkyl, O-(CH2)3-S-CI alkyl or O-CH2CH2-S-C4 alkyl;Rs is hydrogen, methylR7-R10 are hydrogen.
79. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-lsopropoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-2-methyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Formyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylamino-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutoxy-lH-indol- 3-yl)ethyl]acetamide, N-[2-(5-Methylthiomethyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Cyclopropyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Fluoromethyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Ethylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butylthio-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-lH-indol-2-yl)ethyl]acetamide, N-[2-(5-lsopropylthio-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-3-methyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Cyclohexyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylthiomethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutylthio-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-4-methyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-2-propyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Ethylthiomethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Propylthio-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylthioethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsobutylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-3-ethyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butylthiomethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Fluoro-3-methyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-2-butyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Propylsulfonyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Methylthiopropoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-lsopropylthiomethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-4-ethyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-3-propyl-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Butylthioethoxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(5-Fluoro- 4-methyl-lH-indol-3-yl)ethyl]acetamide,N-[2-(5-Butoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Pentoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Hexoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methylpropan-2-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Butan-2-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2,2-Dimethylpropoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Prop-2-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Prop-2-yn-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(But-3-en-l-yloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(Pent-4-enyloxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Cyclopropylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclobutylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclopentylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclohexylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclopropyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclobutyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclopentyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Cyclohexyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(4-Methylbenzyloxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Phenylethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-((4-Fluorophenyl)methoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(2-Fluoroethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Thienylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Pyrrolylmethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Tetrahydrofuran-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(Tetrahydrothiophen-2-ylmethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-[2-(Piperidin-l-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-[2-(Morpholin-4-yl)ethoxy]-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(Oxetan-3-yloxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(Oxetan-3-ylmethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Trifluoromethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Chloromethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Bromomethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Fluoroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Chloroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2,2,2-Trifluoroethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(2,2-Difluoroethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3,3,3-Trifluoropropoxy)-lH-indol-3-yl]ethyl]acetamide N-[2-[5-(3-Fluoropropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-tert-Butoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methylbutoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-[5-(l-Methylpropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(3-Methylbutoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(2-Ethylbutoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-Methoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Ethoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Propoxymethoxy-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Methoxyethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-Ethoxyethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-(2-(Dimethylamino)ethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-(5-(2-(Pyrrolidin-l-yl)ethoxy)-lH-indol-3-yl)ethyl]acetamide N-[2-[5-[3-(Dimethylamino)propoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Methoxycarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[3-(Ethoxycarbonyl)propoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Aminocarbonyl)ethoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-(3-Hydroxypropoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-[5-(2-Hydroxyethoxy)-lH-indol-3-yl]ethyl]acetamideN-[2-(5-(2-(Methylthio)ethoxy)-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Propyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-tert-Butyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-tert-Butylthio-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Chloromethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Bromomethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Trifluoromethyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Ethylamino-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Dimethylamino-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclobutyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Cyclopentyl-lH-indol-3-yl)ethyl]acetamideN-[2-(5-Benzyl-lH-indol-3-yl)ethyl]acetamideN-[2-[5-[2-(Pyridin-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Pyridin-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Pyridin-4-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Thiophen-2-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide N-[2-[5-[2-(Thiophen-3-yl)methoxy]-lH-indol-3-yl]ethyl]acetamide80. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(2-Hydroxy-5-hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Methoxy-5-hydroxy-lH-indol-3- yl)ethyl]acetamide, N-[2-(2-Fluoro-5-hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Hydroxy-5- Hydroxy-lH-indol-3-yl)ethyl]acetamide, N-[2-(2-Methyl-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Chloro-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide, N-[2-(2-Bromo-5-Hydroxy-lH-indol-3- yl)ethyl]acetamide or N-[2-(2-Ethoxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide.
81. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-Hydroxy-4-methoxy-1H-indol-3-yl)ethyl]acetamideN-[2-(5-Hydroxy-4-fluoro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-4-chloro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-4-Methyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-4-Fluoro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-4-Chloro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-4-Bromo-1H-indol-3-yl)ethyl]acetamide orN-[2-(5-Hydroxy-4-Methoxy-1H-indol-3-yl)ethyl]acetamide.
82. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-Hydroxy-1-methyl-1H-indol-3-yl)ethyl]acetamide, N-[2-(5-Hydroxy-l-ethyl-lH-indol-3- yl)ethyl]acetamide,N-[2-(5-Hydroxy-1-propyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-1-Methyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-1-Ethyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-1-Propyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-1-Butyl-1H-indol-3-yl)ethyl]acetamide orN-[2-(5-Hydroxy-1-Pentyl-1H-indol-3-yl)ethyl]acetamide.
83. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-Hydroxy-1H-indol-1-yl)ethyl]acetamide,N-[2-(1-Hydroxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,N-[2-(1-Methyl-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,N-[2-(1-Chloro-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,N-[2-(1-Bromo-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide orN-[2-(1-Ethoxy-5-Hydroxy-1H-indol-3-yl)ethyl]acetamide.
84. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-3-Methyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-3-Fluoro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-3-Chloro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-3-Bromo-1H-indol-3-yl)ethyl]acetamide orN-[2-(5-Hydroxy-3-Methoxy-1H-indol-3-yl)ethyl]acetamide.
85. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-Hydroxy-1H-indol-6-yl)ethyl]acetamide,N-[2-(5-Hydroxy-6-Methyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-6-Fluoro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-6-Chloro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-6-Bromo-1H-indol-3-yl)ethyl]acetamide orN-[2-(5-Hydroxy-6-Methoxy-1H-indol-3-yl)ethyl]acetamide.
86. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-Hydroxy-1H-indol-7-yl)ethyl]acetamide,N-[2-(5-Hydroxy-7-Methyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-7-Fluoro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-7-Chloro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-7-Bromo-1H-indol-3-yl)ethyl]acetamide orN-[2-(5-Hydroxy-7-Methoxy-1H-indol-3-yl)ethyl]acetamide.
87. The TrkB agonist and the mTOR inhibitor for use of claim 65, wherein the TrkB agonist is a compound, or a pharmaceutically acceptable salt, prodrug, hydrate, ester, co-crystal or deuterated form thereof of, selected from:N-[2-(5-Hydroxy-1H-indol-8-yl)ethyl]acetamide,N-[2-(5-Hydroxy-8-Methyl-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-8-Fluoro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-8-Chloro-1H-indol-3-yl)ethyl]acetamide,N-[2-(5-Hydroxy-8-Bromo-1H-indol-3-yl)ethyl]acetamide orN-[2-(5-Hydroxy-8-Methoxy-1H-indol-3-yl)ethyl]acetamide.
88. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 64, wherein the TrkB agonist is a compound of formula (la):or a pharmaceutically acceptable salt thereof, whereinR1a, R2a, R3a, R4a, R7a, R8a, R9a and R10a are each independently H or C1-6 alkyl optionally substituted with 1-3 fluorine atoms;R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;wherein n is 0 to 6;m is 0 to 6;Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; andR6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
89. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 64, wherein the TrkB agonist is a compound of formula (2a):or a pharmaceutically acceptable salt thereof, whereinRlais H or Ci-6 alkyl optionally substituted with 1-3 fluorine atoms;R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;wherein n is 0 to 6;m is 0 to 6;Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; andR6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
90. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 64, wherein the TrkB agonist is a compound of formula (2b):or a pharmaceutically acceptable salt thereof, whereinR1a and R11a are each independently H or C1-6 alkyl optionally substituted with 1-3 fluorine atoms;R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;wherein n is 0 to 6;m is 0 to 6;Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; andR6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
91. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 64, wherein the TrkB agonist is a compound of formula (2c):or a pharmaceutically acceptable salt thereof, whereinR11ais H or C1-6alkyl optionally substituted with 1-3 fluorine atoms;R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ;wherein n is 0 to 6;m is 0 to 6;Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO;Z is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms; andR6ais H, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkenyl optionally substituted with 1-3 fluorine atoms or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms and / or a C1-3 alkyl group.
92. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 64, wherein the TrkB agonist is a compound of formula (3a):or a pharmaceutically acceptable salt thereof, wherein R5ais halo, CN, NO2or a group -(CH2)nQ(CH2)mZ; wherein n is 0 to 6;m is 0 to 6;Q is a bond or is selected from the group consisting of O, S, NH, SO, SO2and CO; andZ is H, OH, Ci-6 alkyl optionally substituted with 1-3 fluorine atoms, C1-6 alkoxy optionally substituted with 1-3 fluorine atoms, C1-6 thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3-6 carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms.
93. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 64, wherein the TrkB agonist is a compound of formula (3b), (3c), (3d), (3e), (3f) or (3g):or awherein m is 0 to 6; andZ is H, OH, C1, 2, 3, 4, 5 or 6alkyl optionally substituted with 1-3 fluorine atoms, C1, 2, 3, 4, 5 or 6alkoxy optionally substituted with 1-3 fluorine atoms, C1, 2, 3, 4, 5 or 6thioalkyl optionally substituted with 1-3 fluorine atoms, or a C3, 4, 5 or 6carbocyclic or heterocyclic group which is optionally substituted with 1-3 fluorine atoms.
94. The TrkB agonist and the mTOR inhibitor for use of any one of claims 65 to 93, wherein the group R1or R1acan be selected from the group consisting of:
95. The TrkB agonist and the mTOR inhibitor for use of any one of claims 65 to 93, wherein the group R5or R5acan be selected from the group consisting of:
96. The TrkB agonist and the mTOR inhibitor for use of any one of claims 65 to 93, wherein the group R6or R6acan be selected from the group consisting of:
97. The TrkB agonist and the mTOR inhibitor for use of any one of claims 65 to 93, wherein the group Rllacan be selected from the group consisting of:
98. The TrkB agonist and the mTOR inhibitor for use of any one of claims 65 to 93, wherein the group X can be selected from the group consisting of:
99. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 98, wherein the method of treatment is a method of treatment of:one or more neurodegenerative diseases;Alzheimer's disease, Parkinson's disease or Huntington's disease;one or more mood disorders;depression, bipolar disorder or anxiety;one or more epilepsy disorders;one or more pain disorders;one or more inflammatory disorders;one or more psychiatric disorders;schizophrenia or borderline personality disorder;one or more disorders resulting from brain injury;one or more addiction disorders;one or more neurodevelopmental disorders;autism spectrum disorders or attention-deficit / hyperactivity disorder; orone or more circadian rhythm disorders.
100. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 99, wherein the mTOR inhibitor is rapamycin and the TrkB agonist is:
101. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 100, wherein the mTOR inhibitor is rapamycin and the TrkB agonist is:
102. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 101, wherein the mTOR inhibitor is rapamycin and the TrkB agonist is:
103. The TrkB agonist and the mTOR inhibitor for use of any one of claims 38 to 102, wherein the amount of the mTOR inhibitor administered is an amount which is ineffective in the absence of the coadministration of the TrkB agonist.
104. The (i) TrkB agonist and the (ii) mTOR inhibitor for use of any one of claims 38 to 103, wherein the efficacy shown by administering by (i) and (ii) in combination is greater than the efficacy shown by administering either of (i) or (ii) alone.
105. A combination pharmaceutical composition comprising: (i) a TrkB agonist; (ii) an inhibitor of mTOR;and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
106. A combination pharmaceutical composition comprising: (i) a compound of formula (II); (ii) an inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
107. A combination pharmaceutical composition comprising: (inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
108. A combination pharmaceutical composition comprising: (inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
109. A combination pharmaceutical composition comprising:inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients, wherein the combination pharmaceutical composition is for use in a method of treatment of a patient in need thereof.
110. The combination pharmaceutical composition for use of any one of claims 105 to 109, wherein the mTOR inhibitor is rapamycin.
111. A combination pharmaceutical composition comprising: (i) a TrkB agonist; (ii) an inhibitor of mTOR;and (iii) one or more pharmaceutically acceptable carriers or excipients.
112. A combination pharmaceutical composition comprising: (i) a compound of formula (II); (ii) an inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
113. A combination pharmaceutical composition comprising: (i)inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
114. A combination pharmaceutical composition comprising: (inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
115. A combination pharmaceutical composition comprising:inhibitor of mTOR; and (iii) one or more pharmaceutically acceptable carriers or excipients.
116. The combination pharmaceutical composition of any one of claims 111 to 115, wherein the mTOR inhibitor is rapamycin.
117. The combination pharmaceutical composition of claim 116, wherein rapamycin is present at a dosage substantially lower than a dosage wherein rapamycin alone is active.118.The combination pharmaceutical composition of claim 116, wherein rapamycin is present at a dosage that substantially produces none of the known adverse effects of rapamycin.119.A method of treating a disease or condition in a patient in need thereof comprising administering: (i) a TrkB agonist; and(ii) an inhibitor of mTOR;wherein the amount of the mTOR inhibitor administered is an amount which is ineffective in the absence of the co-administration of the TrkB agonist.120.The method of claim 119, wherein the efficacy shown by administering by (i) and (ii) in combination is greater than the efficacy shown by administering either of (i) or (ii) alone.121.The method of claim 119 or claim 120, wherein the TrkB agonist and / or the mTOR inhibitor is as claimed in any one of claims 38 to 120.122.A TrkB agonist for use in treating a disease or condition in a patient in need thereof in combination with an inhibitor of mTOR.123.The TrkB agonist and mTOR inhibitor for use of claim 122, wherein the TrkB agonist and / or the mTOR inhibitor is as claimed in any one of claims 38 to 122.124.A kit of pharmaceutical compositions, said kit comprising separate pharmaceutical compositions, one of the pharmaceutical compositions comprising a TrkB agonist and the other pharmaceutical composition comprising an mTOR inhibitor.125.The kit of claim 124, wherein the kit comprises instructions for use.126.The kit of claim 124 or claim 125, wherein the TrkB agonist and / or the mTOR inhibitor is as claimed in any one of claims 38 to 125.127.A kit of pharmaceutical compositions for use in treating a disease or condition in a patient in need thereof, said kit comprising separate pharmaceutical compositions, one of the pharmaceutical compositions comprising a TrkB agonist and the other pharmaceutical composition comprising an mTOR inhibitor.128.The kit of claim 127, wherein the pharmaceutical composition comprising the mTOR inhibitor comprises an amount of the mTOR inhibitor which is ineffective in the absence of the coadministration of the TrkB agonist.129.The kit for use of claim 127 or claim 128, wherein the kit comprises instructions for use.130.The kit for use of any one of claims 127 to 129, wherein the TrkB agonist and / or the mTOR inhibitor is as claimed in any one of claims 38 to 129.
